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Abstract 
Introduction: Androgenic alopecia (AA) patients usually have high levels of 
dihydrotestosterone on their balding scalp area. Currently, dutasteride (DST) is given 
orally and has systemic adverse effects; diminished sexual desire, increased 
depression and ejaculation disorder. Topical administration of DST is an appropriate 
drug-delivery strategy with the potential to reduce systemic side effect, skin irritation 
and cytotoxicity effects.  
Materials and method: Chitosan oligomer (CSO) conjugated with stearic acid (SA) 
or lauric acid (LA) was synthesised and characterised. Dutasteride-loaded 
nanostructured lipid carriers (DST-NLCs) were prepared using a melt-dispersion 
ultrasonication method. DST-NLCs were optimised using a design of experiments 
approach. DST-NLCs, uncoated and coated with CSO-SA or CSO-LA were 
characterised for particle size distribution, surface charge and morphology. In vitro 
release and permeation studies were performed. Cytotoxicity was investigated using 
human hair follicle dermal papilla cells, and skin irritation was performed using an 
EpiDerm™ RHE model. Cou-6 loaded NLCs were prepared and characterised before 
proceeding with the cell and skin uptake study. 
Results: CSO-SA and CSO-LA were successfully synthesised; confirmed using 
1
H 
NMR and FTIR. The mean size of DST-NLCs was significantly increased (p<0.05) 
when coated with 5% CSO-SA but not with 5% CSO-LA (p>0.05). The zeta 
potential changed from negative to positive charge when coating DST-NLCs with 
CSO-SA or CSO-LA. All formulations were physically stable over six months when 
stored at 4-8°C. However, DST-NLCs coated with CSO showed aggregation. All 
formulations exhibited rapid drug release. No dutasteride permeated through pig ear 
skin after 48
 
h for all formulations. The cytotoxicity (IC50) for DST nanoparticles, 
coated and uncoated, was greater than for DST alone (p<0.05). The in vitro skin 
irritation study indicated no irritation for all nanoparticle preparations. For the cell 
and skin uptake studies, all samples showed time-dependent skin and cell uptake.  
Conclusions: These stable, low cytotoxic and irritant, positively-charged DST-NLCs 
with CSO-SA or CSO-LA, represents a promising strategy for topical/ transfollicular 
delivery of DST. 
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Research Impact Statement 
 Androgenic alopecia is a common disorder affecting almost 50% of men in 
their lifetime due to the androgen effect. Based on the Euromonitor market study 
predicted in 2013, it was expected that the hair loss treatment would attract up to 
US$100 million in sales globally by 2016. Even though hair loss is not a life-
threatening disease, but it has a psychological and emotional effect, especially in 
young people. This study aims to prepare and characterise dutasteride-loaded 
nanostructured lipid carriers (DST-NLCs), coated with chitosan oligomer conjugated 
with stearic acid, and lauric acid to enhance local drug delivery and reduce toxicity.  
This study will help in our understanding of the potential of nanoparticle 
formulations for topical delivery of hair growth molecules, which will benefit society 
especially, androgenic alopecia patients, improving their quality of life. Currently, 
few products are available in the markets which are prescribed for the androgenic 
alopecia patient. Due to their systemic adverse effects, the delivery of dutasteride for 
promoting hair growth using topical route would be a great advance. Phase III 
clinical studies on the use of dutasteride for promoting hair growth have shown 
significant hair growth for the people with hair loss. Unfortunately, no topical 
product based on dutasteride has been approved.  
This research can generate good networks between researchers in the 
academia and people from industries whereby they can exchange the idea, skills and 
knowledge on the research and business areas. Also, this research can be one of the 
platforms for other molecules to be applied for topical or non-topical applications. A 
trained and skilled researcher who has cross-disciplinary generated from this study 
would be one of the main impacts on the academic area. In term of the economic, it 
would generate a knowledge transfer between researchers and industrial people who 
will lead to spin out companies, and the creation of new processes and products.  
. 
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1.1 Skin structure and function 
Skin is the largest, heaviest and most versatile organ of the human body. The 
vital roles of the skin are the protection of the body, regulation of body temperature 
and sensory perception. The skin protects the body from water loss and the 
possibility of access by potentially toxic compounds, allergens, irritants and microbes 
(Bartosova and Bajgar, 2012). To ensure these diverse functions can be fulfilled, 
healthy skin is needed. For an adult, the skin surface area is approximately 1.8 - 2.0 
m
2 
(Uchechi et al., 2014). Figure 1.1 shows the structure of the skin.  
 
 
 
Figure 1.1 Structure of skin (adapted from MacNeil, 2007) 
 
The skin consists of three main layers (Figure 1.2). The outermost layer is the 
epidermis which is made up of stratum corneum, stratum lucidum, stratum 
granulosum, stratum spinosum and stratum basal (Williams, 2018). The barrier 
properties of the skin are due to the stratum corneum. The stratum corneum is a very 
hydrophobic layer, comprising differentiated non-nucleated cells, corneocytes, filled 
with keratins embedded in the lipid domain (Godin and Touitou, 2007). The lipid 
domain is composed of equal proportions of ceramides, cholesterol and free fatty 
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acids (Pappas, 2009). The synthesis of these three components promotes the acidic 
condition of the skin.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Skin structure and layer (redrawn from Bensouilah and Buck, 2006) 
 
The second layer is dermis. The dermis is composed of connective tissues 
such as collagen fibrils and elastic tissues that mostly provide support, mechanical 
strength, elasticity and flexibility of the skin. The dermis is supplied with a reticulate 
network of blood vessels, lymphatic vessels, nerve endings, hair follicles, sebaceous 
glands and eccrine glands (Thakur et al., 2008). 
 
Finally, the inner layer of the skin is subcutaneous tissue or hypodermis 
which contains adipose cells in and between the connective tissue. The primary 
function of subcutaneous tissue is to provide insulation to the body (Williams, 2018).  
1.2 Hair  
The largest appendages, which consist of hair follicles and sebaceous glands, 
can provide ‘short cut’ routes which drugs can pass across the stratum corneum 
barrier (Williams, 2018). The hair follicle is an organ and part of the skin. It starts in 
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the dermis and goes through the outer part of the skin to the epidermis layer (Figure 
1.3). Hair consists of proteins, lipids, water, trace elements and pigments (Robbins, 
2012). The hair protein is called keratin. Hair can be divided into two types. First is 
vellus hair, appearing on the body, or hair that changes to terminal hair at puberty. 
The second is called terminal hair. Terminal hair may be short (eyebrows, ears, nose) 
and long (head hair, beard, underarm, pubic area).  
 
 
 
 
 
 
 
 
 
Figure 1.3 Structure of the hair follicles (adapted from Adolphe and Wainwright, 
2005) 
 
Hair that is visible above the skin is called the hair shaft. It consists of cuticle, 
cortex and medulla. Previous studies have found the hair diameter on the scalp and 
face differ (Tolgyesi et al., 1983). The normal adult hair shaft diameter (Caucasian) 
is approximately 70 µm, whereas in the beard it is 126 µm. These have made skin 
appendages (sweat gland and hair follicle) which is only 0.1% to 1% of the area of 
the skin (Schaefer and Redelmeier, 2001) used as a follicular route for targeted 
delivery of drugs. 
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Hair that is invisible or within the skin is called the hair root. The bulbous end 
of the hair root is called the hair bulb (Williams, 2018). All biological processes 
including cell division happen in this part. The hair bulb is positioned in a tubular 
pocket called the hair follicle. Human hair follicles are one of the organs that are 
affected by hormones such as androgens (Randall et al., 1991). Androgen promotes 
hair growth and also sometimes inhibits scalp hair growth causing androgenetic 
alopecia (AGA). As it is specific to the hair follicle itself, the response to androgens 
varies with the body site. In the case of AGA, androgens cause the miniaturisation of 
the scalp hair follicle (Hibberts et al., 1998). 
1.3 Hair growth cycles 
Hair is produced by the hair follicle and undergoes a cycle with different 
phases. It starts at the anagen phase, then passes through catagen and lastly telogen 
phases. All hair growth phases in the body occur at the same time; one hair might be 
in the anagen phase and others in the catagen or telogen phase. The original lower 
follicle will be destroyed, and the new follicle will regenerate to form a new hair 
(Randall and Botchkareva, 2008).  
Figure 1.4 shows the cycles of hair growth in the normal human body. 
Different areas have different hair growth cycle. Hair is produced in the anagen 
phase or so-called growth phase. Scalp follicles have the longest anagen phases, 
lasting up to several years (Randall, 2008). Once hair reaches its full length in the 
anagen phase, then the catagen phase (regression) will take place, in which cell 
proliferation, differentiation, and pigmentation will stop, and extensive apoptosis 
occurs, and the dermal papilla shrinks (Randall, 2008). The catagen phase normally 
takes 1 to 2 weeks. In the catagen stage, the hair is fully keratinised and a specialised 
structure, the club hair is formed and moves upwards (Randall and Botchkareva, 
2008). After this, the telogen phase takes over, which lasts for several months. 
During the telogen phase, the round-shaped dermal papilla is closely situated near to 
the secondary hair germ keratinocytes containing hair follicle stem cells. In an early-
mid anagen phase, a new lower follicle develops inside the same dermal sheath, and 
the new hair grows into the original upper follicle, and the existing hair ejected 
(Randall and Botchkareva, 2008).  
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Figure 1.4 The hair follicle growth cycle (adapted from Randall and Botchkareva, 
2009) 
1.4 Mechanism of hair loss  
Most problems associated with hair relate to either hirsutism (excessive hair 
growth) or alopecia. Alopecia is a common medical term for hair loss or baldness. 
Baldness which is affected by androgens is called AGA, also known as male pattern 
hair loss (MPHL) or female pattern hair loss (FPHL) (Kaufman, 2002). Testosterone 
and dihydrotestosterone are the major androgens that regulate the hair growth.  
Dihydrotestosterone (DHT) has approximately a five-fold greater affinity for 
the androgen receptor than testosterone (Kaufman, 2002). In hair loss patients, the 
5α-reductase enzyme acts as a catalyst that converts testosterone, which is the 
primary androgen, to the more potent androgen, DHT which makes the hair follicle 
miniaturise and shed hair (Olsen et al., 2006).  
Figure 1.5 shows the hair loss cycle for a patient with hair loss. Due to the 
effect of the potent androgen (DHT), their normal hair starts as long, thick and 
pigmented, then changes to be thin, short and less pigmented at the end of the 
process. The new hair colour becomes less pigmented from one cycle to another, the 
hair shaft becomes thinner, and there is the appearance of baldness. Two isozymes 
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participate in androgen synthesis; namely, Type I 5α-reductase isozyme which is 
present in the skin, hair follicles and sebaceous glands, liver, prostate, and kidney and 
Type II 5α-reductase isozyme which is present in hair follicles, male genitalia and the 
prostate (Russell and Wilson, 1994; Kandavilli et al., 2010). Both these isozymes are 
involved in steroid metabolism and interact with the androgen receptors. In androgen 
synthesis, the 5α-reductase enzyme acts as catalyst converting testosterone to the 
more potent dihydrotestosterone. By introducing a 5α-reductase inhibitor, the 
conversion of testosterone to DHT can be decreased and reduce hair loss.        
 
 
 
 
 
 
 
 
Figure 1.5 Hair loss cycle in patients with male pattern baldness (adapted from 
Randall, 2010) 
1.5 Anti-androgenic activity for treating hair loss 
Hair loss is not a life-threatening disease, but has an emotional impact and 
affects certain individuals, especially young people and they may experience 
psychological distress (Hunt and Mchale, 2005). Androgenic alopecia (male pattern 
baldness) is a common disorder affecting almost 50% of men in their life (Yassa et 
al., 2011) due to effect from androgen. Androgen is one of the prerequisites for male 
pattern baldness (Randall and Botchkareva, 2008). Normally, patients with 
androgenic alopecia have higher levels of DHT (dihydrotestosterone) and 5α-
reductase enzyme activity on their balding scalp area than those with a non-balding 
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scalp area (Hibberts et al., 1998). Figure 1.6 shows the circulation of androgens in 
the hair follicles. Testosterone (T) is mainly secreted by the Leydig cells of the testes 
of males and a lesser amount by the ovaries of female (Brownlee et al., 2005).  
 
 
 
 
 
 
 
 
 
Figure 1.6 The action of androgen in the hair follicle (redrawn from Randall and 
Botchkareva, 2009)  
 
Testosterone will circulate in the blood and enter the hair follicle through the 
dermal papilla’s blood supply and interact with the androgen receptors in the dermal 
papilla cells. Several studies have focussed on the inhibition of the activity of the 5α-
reductase enzyme, either by using natural extracts or drugs. One example of natural 
extract for 5α-reductase inhibitor was the use of fatty acids (Liu et al., 2009); those 
with C12-C16 and C=C double bond which enhanced Type II 5α-reductase inhibition 
activity. Finasteride which has Type II 5α-reductase inhibitor activity is approved by 
the FDA to treat benign prostatic hyperplasia and male pattern baldness. Dutasteride 
is approved for treating benign prostatic hyperplasia (BPH) and has both Types I and 
II 5α-reductase inhibitor. Finasteride and dutasteride are discussed in detail in 
Section 1.8.2 and 1.8.3 respectively. 
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1.6 Market overview of hair loss products 
Figure 1.7 shows the estimated size of the global hair care market in 2013 
from 2006 to 2016 (Euromonitor International, 2013). Hair care products comprise 
products that promote health; hair nourishment, prevention of hair damage and hair 
loss treatment.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Size of the global hair care market in 2006, 2011 and the estimated 
market in 2016 (in billion U. S. dollars) (adapted from Euromonitor International, 
2013) 
 
From this data, the sales of the hair loss treatments are dominated by 
minoxidil (Regaine®, Johnson and Johnson) which exhibits a significant sales 
growth especially in Western Europe (Euromonitor International, 2013). Minoxidil is 
an over-the-counter drug and has been approved for treating hair loss in both men 
and women. However, some people use cosmetic products to treat hair loss rather 
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than pharmaceutical products due to their adverse effects. In this case, cosmetics are 
defined in Regulation (EC) No. 1223/2009 as: 
"any substance or mixture intended to be placed in contact with the external 
parts of the human body (epidermis, hair system, nails, lips and external genital 
organs) or with the teeth and the mucous membranes of the oral cavity with a view 
exclusively or mainly to cleaning them, perfuming them, changing their appearance, 
protecting them, keeping them in good condition or correcting body odours.” 
(European Commission, 2009). 
Cosmetics or drugs used for treating hair loss are not permanent and their 
activity is reversible, which means when someone uses the product; hair loss will 
decrease or stop, but when they stop using the product, then the hair loss returns. To 
reduce this problem, an effective delivery system for a drug acting as a potential hair 
growth promoter should be designed to have a long-lasting effect such as having 
controlled release properties which is targeted to the hair follicle area and at the same 
time reduce the adverse effects. 
1.7 Delivery of drugs to the skin 
Many studies have been conducted to deliver drugs to the transfollicular 
region (Bhatia et al., 2013; Mittal et al., 2015). Figure 1.8 shows the potential 
penetration pathways of a drug through the skin. The drug can pass either through the 
skin barrier (No. 1 - 3) or to the transfollicular area (A - D). Drug delivery through 
the skin offers convenience to the patient, is pain-free and allows self-administration, 
and may eliminate frequent administration especially when long-term treatment is 
needed (Paudel et al., 2010). 
The transfollicular route has shown promise for delivery; particulate delivery 
would be ideal by allowing deep intrafollicular penetration, sustained release and 
selectively targeted delivery (Patzelt and Lademann, 2013). The size of particulate 
materials is one of the key criteria to deliver the drug to the transfollicular area. Hair 
follicles have a size range from 10 - 70 μm depending on the hair type, location and 
race (Singh et al., 2000) making it a suitable site for delivering nanoparticles to the 
dermal papilla cells for hair growth products.  
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Previous research has found that, applying 320 nm fluorescence dye-
containing nanoparticles, and massaging the area enhanced the penetration for up to 
10 days (Lademann et al., 2007); with nanoparticulates of dye penetrating deeper 
than the dye in solutions. 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic illustration of the potential penetration pathways of drugs 
through the skin (redrawn from Patzelt and Lademann, 2013) 
 
Lipophilic vehicles rather than hydrophilic are able to improve the delivery of 
drug to the skin (Motwani et al., 2004), and many  studies have been conducted using 
lipid-based vehicles for dermal delivery (Doktorovova et al., 2011; Wang et al., 
2012; Uprit et al., 2013; Montenegro et al., 2016). Due to the occlusive properties of 
lipid nanoparticles, an increased skin hydration effect is observed (Hommoss, 2008). 
Previous studies found that a lipid film formed on the top of the skin, and the 
subsequent occlusion effect was reported for lipid nanoparticles (Müller et al., 2002; 
Wissing and Müller, 2003; Escobar-Chávez et al., 2012). Particles smaller than 400 
nm containing at least 35% lipid of high crystallinity have been most effective for the 
occlusive properties (Wissing and Müller, 2003).  
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Figure 1.9 shows that the occlusion factor of lipid nanoparticles depends on 
the sizes; reducing the particle size leads to an increase in particle number, the film 
becomes denser (left) and therefore the occlusion factor increases. Other criteria on 
the occlusion factor have been considered, such as identical lipid content; increasing 
the lipid concentration increases particle number and density of the film (right) which 
also leads to a higher occlusion factor (Pardeike et al., 2009). In solid lipid 
nanoparticles (SLN) or nanostructured lipid carriers (NLC) system, the skin 
hydration after applying these nanoparticles leads to a reduction of corneocytes 
packing and an increase in the size of the corneocytes gaps and facilitate the 
percutaneous absorption and drug penetration to the deeper skin layers (Hommoss, 
2008). 
 
 
 
 
 
 
Figure 1.9 The occlusion factor of lipid nanoparticles depends on different sizes 
(redrawn from Escobar-Chávez et al., 2012) 
 
 Campbell et al., (2012) investigated the deposition of nanoparticles in 
mammalian skin and found that nanoparticles (mean size of 20 – 200 nm) cannot 
penetrate beyond the superficial layers of the barrier.  Figure 1.10 shows the intensity 
of fluorescence nanoparticles at different sizes. Even at the smallest mean size of 
nanoparticles (20 nm), there is no penetration of nanoparticles to the deeper layer of 
the skin. This result proved that nanoparticles could not penetrate the skin barrier, but 
it is useful as skin surface reservoirs to control the drug release over time (Campbell 
et al., 2012).  
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Figure 1.10 Fluorescence intensity of different sizes of nanoparticles (without 
removing the stratum corneum) (modified from Campbell et al., 2012) 
 
 Fang et al. (2014) reported the mechanism of skin permeation by drug-loaded 
NLCs (Figure 1.11). As mentioned before, occlusion factor which increases 
hydration of the stratum corneum (SC) become the main factor that can reduce the 
corneocytes packing and increase drug permeation (Fang et al., 2014). These findings 
suggest that nanoparticles could go deep in the skin and systemic circulation through 
transfollicular region as seen in Figure 1.11. 
 
 
 
 
 
 
Figure 1.11 Mechanism of drug permeation by NLCs (redrawn from Fang et al., 
2014) 
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1.8 Drugs used for treating hair loss 
1.8.1 Minoxidil 
For many years, minoxidil has been the first-choice for topically applied drug 
recommended by medical practitioners to treat hair loss for both men and women. 
Currently, Rogaine® (USA) or Regaine® (Europe and UK) is an approved hair-loss 
product based on minoxidil which is available on prescription and as an over-the-
counter medication. Minoxidil (Figure 1.12), a pyridine derivative drug was used in 
the 1970s as a treatment for hypertension in patients where therapy had failed with 
multidrug regimens (Messenger and Rundegren, 2004; Sica, 2004). In 1988, 1% 
minoxidil mixed with an alcohol-based carrier was approved by the FDA to treat 
alopecia in men.  
In a 12-month randomised double-blind trial of 150 men, 82% of the 
minoxidil group increased hair count (Kreindler, 1987). Sato et al., (1999) used 
cultured human dermal papilla cells from the balding scalp and found that minoxidil 
increased 17β-hydroxysteroid dehydrogenase activity by approximately 40% but had 
an insignificant effect on 5α-reductase activity and such as the mechanism of 
minoxidil action remains unknown (Silva et al., 2009). Another study  (Han et al., 
2004) found minoxidil prolonged the anagen phase where the dermal papilla cells 
proliferated and had an anti-apoptotic effect on dermal papilla cells. 
 
 
Figure 1.12 Chemical structure of minoxidil 
 
Chapter 1  Introduction 
 39   
 
1.8.1.1 Nanocarrier delivery of minoxidil and minoxidil derivatives 
In order to overcome the severe adverse reaction such as scalp dryness, 
irritation from propylene glycol-water-ethanol ingredients in the current minoxidil 
products, several studies have investigated the delivery of minoxidil using 
nanoparticle formulation. Nanostructured Lipid Carrier (NLCs) have been used for 
the delivery of minoxidil (Silva et al., 2009) for promoting hair growth, with a 
particle size of approximately 250 nm before adding to a hydrogel; particles 
remained below 500 nm when incorporated in the hydrogel. These formulations of 
minoxidil-NLCs hydrogel were a promising alternative to the conventional alcoholic 
solutions, as the drug is physically entrapped within the lipid matrix which can be 
useful to increase the bioavailability for skin delivery (Silva et al., 2009). No efficacy 
study on hair growth activity between the minoxidil-NLCs hydrogel and 
conventional minoxidil solutions was conducted. However, this formulation 
approach would help in reducing the risk of occurrence of adverse side effects, such 
as skin dryness and irritation. 
The Globally Harmonized System of Classification and Labeling of 
Chemicals (GHS) defines skin irritation as “the production of reversible damage to 
the skin following the application of a test substance for up to 4 hours” and skin 
corrosion as “the production of irreversible damage to the skin; namely, visible 
necrosis through the epidermis and into the dermis, following the application of a test 
substance for up to 4 hours” (United Nations, 2013). Padois et al., (2011) used solid 
lipid nanoparticles (SLNs) as a carrier for minoxidil and found SLNs suspensions 
which was approximately 190 nm of particle size proved efficient as commercial 
solutions for skin penetration; and were non-corrosive while commercial solutions 
presented a corrosive potential. 
Some examples of minoxidil-loaded nanoparticulate carriers include research 
by Aljuffali et al. (2014), which used squalene-based NLCs for targeted drug 
delivery, known as “squarticles” and delivered minoxidil together with 
diphencyprone. The size was approximately 177 nm for the NLCs-based carrier. The 
encapsulation efficiency and zeta potential for minoxidil-loaded squalene NLCs were 
63.3% and -54.0 mV respectively. They found that compared to the free control 
(drugs in 30% propylene glycol in water), squarticles-NLCs reduced minoxidil 
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penetration through the skin, indicating minimised absorption in the systemic 
circulation. The result also showed an improvement of drug deposition by 2-fold in 
the skin, using an in vitro skin absorption test and good tolerability of squarticles to 
skin based on the in vitro papilla cell viability and in vivo skin irritancy tests in nude 
mice. 
 Matos et al. (2015) formulated minoxidil sulphate-loaded chitosan 
nanoparticles (MXS-NP) which demonstrated sustained drug release (5-fold) 
compared to drugs in solutions. The MXS-NP formulation (chitosan/MXS; 1:1 w/w) 
had mean diameter 236 nm and positive zeta potential. They found that the drug 
permeation studies through the skin in vitro showed that MXS-NP application 
resulted in a 2-fold increase in MXS in uptake hair follicles after 6 h in comparison 
to the control solution.  
1.8.2 Finasteride 
Finasteride, (Figure 1.13) an anti-androgen steroidal drug has been used 
widely to treat patients with benign prostatic hyperplasia. A clinical open, 
randomised, parallel-group study for 12 months on 100 male patients with 
androgenic alopecia to investigate the efficacy of oral finasteride (1 mg per day), 
topical 2% minoxidil solution and topical 2% ketoconazole shampoo alone and in 
combination was conducted (Khandpur et al., 2002). The results demonstrated a 
significant increase in hair growth between a combination group having finasteride 
orally (1 mg) and 2% minoxidil (topically) and finasteride (orally) alone (Khandpur 
et al., 2002).  
 
 
 
 
Figure 1.13 Chemical structure of finasteride 
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1.8.2.1 Nanocarrier delivery of finasteride 
Several studies have been conducted using nanoparticle formulations of 
finasteride for topical delivery. Madheswaran et al., (2013) prepared liquid 
crystalline nanoparticles from monoolein, with size 154 – 170 nm which showed a 
potential for topical delivery of finasteride. The addition of different types of 
additives (glycerol, propylene glycol, and polyethylene glycol 400) had little or no 
influence on the size. The formulations produced slow release profiles and high 
permeation to the dermis. The release profile was significantly altered with the 
addition of different additives. Formulation with monoolein exhibited skin 
permeation which increased significantly with the inclusion of glycerol, propylene 
glycol, and polyethylene glycol 400, while it decreased with the addition of oleic 
acid. The release rate of finasteride increased when glycerol, propylene glycol, or 
polyethylene glycol 400 was added and decreased with the addition oleic acid.  
Gomes et al. (2014) formulated lipid nanoparticles of finasteride with mean 
size around 200 nm and stable up to 28 days. Penetration studies using pig ear skin 
found that only a small amount of finasteride crossed the skin, suggesting the 
suitability of this formulation for dermal delivery of anti-alopecia active compounds. 
Caon et al. (2014) found chitosan coated polymersomes of finasteride 
interacted more strongly with the skin components than non-coated formulations due 
to the positive surface charge. It was observed that the addition of chitosan 
contributed to an increase in the accumulation of finasteride in the epidermis. It was 
proposed that the particles (mean diameter of 180 - 404 nm) were preferentially 
accumulated in the follicular openings and that follicular localization was favoured 
by the smaller particle size, which would be more easily transported via the follicular 
route than the larger size.  
1.8.3 Dutasteride 
Dutasteride, approved for treating benign prostatic hyperplasia also affects 
hair growth. Due to its androgenic activity, dutasteride can only be taken by male 
patients. Dutasteride (MW = 528.5 g/mol) (Figure 1.14) is classified as Class II/IV in 
the Biopharmaceutics Classification System (BCS) (Tiwari et al., 2014). It has very 
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low water solubility (0.038 ng/mL, Log P = 5.09 and pKa = 13.5) and high solubility 
in ethanol (44 mg/ml) and methanol (64 mg/ml) at 25° C and has a half-life of 
approximately 3-5 weeks (GlaxoSmithKline Inc., 2013). 
In 2009, dutasteride (0.5 mg daily orally intake) was approved in Korea for 
treating hair loss in men (Harcha et al., 2014), but until now no dutasteride-based 
product been approved for androgenic alopecia in Europe or USA. However, it is 
commonly prescribed as an off-label for hair loss treatment (oral administration) in 
the USA and Europe. This product is swallowed without chewing, crushing, or 
opening the capsule because it might irritate the lips, mouth, and throat. The 
prescribed dosage for treating benign prostatic hyperplasia (BPH) is 0.5 mg per day 
(GlaxoSmithKline Inc., 2013). 
 
 
Figure 1.14 Chemical structure of dutasteride 
 
Olsen et al. (2006) found dutasteride increased scalp hair growth in men with 
hair loss, at 2.5 mg of dutasteride (orally), it and was superior to finasteride (5 mg) 
(orally) at 12 and 24 weeks. Eun et al. (2010) used dutasteride for treating hair loss in 
male patients at 0.5 mg daily orally and reported that the dutasteride group had 
significant hair growth compared to the placebo group within six months. Another 
study (Stough, 2007) reported evidence that dutasteride significantly reduced hair 
loss progression in men with male pattern hair loss when tested in a randomised 
study in 17 pairs of identical twin males for 1 year period. They found that treatment 
with dutasteride (0.5 mg/day orally) slowed the progression of hair loss and enhanced 
hair growth compared to treatment with placebo. In 2014, a randomised, active- and 
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placebo-controlled study of dutasteride versus placebo and finasteride in the 
treatment of 917 male subjects with androgenetic alopecia was conducted by Harcha 
et al. (2014). They found that dutasteride 0.5 mg significantly increased the hair 
count, width diameter and improved hair growth at week 24 compared with 
finasteride and placebo. 
1.8.3.1 Nanocarrier delivery of dutasteride 
Based on the summary of product characteristics for oral dutasteride 
(Avodart®), the side effects of taking oral dutasteride are: it may increase the risk of 
development of high-grade prostate cancer, decrease libido, and may cause breast 
enlargement and ejaculation disorders (GlaxoSmithKline Inc., 2013). Dutasteride has 
a toxicity effect on the skin, with multiple red areas produced in the skin (animals at 
40 mg/kg) suggesting that dutasteride is a dermal irritant (GlaxoSmithKline Inc., 
2013). In order to reduce these side effects, drug delivery with sustained release 
should preferably target the skin, especially to the hair follicle. Delivery of 
dutasteride using nanocarriers has been studied by the oral route with little research 
of topical delivery (Table 1.1).  
Previous research on topical delivery has used a liposome system (Sharma et 
al., 2011). The liposomes produced significantly higher skin permeation of 
dutasteride through excised abdominal mouse skin compared to a hydro-alcoholic 
solution and conventional gels. Ansari et al. (2013) prepared different ratios of oleic 
acid and eucalyptus oil to prepare nanoemulsion to deliver dutasteride to the skin. 
The mean size range was around 18 - 213 nm, no measurements were undertaken on 
zeta potential, entrapment efficiency, and drug loading. Madheswaran et al. (2015) 
used monoolein to produce dutasteride nanoparticles, with their surface modified 
using different concentrations of chitosan (low molecular weight) to give a positive 
charge.  The particle size was 239 - 259 nm, with mean zeta potential of +19.8 to 
+48.5 mV. The surface modified liquid crystalline nanoparticles enhanced 
transdermal delivery of dutasteride and increased the permeation of dutasteride using 
a porcine skin (700 – 800 µm thickness). Release studies on this formulation 
produced the cumulative amount of dutasteride released only about 5% after 24 h. 
The highly lipophilic nature of dutasteride, which had a stronger interaction with 
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lipid inside the nanoparticles produced slower release compared to finasteride 
(Madheswaran et al., 2015). 
 
Table 1.1 Published studies on the delivery of dutasteride using different types 
of nanocarriers 
Delivery system Particle Size Application Authors 
Liposome 1.82 ± 0.15 μm Topical for 
dermal 
delivery 
Sharma et al. 
(2011) 
Eudragit E® nanoparticles 62.2 – 180.6 nm Oral Park et al. 
(2013) 
Hydroxypropyl- 
β-cyclodextrin nanostructures 
<160 nm Oral Kim, (2013) 
Self-microemulsifying drug 
delivery system (SMEDDS) 
43.9 nm Oral Kim et al. 
(2015) 
Self-microemulsifying drug 
delivery system (SMEDDS) 
35.3 nm Oral Choo et al. 
(2013) 
Nanoemulsion 58.8 – 88.7 nm Topical for 
systemic 
delivery 
Sajid et al. 
(2014) 
Liquid crystalline nanoparticles 197.9 ± 2.5 nm Topical for 
dermal 
delivery 
Madheswaran 
et al. (2015) 
 
1.9 Positively-charged nanoparticles 
Nanoparticles having a positive surface charged have received great interest 
in drug delivery, especially for topical and transfollicular delivery, where hair and the 
lipid layer in the SC contain high ratio of negatively-charged lipids (Bhushan, 2010; 
Madheswaran et al., 2015). For instance, the anionic surfactant is often added in 
shampoos to remove grease from the hair. The surfactant has two different regions; 
one region is soluble in water (hydrophilic) and the other region is soluble in the 
greasy material (lipophilic). The lipophilic/hydrophobic part will encircle the greasy 
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matter, and the other part (negative-charged) will repel the fibres because hair fibres 
are negatively-charged, and remove the greasy material easily. 
On the other hand, cationic surfactants are normally added to hair 
conditioners to neutralise the charge of hair after washing. Based on this, many 
studies on positively-charged nanoparticles have been undertaken in order to promote 
interaction with the negative target site, especially for dermal/transdermal and 
transfollicular delivery (Şenyiǧit et al., 2010; Gelfuso et al., 2011; Ridolfi et al., 
2012; Özcan et al., 2013; Madheswaran et al., 2015). 
1.10 Chitosan 
Chitosan is a natural polymeric material being used increasingly by the 
pharmaceutical industry. It contains free amine groups, and this makes it is insoluble 
in water (water-soluble only at pH<6) (Sogias et al., 2010).  Chitosan oligomers or 
chitosan oligosaccharide (Figure 1.15) are the hydrolysates of chitosan, mainly made 
up of -1,4 linked D-glucosamine and partially of -1,4 linked N-acetyl-D-glucosamine 
(Ibrahim et al., 2016). Chitosan oligomer has been used widely for different 
bioactivity such as antibacterial (No et al., 2002; Merchant et al., 2014; Yildirim-
Aksoy and Beck, 2017), antitumour activity (Jeon and Kim, 2002; Hu et al., 2009; 
Xie et al., 2012), anti-cancer activity (Nam et al., 2007a; 2007b), wound healing 
activity (Kang et al., 2016) and antioxidant activity (Sun et al., 2007). 
 
 
 
 
 
 
Figure 1.15 Structure of chitosan oligomer 
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In this project, chitosan oligomer (Carbosynth Ltd, United Kingdom) with 
molecular weight less than 3 kDa and 85% deacetylation degree was chosen. This 
chitosan is positively charged, which is likely to be advantageous for skin and hair,  
such skin and hair are negatively charged and will be attracted to positively charged 
moieties (Bhushan, 2010). Mittal et al. (2015) demonstrated that a nanoparticle 
formulation of antigen ovalbumin with chitosan increased follicular uptake when 
compared to a nanoparticle formulation without chitosan.  
1.10.1 Hydrophobic derivatives of chitosan  
Table 1.2 shows the potential delivery of drugs by using different types of 
chitosan conjugated with a hydrophobic chain (fatty acid). From Table 1.2, it can be 
seen that chitosan conjugated with fatty acid has been employed in many areas using 
nanoparticles and micellar systems. 
 
Table 1.2 Chitosan conjugation with different type of fatty acids and their 
application 
Delivery system Chitosan and Fatty acid Application Authors 
Micelles Chitosan 18 kDa and 
stearic acid 
Brain targeting Xie et al. (2012) 
Immobilization Chitosan LMW and lauric 
acid 
Osteoblast 
proliferation and 
antibacterial 
Zhao et al. (2014) 
Micelles Chitosan 5 kDa and stearic 
acid 
Oral delivery Li et al. (2010) 
Micelles Chitosan 9.2 kDa and 
stearic acid 
Anti-tumour 
activity 
Hu et al. (2009) 
Nanoparticles Chitosan 9.2 kDa and oleic 
acid 
Optical 
MR/Imaging 
Lee et al. (2011) 
Micelles Glycol chitosan  different 
MWs with palmitic acid 
(GCPQ) 
Oral, ocular, 
parenteral 
Uchegbu et al. 
(2014) 
 
Chapter 1  Introduction 
 47   
 
The surface activity of chitosan (non-conjugated) is low as it does not possess 
any hydrophobic portions and can be improved by chemical modifications at its 
glucosidic group with a hydrophobic substituent (Cheung et al., 2015). Szymańska 
and Winnicka (2015) reported chemical crosslinking with chitosan as a strategy to 
increase the stability of chitosan, whereby the stability of modified chitosan was 
based on the covalent bonds, and also interactions—hydrogen or hydrophobic bonds.  
 Xie et al. (2012) prepared chitosan oligosaccharide (MW 18 kDa) conjugated 
with stearic acid (CSO-SA) for brain targeting. The blood-brain barrier (BBB), 
makes it difficult for the drug to penetrate, however, the delivery of doxorubicin in a 
CSO-SA micellar system was beneficial. The micellar system (22 nm sizes; zeta 
potential +36 mV) demonstrated high drug loading and a slow release pattern. High 
amounts of doxorubicin were found in the brain and low amounts accumulated in the 
heart. This result was due to the ability of micelles to transport across the blood-brain 
barrier and into the brain (Xie et al., 2012). The lower toxicity of CSO-
SA/doxorubicin micelles than doxorubicin in solutions might be relevant with a slow 
release of doxorubicin from micelles (Xie et al., 2012). 
1.11 Nanoparticulate dermal drug delivery 
Topical application of drugs has many advantages especially reducing 
systemic effects and targeting affected local areas, such as for skin diseases. The 
stratum corneum (SC) provides the main barrier function of skin, limiting the loss of 
essential substances from inside the body and reducing chemically or toxic materials 
entering the body (Trommer and Neubert, 2006). Even though the drug in the 
formulation for hair loss therapy should ideally target the transfollicular region, drugs 
will also likely permeate through the dermal or transdermal regions which represent 
the main permeation pathways. Due to the limited permeability of the SC (the drug 
should be in low molecular weight and moderate lipophilicity), several methods have 
been employed to enhance the delivery of the drugs to the skin. These include 
chemical permeation enhancers such as fatty acids, urea, phospholipids, alcohols, 
amide, and sulfoxides and physical permeation enhancement such as iontophoresis, 
sonophoresis, ultrasound and microneedles (Finnin and Morgan, 1999; Pathan and 
Setty, 2009; Akhtar et al., 2011; Shaji and Varkey, 2012). 
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Other skin penetration enhancers, more recently investigated are micro or 
nanoscale size drug formulations, such as liposomes, polymeric nanoparticles, 
nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers (Müller et 
al., 2002; Sintov and Shapiro, 2004; Guterres et al., 2007; Escobar-Chávez et al., 
2012; Wang et al., 2012; Gomes et al., 2014). Mahe et al., (2009) found the particles 
of approximately 200 nm mean sizes applied to the skin were found around the hair 
follicles. Further studies reported that particles with a size approximately 300 nm 
were found in the transfollicular region (Mittal et al., 2015). These studies suggest to 
deliver the drug into the hair follicle regions, a size of particles in the range of 200-
300 nm is appropriate.  
1.11.1 Liposomes 
Liposomes, sphere-shaped vesicles with mean size 30 nm to several 
micrometres, produced by self-forming enclosed lipid bilayers upon hydration 
consisting of one or more phospholipid bilayers, were first described in the mid-60s 
(Akbarzadeh et al., 2013). Liposome formulations consist of one or more non-toxic 
natural phospholipids such as soy phosphatidylcholine and egg phosphatidylcholine 
or a synthetic phospholipid such as distearoyl-phosphatidylcholine (Figure 1.16).  
 
 
 
 
 
 
Figure 1.16 Schematic representation of a liposome, showing the location of 
entrapped drugs (redrawn from Lembo and Cavalli, 2010) 
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Liposomes differ based on the different type of phospholipid used, lipid 
composition, method of preparation, surface charge, lamellarity and size (Du Plessis 
et al., 1994). Liposomes have a characteristic Tc (phase transition temperature), at 
which the liposome membranes transit from the gel phase to liquid crystalline phase, 
and the encapsulated drugs are released from the vesicles (Li et al., 2015). The Tc 
depends on the nature of the polar head group, the length of the hydrocarbon chains, 
the degree of saturation of the hydrocarbon chains and the purity of phospholipids (Li 
et al., 2015). In liposomes system, hydrophobic drugs will be encapsulated in the 
hydrophobic region of the phospholipid bilayers whereas hydrophilic drugs will be 
entrapped in the aqueous core and between bilayers. The ‘rigidity’ or ‘fluidity’ and 
the charge of the bilayer of the liposome are dependent on the bilayer components 
(Akbarzadeh et al., 2013). 
Liposomes have been widely used for dermal and transfollicular delivery of 
drugs. Du Plessis et al. (1994) found that the particle size influenced the deposition 
of drugs in the skin, for a liposome preparation containing ciclosporin as a model 
drug. They found the intermediate particle size (0.3 µm) studied resulted in the 
highest amount of drug in the deeper skin strata and the receiver chamber for both 
hamster and hairless mouse skin except the pig skin after 24 h using Franz diffusion 
cells. The same was not seen for pig skin because of the lipophilic nature of both 
ciclosporin and the pigskin with the release of ciclosporin to the receiver retarded 
(Du Plessis et al., 1994). 
Esposito et al. (1998) found the permeability of a liposome preparation of 
methyl nicotinate through a synthetic membrane was influenced by the charged 
particles, a higher amount of phosphatidylcholine, the smaller size of particles and 
also the higher viscosity of the samples. In the case of the non-extruded sample, the 
permeability was affected by the vesicle size, where smaller size increased the 
permeability rather than the viscosity. However, for extruded samples, the 
permeability was affected by the viscosity of the formulation. 
Flexible liposomes, which are mixtures of lipids and surfactants have been 
studied in order to penetrate the SC (Cevc et al., 1998; Ogunsola et al., 2012). Cevc 
et al. (1998) prepared flexible liposomes, called as Transferosomes® containing 
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soybean phosphatidylcholine, sodium cholate and biocompatible surfactants 
produced liposome dispersion that passed through a filter of much smaller pore size.  
Another study conducted by Ogunsola et al. (2012) prepared flexible 
liposomes with egg phosphatidylcholine and Tween 80 or sodium cholate or ethanol 
with the mean size range from 74 – 110 nm that passed through the filter with 50 nm 
pore size.  In vitro penetration studies found that fluorescent-tagged lipid to 
liposomes with a higher amount of Tween 80 (60 or 68%) showed penetration of 
fluorescent-tagged lipid flexible liposomes into the epidermis of hairless guinea pig 
and excised human skin.  
Although liposomes have been used for drug delivery to reduce the toxicity of 
drugs, increase efficacy and stability and site-specific drug delivery, there are also 
some disadvantages. Conventional liposomes have poor drug loading capacity, poor 
stability, production costs are high, and the use of volatile solvents are required in 
their preparation. 
1.11.2 Polymer-based carrier for drug delivery 
Figure 1.17 shows different types of the polymer-based carrier for drug 
delivery. Hydrogels are produced by a group of polymeric materials having a 
hydrophilic structure which is capable of holding large amounts of water in their 
three-dimensional networks (Ahmed, 2015). Drugs can be loaded into the gel matrix 
and the drug release rate is dependent on diffusion of the small molecule or 
macromolecule through the gel network (Hoare and Kohane, 2008). Many studies 
have reported incorporation of nanoparticles or microparticles into a hydrogel in 
order to improve dermal delivery. Bhaskar et al. (2009) produced flurbiprofen loaded 
SLNs or NLCs (average particles sizes of less than 300 nm) incorporated with a 
hydrogel and found that sustained drug release over a period of 24 h was higher with 
the SLNs and NLCs hydrogel compared to SLNs and NLCs without hydrogel.  
Biodegradable polymers such as poly(D,L-lactic acid) (PLA), poly(D,L-
lactic-co-glycolic acid) (PLGA), and poly (ε-caprolactone) (PCL) and their 
copolymers diblock or multiblock with poly(ethylene glycol) (PEG) have been 
commonly used to form polymeric nanocarriers (polymeric micelles, capsules, 
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spheres) in order to encapsulate a variety of therapeutic compounds (Chan et al., 
2010). Polymeric nanocarriers such as micelles are formulated by self-assembly of 
block copolymers consisting of two or more polymer chains with different 
hydrophobicities (Chan et al., 2010) such amphiphilic polymers which have both 
hydrophilic blocks and hydrophobic blocks can be used for drug delivery where 
normally the hydrophobic blocks form the core to minimize their exposure to 
aqueous surroundings  (Chan et al., 2010; Trivedi and Kompella, 2010).  
 
 
 
 
 
 
 
 
Figure 1.17 Different structures of nanocarriers (redrawn from Janssen et al., 
2014) 
 
Nanospheres (matrix system) or nanocapsules (reservoir system) are both in 
the polymeric nanoparticle group. Nanocapsules are polymeric nanoparticles 
containing either an oily or aqueous core surrounded by a polymeric shell 
(combination with a mixture of lipophilic and hydrophilic surfactants), whereas 
nanospheres are polymer-only matrix systems (Elmowafy et al., 2017). Nanospheres 
and nanocapsules are able to modify the activity of drugs, sustain and control drug 
release, and increase the drug adhesivity in the skin (Guterres et al., 2007).     
Elmowafy et al. (2017) reported indomethacin loaded into polymeric 
nanocapsules and nanospheres produced a higher cumulative amount of drug in 
human skin compared to a marketed product (indomethacin in gel) at 24 h. They 
= drug 
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found significantly higher skin permeation from nanocapsules of indomethacin 
compared to nanospheres. Even though nanocapsules had a larger particle size (186 – 
193 nm) than nanospheres (138 - 142 nm), higher permeability was attributed to 
higher nanocapsules deformability than nanospheres (rigid matrix system).  
Biodegradable, natural polymers are the first choice materials for producing 
polymeric nanoparticles, in order to minimise toxicity. In some studies, investigators 
have developed new compounds for nanoparticle production by conjugating the 
polymer with drugs especially for tumour targeting (Dragojevic et al., 2015). 
Ringsdorf (1975) introduced a model for pharmacologically active polymers, 
consisting of a biocompatible polymer backbone bound to three components; 
solubilizer, drug which is bound to the polymeric backbone via a linker, and a 
targeting moiety whose function is to provide transport to a desired physiological 
destination or to bind to a particular biological target (Larson and Ghandeharia, 
2012). Castleberry et al. (2017) prepared all-trans retinoic acid conjugated with 
polyvinyl alcohol and produced sustained controlled delivery of active up to 10 days 
and significantly increased dermal accumulation of the all-trans retinoic acid in the 
pig skin. Polymer-conjugated drugs generally exhibit prolonged half-life, higher 
stability, water solubility, lower immunogenicity and antigenicity and often also 
specific targeting to tissues or cells (Pasut and Veronese, 2007).  
The disadvantages of polymeric nanoparticles are the need for the approval 
by regulatory authorities on the safety issues, and also their high production costs 
(Bala et al., 2004). 
1.11.3 Lipid nanocarriers 
There are different types of lipid nanocarriers used for drug delivery system. 
Nanoemulsions comprise liquid mixtures of oil, water, surfactant and sometimes a 
co-surfactant having a droplet size in the range of 50 - 200 nm (Kong et al., 2011).  
In terms of production, the concentration of surfactant used is much lower (3-10%) 
compared to microemulsion preparation (more than 20%) (Bouchemal et al., 2004). 
Borges et al. (2013) found a dapsone-loaded nanoemulsion with isopropyl myristate 
as the oil phase promoted high in vitro epidermal permeation using Franz cells on 
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porcine ear epidermis. Hussain et al. (2016) formulated an amphotericin B-loaded 
nanoemulsion (mean droplet size 76 nm) and found a higher skin percutaneous 
permeation flux rate through rat skin as compared to drug solution using Franz 
diffusion cell. Amphotericin B in solution showed the highest release at 2 h, while 
amphotericin B-loaded nanoemulsion gel showed slower release compared to 
amphotericin B loaded-nanoemulsion alone. However, there are some disadvantages 
of nanoemulsions such as limited controlled release properties due to the liquid state 
of the carrier (Martins et al., 2007).  
A second type of lipid-based nanocarriers is solid lipid nanoparticles (SLNs).  
In the 1990s, these were introduced as drug carrier system (Müller et al., 2002), and 
produced by replacing the liquid lipid (oil) of an emulsion by solid lipids or a blend 
of solid lipids (Müller et al., 2007). SLNs have a mean particle size of between 50 
and 1000 nm (nanoparticles) (Müller et al., 2000). SLNs have been produced for 
pharmaceutical, traditional Chinese medicine and cosmetic applications. SLNs have 
been used to deliver bioactive ingredients such as vitamin A (Jenning et al., 2000), 
rifampicin, isoniazid and pyrazinamide (Pandey and Khuller, 2005), oridonin  (Zhang 
et al., 2006), isotretinoin (Liu et al., 2007), Artemisia arborescens essential oil (Lai et 
al., 2007), repaglinide (Vijayan et al., 2010), virgin coconut oil (Noor et al., 2013), 
docetaxel (Naguib et al., 2014) and olanzapine (Iqbal et al., 2017). Different methods 
have been proposed in order to produce SLNs including high-pressure homogeniser, 
solvent evaporation, ultrasonication or melt dispersion techniques (Gasco, 1993; 
Müller et al., 2000; Trotta et al., 2003).   
The second generation of SLNs is called as nanostructured lipid carriers 
(NLCs). NLCs are produced by incorporating blends of solid lipids and liquid lipids 
(oils) (Pardeike et al., 2009). Some examples of liquid lipid used in NLCs production 
are medium chain triglyceride such as oleic acid. Figure 1.18 shows the structural 
differences between SLNs and NLCs. Due to the main ingredients in SLNs being 
solid lipid (at room temperature), SLNs are in a highly crystalline form, limiting drug 
loading, whereas NLCs (combination of solid and liquid lipid) have a less crystalline 
structure, increasing drug loading. NLCs were introduced in order to overcome some 
of the problems associated with SLNs by increasing drug loading and reducing the 
burst release of drugs (Wissing and Müller, 2002; Hommoss, 2008; Silva et al., 
2009). The mean particle size for NLCs is usually less than 1000 nm. 
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Figure 1.18 Schematic illustration of SLN and NLC structures (modified from 
Beloqui et al., 2016)  
 
Several different types of solid lipid can be used in the production of SLNs 
and NLCs. The term ‘solid lipid’ includes fatty acids (e.g. myristic, stearic and 
palmitic acid), triglyceride (e.g. tripalmitin and tristearin), diglyceride (e.g. glyceryl 
behenate), monoglyceride (e.g. glyceryl monostearate), steroid (e.g. cholesterol) and 
waxes (e.g. cetyl palmitate and beeswax). Lipids used in SLNs or NLCs are generally 
regarded as safe (GRAS) (Attama et al., 2012). Different types of solid lipid have 
various degrees of crystallisation that may impact the drug entrapment efficiency and 
loading, size and charge of the resulted carriers. The lipid particle matrix is solid at 
both room and body temperatures (Müller et al., 2014).  
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1.12 Aim of the study 
The aim of this project is to prepare and characterise dutasteride-loaded 
nanostructured lipid carriers (DST-NLCs), coated with chitosan oligomer conjugated 
with stearic acid, and lauric acid to enhance local drug delivery and reduce toxicity 
(Figure 1.19).  
 
 
 
 
 
 
 
 
  
 
 
Figure 1.19 Schematic representation of DST-NLCs coated with CSO-SA or 
CSO-LA to be prepared and characterised in this project 
 
Figure 1.20 shows the flow of the project outlined in this thesis. The project 
began with the conjugation and characterisation of CSO-SA and CSO-LA (Chapter 
2). This was followed by optimisation of the formulation and manufacture of 
nanoparticles containing dutasteride and their characterisation (Chapter 3) and the in 
vitro studies (Chapter 4). Dutasteride was chosen as a drug having anti-androgenic 
activity, exhibiting Type I and Type II 5α-reductase inhibitions.  
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Figure 1.20 Schematic diagram of overall preparation, characterisation and in 
vitro study of dutasteride-loaded nanostructured lipid carrier coated with 
chitosan oligomer-stearic or lauric acid 
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Moreover, the fatty acid used in the conjugation and DST-NLCs preparation 
also has 5α-reductase inhibitor activity and may promote hair growth. The hypothesis 
of this project is that modifying the surface of NLCs with chitosan conjugated with 
CSO-SA or CSO-LA will enhance the stability of nanoparticles, delivery and safety 
of dutasteride. Delivering the NLC-drug system by topical application is 
hypothesised to enhance the retention of drug in the skin due to the particles’ positive 
charge, achieve slow drug release, reducing toxicity and irritation. 
1.13 Objectives of study 
In order to achieve the aim of the study, the specific objectives of the study are as 
follows: 
(i) To synthesis chitosan oligomer with stearic or lauric acid  
(ii) To develop, optimise and characterise DST-NLCs, uncoated and coated with 
chitosan oligomer-stearic or lauric acid, based on particle size distribution, 
surface charge, entrapment efficiency, drug loading, morphology, crystallinity 
and viscosity 
(iii) To determine in vitro drug release of DST-NLCs, uncoated and coated with 
different concentrations of chitosan oligomer-stearic or lauric acid 
(iv) To determine in vitro drug permeation through pig ear skin of DST-NLCs, 
uncoated and coated with chitosan oligomer-stearic or lauric acid 
(v) To investigate cell cytotoxicity and proliferation for hair follicle dermal 
papilla cells of DST-NLCs, uncoated and coated with chitosan oligomer- 
stearic or lauric acid  
(vi) To investigate skin irritation of DST-NLCs, uncoated and coated with 
chitosan oligomer-stearic or lauric acid using 3D Epiderm™ SIT tissue 
(vii) To formulate and develop Cou-6-loaded NLCs, uncoated and coated with 
chitosan oligomer-stearic or lauric acid (coumarin-6 as a model drug) 
(viii) To investigate cell and skin uptake using Cou-6-loaded NLCs uncoated and 
coated with chitosan oligomer-stearic or lauric acid 
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2.1 Conjugation of chitosan oligomer with stearic acid (CSO-SA) 
2.1.1 Introduction 
In this project, dutasteride was encapsulated in nanostructured lipid carriers 
(NLCs) which were then coated with chitosan oligomer-stearic acid, with the aim of 
increasing the stability of nanoparticles, sustaining the release of the drugs at the 
targeted area and prolonging the drug’s residence in the epidermis/dermis layer of the 
skin. In this chapter, chitosan oligomer and stearic acid were chosen as a 
biodegradable polymer and lipid respectively, for conjugation. The experiments were 
designed in order to obtain the highest degree of substitution for use as a coating 
material. The independent variables were the different amount of stearic acid, 
different ratio of stearic acid and coupling reagent (1-ethyl-3-(3-(dimethylamino) 
propyl) carbodiimide, EDC) and different duration of reactions. The degree of 
substitution (%DS) was chosen as a dependent variable in order to calculate the 
amount of amine group substituted in the chitosan oligomer conjugated with stearic 
acid.  
2.1.2 Materials 
Stearic acid (purity > 98%) and lauric acid (purity > 98%) were purchased 
from the Tokyo Chemical Industry (TCI, UK). Chitosan oligomer (CSO) with 
molecular weight less than 3000 Da (deacetylation >85%) was obtained from 
Carbosynth Ltd (UK). Ethanol (96% v/v analytical grade), 1-(3-
dimethylaminopropyl)-3- hydrochloride (EDC.HCl), acetic acid-d4 (99.9 atom %D), 
ninhydrin, D-glucosamine, sodium acetate anhydrous (purity > 99%) and pyrene for 
fluorescence, ≥99.0% were obtained from Sigma-Aldrich Company Ltd (UK). 
Deuterium oxide (99.9 atom %D) was purchased from Cambridge Isotope Lab Inc 
(USA). Acetic acid glacial (analytical reagent) and acetone were purchased from 
Fisher Scientific (UK). Deionised water (PURELAB Option, ELGA, UK) was 
obtained on site from a water system. 
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2.1.3 Synthesis of chitosan oligomer-stearic acid (CSO-SA) 
The free amine group of chitosan oligomer (CSO) was conjugated with the 
carboxyl group of the fatty acid in stearic acid (SA) using 1-(3-dimethyl 
aminopropyl)-3-ethyl carbodiimide hydrochloride (EDC.HCl) as a coupling reagent 
(Figure 2.1; Hu et al. (2009) and Xie et al. (2012)). Due to the long hydrocarbon 
chain, stearic acid has 5α-reductase inhibitory activity, though less potent than 
shorter chain hydrocarbons (Liu et al., 2009). This strategy would provide potential 
inhibition activity and a synergistic effect at higher concentration when combined 
with dutasteride.  
   
                                                                          
 
 
 
 
 
 
 
 
Figure 2.1 Conjugation between chitosan oligomer and stearic acid 
 
The hydrophobic region in chitosan oligomer-stearic acid would be expected 
to produce self-assembled nanoparticles in the aqueous phase. This would also result 
in more stable particles when coating the nanoparticles compared to chitosan 
 
80°C 
For 6 or 24 hours 
Stearic acid-EDC.HCl 
Chitosan oligomer-stearic 
acid (CSO-SA) 
Chitosan oligomer 
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oligomer without conjugation because the surface activity of chitosan (non-
conjugated) is low due to the absence of hydrophobic portions (Cheung et al., 2015).  
CSO (1 g) was dissolved in 120 mL of deionised water using magnetic stirrer 
for 2 h at 80°C on a hot plate. On another hot plate, SA (0.5 or 1.0 g) was dissolved 
in ethanol (80 mL), heated at 60°C with constant stirring. SA solutions were then 
activated with EDC.HCl (1.68 or 3.37 g; molar ratio SA: EDC.HCl; 1:5 or 1:10) and 
stirred for 2 h at 60°C. The solutions of SA were added using a syringe with a needle 
(25 gauge, 5/8th inch, BD Microlance™ 3, Becton Dickinson, Spain) into the CSO 
solutions with continuous magnetic stirring for 6 or 24 h. To remove the unreacted 
EDC.HCl and SA in the solutions, dialysis (molecular weight size cut off 1000 Da, 
Spectrum Laboratories, USA) was undertaken. The product was evaporated to reduce 
volume (final volume is approximately 70 mL) under vacuum using rotary 
evaporator (Rotavapor® R-100, Buchi, Switzerland) at 70°C. After dialysis for two 
days, the product was precipitated using 300 mL acetone and filtered using filter 
paper (Fisherbrand QL100, Fisher Scientific, UK) to obtain the product. The product 
was dissolved in 10 mL of water and precipitated again with 300 mL acetone. This 
step was repeated for a further two times. Finally, the sample was stored in a 
desiccator prior to use.  
The conjugation between chitosan oligomer and stearic acid was investigated 
using a design of experiments approach (Design Expert 6.0.8 Software, Stat-Ease, 
USA). The independent variables were the ratio of SA to EDC.HCl, time of reaction 
and the amount of SA used. The dependent variable selected was the degree of 
substitution (%DS). %DS was calculated in order to determine the amount of amine 
groups substituted with the stearoyl chain. Table 2.1 shows the design of experiments 
for the synthesis, while the coded and value for the design of experiment are shown 
in Table 2.2. 
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Table 2.1 Design of experiments for preparing CSO-SA using a 2
3
 full factorial 
design 
Product SA: EDC.HCl Time (h) Stearic acid 
(mg) 
S1 1:5 6 0.5 
S2 1:10 6 0.5 
S3 1:5 24 0.5 
S4 1:10 24 0.5 
S5 1:5 6 1.0 
S6 1:10 6 1.0 
S7 1:5 24 1.0 
S8 1:10 24 1.0 
 
Table 2.2 Value and coded units of the 2
3
 full factorial design for conjugation of 
chitosan oligomer with stearic acid 
Variables Coded Level 
Low (-1) High (+1) 
Molar ratio SA:EDC.HCl  A 5 10 
Time of reaction (hours) B 6 24 
Stearic acid (mg) C 0.5 1.0 
 
2.1.4 Characterisation of chitosan oligomer-stearic acid (CSO-SA) 
2.1.4.1 Characterisation of chitosan oligomer-stearic acid using 1H NMR  
In order to confirm the presence of the fatty acid chain in the chitosan 
oligomer conjugate, samples were characterised using proton nuclear magnetic 
resonance spectrometer (NMR).  The 
1
H NMR spectra of CSO, CSO-SA, and SA 
were obtained by using an NMR Bruker Avance 500 spectrometer (Bruker 
Instruments, USA). 5 mg of each sample was diluted in 1 mL deuterium oxide (D2O) 
with the addition of one drop of acetic-d3 acid-d to dissolve the product. Meanwhile, 
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stearic acid (5 mg) was dissolved in chloroform-d (CDCl3). The 
1
H NMR Bruker 
Avance 500 with 32 scans was run for all the samples, and the spectrum of each 
sample analysed. 
2.1.4.2 Characterisation of chitosan oligomer-stearic acid using Fourier 
Transform Infrared Spectroscopy (FTIR) 
Samples of CSO-SA, CSO and SA were analysed using FTIR. Approximately 
5 - 10 mg of sample was pressed on the top of the pan and four scans were obtained. 
Samples were analysed from 660 to 4000 cm
−1
 using a PerkinElmer Spectrum100 
FTIR (PerkinElmer, UK). The spectra of CSO-SA, pure CSO and SA were then 
compared.  
2.1.4.3 Determination of amine groups substitution using the ninhydrin assay 
In order to measure the amount of chitosan conjugated with stearic acid, 
ninhydrin was used as a reagent to react with the primary and secondary amine group 
in the conjugated product (Curotto and Aros, 1993). The two most common 
calorimetric assays used for the primary amines determination are ninhydrin and 
trinitrobenzene sulfonic acid (TNBS) assays. Based on the previous study (Pearce et 
al., 1988), the ninhydrin assay has advantages compared to TNBS assay. For the 
TNBS assay, the chromophore appears to be an orange colour. However, in the 
ninhydrin assay, the chromophore which is called Ruhemann’s purple is produced for 
all primary amines that react with ninhydrin and this chromophore is fully soluble 
under the conditions of that assay with no interference from yellow chromophores 
common in other products (Pearce et al., 1988). Also, the prepared buffer is 
sufficiently strong (4N sodium acetate at pH 5.5) so that the preliminary adjustment 
of the pH of the samples is not necessary (Moore and Stein, 1954). 
For this study, 4M acetate buffer (pH 5.5) was used to maintain the conditions 
of the reaction. Generally, in this assay, the reagent changes colour from yellow to 
purple if there is a free amine group in the product after a certain time and at high 
temperature (Figure 2.2). Theoretically, in this study, when the chitosan oligomer 
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reacts with stearic acid, the amine groups are replaced with a fatty acid chain with a 
reduction in intensity of the purple colour. 
 
    
                                                                                                 
 
 
  
 
 
 
 
Figure 2.2 Ninhydrin assay: Reaction of ninhydrin reagent with amine groups 
from CSO or CSO-SA or CSO-LA (colour of ninhydrin changes from light 
yellow (left) to purple (right)) 
 
The percent of free amine groups present in the CSO-SA conjugate was 
determined using the ninhydrin assay by comparing the gradients of the slopes 
(absorbance versus concentration) produced for D-glucosamine, CSO and conjugated 
CSO. Serial dilution of glucosamine, CSO and CSO-SA (stock solution: 2000 
µg/mL) were prepared in 0.2% acetic acid solution. The working solutions for CSO 
and CSO-SA were 100, 60, 40 and 20 µg/mL. Ninhydrin solution was prepared by 
dissolving 0.35g of ninhydrin in 100 mL ethanol.  4M acetate buffer was prepared by 
dissolving 32.82 g of sodium acetate anhydrous in 60 mL deionised water and 22.82 
mL acetic acid made up to 100 mL with deionised water after complete dissolution. 
90°C 
15 min 
Ninhydrin reagent 
(yellow) 
Amine groups from 
CSO or CSO-SA 
 
Purple pigment 
Before After 
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The reaction was achieved by adding 0.5 mL of sample, 0.5 mL of 4M acetate 
buffer and 2 mL of ninhydrin solution into a 10 mL volumetric flask and heating at 
90°C in a water bath with stirring for 15 min. 4M acetate buffer was used to maintain 
the reaction. After 15 min, the volumetric flask was taken out from the water bath 
and cooled down to room temperature. The solution was then made up to 10 mL with 
ethanol. The absorbance of samples was measured at 570 nm using an Agilent Cary 
100 UV-Vis Spectroscopy (Agilent Technologies UK Ltd. Berkshire, UK). The 
amount of free amine groups in glucosamine, CSO and CSO-SA samples was 
determined by comparing the slopes using linear regression, where the absorbance 
(y) for each sample were plotted as a function of concentration (x).  
2.1.5 Statistical analysis 
The % degree of substitution of all synthesised CSO-SA were analysed using 
Design Expert 6.0.8 Software (Stat-Ease, USA). A p-value of less than 0.05 was 
considered significant.  
2.2 Conjugation of chitosan oligomer with lauric acid (CSO-LA) 
2.2.1 Introduction 
In order to determine the effect of chain length of the conjugated chitosan 
oligomer on the stability, mean particle size, and the proliferation of the hair follicle 
dermal papilla, lauric acid as a medium chain fatty acid was chosen for conjugation 
with chitosan oligomer. Lauric acid previously showed good inhibition of androgenic 
activity and also has an inhibitory effect on lymph node carcinoma of the prostate 
cancer (LNCaP) cells (Liu et al., 2009). As the melting point of lauric acid is 
relatively low (43.8°C) compared to stearic acid (69.3°C), formulating lauric acid 
into solid lipid nanoparticles or nanostructured lipid carriers system may be difficult. 
Liu and Wu, (2010) prepared lutein loaded-NLCs formulation with lauric acid as a 
solid lipid and found unstable NLCs formulation even at day 1. Due to that, by 
conjugating lauric acid with chitosan oligomer and acts as a coating material for 
NLCs, it would help to deliver lauric acid in the nanocarrier system to be delivered to 
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the skin. Having lauric acid conjugated with CSO may inhibit the 5α-reductase 
enzyme and promote hair growth. The conjugation between chitosan oligomer and 
lauric acid was performed using the methodology described in 2.1.3. The degree of 
substitution (%DS) was determined in order to calculate the amount of amine group 
substituted in the chitosan oligomer conjugated with lauric acid. 
2.2.2 Synthesis and characterisation of chitosan oligomer-lauric acid (CSO-
LA) 
The conjugation between chitosan oligomer and lauric acid was performed 
using the methodology described in Section 2.1.3. The amount of materials used in 
the conjugation between CSO and lauric acid was obtained from the optimised ratio 
from the previous conjugation; CSO (1 g) was conjugated with SA: EDC.HCl (0.5 g 
SA and 1.68 g EDC.HCl) for 6 hours. The characterisation of CSO-LA using 
1
HNMR, FTIR and the %DS was undertaken using the method described in Sections 
2.1.4.1, 2.1.4.2 and 2.1.4.3, respectively. 
2.3 Preparation and characterisation of selected CSO-SA or CSO-LA micelles  
CSO-SA or CSO-LA micelles were prepared by dissolving 5 mg/mL of CSO-
SA into 0.2% v/v acetic acid in water. The sample was bath sonicated for an hour in 
order to dissolve completely. Samples were prepared in triplicate. 
2.3.1 Measurement of particle size distribution of selected CSO-SA or CSO-
LA micelles 
Dynamic light scattering (DLS) determines the mean size of particles 
(hydrodynamic diameter) undergoing Brownian motion and estimates the width of 
the distribution (polydispersity index). When a laser passes through the dispersion, 
the intensity of the scattered light fluctuates depending on the size of particles. The 
small particles diffuse faster which results in the intensity fluctuating more rapidly 
compared to the larger sizes in the dispersion. Hydrodynamic diameter is calculated 
from the translational diffusion coefficient using the Stokes-Einstein equation with 
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the assumption that all particles are spherical in shape, while polydispersity index 
(PDI) is the measurement of the heterogeneity of size distribution in a mixture. 
Samples were analysed using dynamic light scattering (DLS) equipment 
(Zetasizer Nano ZS, Malvern Instruments, UK) for determination of the particle size 
distribution. 1 mL of the sample was pipetted directly into the zeta potential 
DTS1070 folded capillary cell (Malvern, UK) without dilution at 25°C. The size 
distribution of micelles was obtained as the hydrodynamic diameter (ZAve) and 
polydispersity index (PDI). The measurement was performed in triplicate, and mean 
values were taken.  
2.3.2 Measurement of zeta potential of selected CSO-SA or CSO-LA micelles 
In order to measure the surface charge of the micelles, zeta potential (ZP) was 
measured using the Zetasizer Nano ZS (Malvern Instruments, UK). This equipment 
uses electrophoretic light scattering technology to measure zeta potential, calculated 
from electrophoretic mobility using the Helmholtz-Smoluchowski equation by the 
Malvern data analysis software.  
1 mL of the sample was pipetted directly into the zeta potential DTS1070 
folded capillary cell (Malvern, UK) without dilution. The measurements were 
recorded at 25ºC. The prepared formulation was analysed without further dilution, 
and the measurement was performed 3 times, and the average values were recorded.  
2.3.3 Determination of micelles morphology by transmission electron 
microscope  
The morphological observation of 5 mg/mL of CSO-SA and CSO-LA 
micelles was determined using a transmission electron microscope (TEM; 
Philips/FEI CM120 Bio Twin, FEI Netherlands). Samples were placed on copper 
grid formvar/carbon support film 300 mesh (Agar Scientific, Stansted, Essex, UK), 
and excess droplets were blotted with filter paper. After a few seconds, a drop of 1% 
uranyl acetate was placed onto the copper grid for negative staining. The grid was 
air-dried at room temperature and observed using TEM.  
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2.3.4 Measurement of critical micelle concentration (CMC) using UV 
spectrophotometer of selected CSO-SA and CSO-LA 
In order to determine whether CSO-SA and CSO-LA coated nanoparticles 
exist as micelles or monomers in water, a study on CMC was conducted. CMC of 
final CSO-SA and CSO-LA were performed in order to determine the minimum 
concentration of product that can produce a micellar system. CMC was performed 
based on a previous method (Tanhaei et al., 2013) with slight modification. CMC is 
determined by a sudden change in the related physical properties upon micelle 
formation (Tanhaei et al., 2013).  In this study, pyrene was used as a probe.  
CSO-SA or CSO-LA micelles were diluted in a serial dilution concentration 
starting from 2.5 to 0.001 mg/mL in water. Pyrene stock solution was prepared by 
dissolving 40 mg pyrene in 1 mL acetone. The pyrene stock solution was further 
diluted by transferring 100 µL to a 10 mL volumetric flask and making up to volume 
with acetone. 7 µL of pyrene was pipetted into each serial dilution of samples.  As 
pyrene is a hydrophobic probe, it will be incorporated into the hydrophobic area in 
the micellar system.  
Pyrene in acetone was scanned from 200 – 800 nm using UV-Vis 
Spectrophotometer (Agilent Cary 100, UK). Blank and samples were transferred into 
a 96-well plate (Nunc, Wiesbaden, Germany) and the absorbance was read at 334 nm 
using microplate reader (SpectraMax®M2e, Molecular Devices, USA). The value of 
CMC was determined from the absorbance versus concentration of samples plotted 
graph. The inflection point of the absorbance versus concentration of the samples 
plot was taken as the CMC of the surfactant in the corresponding pyrene solutions 
(Tanhaei et al., 2013) 
2.3.5 Statistical analysis 
Statistical analysis using Student t-test, with IBM SPSS 23 Statistic Data 
Editor Software (USA) was undertaken. A p-value of less than 0.05 was considered 
significant for all experiments. 
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2.4 Results and discussion 
2.4.1 Conjugation between chitosan oligomer and stearic acid (CSO-SA) 
2.4.1.1 1HNMR and FTIR of CSO-SA 
The formation of CSO-SA was confirmed using FTIR and 
1
H NMR. Figure 
2.3 shows the IR spectra of all samples. Compared to the spectra of raw materials 
(stearic acid and CSO), there were some changes in the IR spectrum of chitosan-
stearic acid resulting from the binding between the stearic acid carboxylic group and 
the chitosan amine group. The IR spectra for CSO (without conjugation) showed 
absorption peaks at 1620 cm
-1
 attributed to C=O stretching of the secondary amine 
(amide I band). The IR spectra of all eight products of the CSO-SA synthesis showed 
two peaks around 1636 and 1584 cm
-1
 corresponding to the N-stearoyl (attributed to 
the C=O stretching (amide I band) and N-H bending vibrations (amide II band), 
respectively). The increase of the C-H absorption around 2977 and 2855 cm
-1
 
indicated the presence of the stearoyl chain. The broad peak at around 3306 cm
-1
 
represented the -OH group from the chitosan oligomer. 
The other peak indicating the presence of carboxyl groups (-COOH) from 
stearic acid was shown around ~1699 cm
-1
. After conjugation of different amount of 
stearic acid to chitosan oligomer, the peak around 1699 cm
-1
 was reduced which 
suggested that stearic acid had reacted with chitosan oligomer. Meanwhile, the 
presence of amide band was in agreement with a previous study (Zhao et al., 2014) 
where chitosan was conjugated with fatty acid (lauric acid) and produced N-lauroyl 
bond (amide I band). They found that, the –OH bond stretching attributed from 
chitosan appeared at 3430.6 cm
-1
. Meanwhile the stretching vibration of amide I band 
was found at 1642.9, 1641.1 and 1641.0 cm
−1
 which were slightly shifted from our 
study.  
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Figure 2.3 FTIR spectra of chitosan oligomer-stearic acid from eight different 
condition of synthesis; varying ratio of SA:EDC.HCl/time of reaction 
(hours)/amount of stearic acid (g). S1 (1:5/6/0.5), S2 (1:10/6/0.5), S3 (1:5/24/0.5), 
S4 (1:10/24/0.5), S5 (1:5/6/1), S6 (1:10/6/1), S7 (1:5/24/1) and S8 (1:10/24/1.0) 
 
Figure 2.4 shows 
1
H NMR spectra for all conjugations. The chemical shifts 
represent the methyl and methylene hydrogen of the stearate group. The chemical 
shifts shown at 1.0 - 1.1 ppm represent protons from CH3 of stearic acid whereas the 
other peaks at 1.13 - 1.15 ppm corresponded to the protons of the CH2 group of the 
acyl chain. The remainder of the peaks shown are the hydrogen peaks from the 
chitosan oligomer.  
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S1 
S2 
 
 
Figure 2.4 
1
H NMR spectra of chitosan oligomer-stearic acid from eight synthesis; 
varying ratio of SA: EDC.HCl/time of reaction (hours)/amount of stearic acid (g). S1 
(1:5/6/0.5), S2 (1:10/6/0.5), S3 (1:5/24/0.5), S4 (1:10/24/0.5), S5 (1:5/6/1), S6 
(1:10/6/1), S7 (1:5/24/1) and S8 (1:10/24/1.0) 
 
 
 
Chapter 2  Conjugation of chitosan oligomer with different types of fatty acids 
 72   
 
(continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S3 
S4 
S5 
Chapter 2  Conjugation of chitosan oligomer with different types of fatty acids 
 73   
 
(continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S6 
S7 
S8 
Chapter 2  Conjugation of chitosan oligomer with different types of fatty acids 
 74   
 
These NMR results demonstrated that stearic acid was conjugated to the 
chitosan oligomer. This finding is in agreement with Xie et al. (2012) and Hu et al. 
(2009). However, both researchers used different molecular weight of CSO as a 
starting material. Xie et al. (2012) prepared CSO-SA from 18  kDa MW CSO and Hu 
et al. (2009) prepared CSO-SA with different molecular weights of chitosan (9.28 
kDa and 18.0 kDa). 
2.4.1.2 Ninhydrin assay of D-glucosamine, CSO and different samples of CSO-
SA 
A preliminary study of the ninhydrin assay was conducted on 96-well plate. 
Samples with different concentration were pipetted into a 96-well plate with buffer 
and ninhydrin solutions and placed in an oven (set up at 90°C) for 15 min. After 15 
min, the absorbance was measured using microplate reader (SpectraMax®M2e, 
Molecular Devices, USA). The absorbance reading for all samples was not consistent 
due to uneven heating in the oven. 
A further study of the ninhydrin assay was undertaken in the volumetric 
flasks. Different concentration of samples with acetate buffer and ninhydrin solutions 
were placed in 10 mL volumetric flasks at the same time in the water bath. The same 
problem occurred whereby the absorbance of the samples was found to be 
inconsistent and the graph of absorbance versus concentration of samples was not 
linear, due to uneven heating in the water bath.  
Consequently, in subsequent experiments, only one volumetric flask at a time 
was placed in the water bath which was maintained at 90°C. This protocol gave a 
consistent reading of the absorbance even though it was time-consuming. These 
showed that, the temperature of reaction in this assay was really important and slight 
changes of temperature would affect the absorbance measurement.            
The slopes for absorbance versus concentration were plotted and gradients 
calculated (Figure 2.5). The slope for chitosan oligomer (CSO) and D-glucosamine 
were 0.0126 and 0.0676, respectively (Figure 2.5). In Samples S1, S5, S6, and S7; 
the amount of free amine groups decreased due to the substitution of stearic acid. 
Samples S2, S4 and S8 showed low %DS.  
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Figure 2.5 Absorbance versus concentration from ninhydrin assay of                
D-glucosamine, CSO and different samples of CSO-SA (n=3, mean ± SD) 
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By comparing the slope from D-glucosamine, CSO and CSO-SA; the %DS of 
the synthesised CSO-SA was calculated (Table 2.3). Sample S3 showed a negative 
value of %DS. This may possibly be due to the high temperature and prolonged 
reaction time combined with low amounts of materials (SA: EDC.HCl/Time/SA-
1:5/24/0.5). By comparing the slope of CSO and D-glucosamine, CSO has 
approximately 81% of D-glucosamine and 19% of N-acetyl-D-glucosamine. These 
N-acetyl-D-glucosamine groups could be further deacetylated causing an increasing 
number of free amine groups in the final product. 
A wide range of results has been reported in previous research on the amount 
of %DS. Xie et al. (2012) reported that %DS of stearic acid conjugated with chitosan 
was approximately 27% using a TNBS assay. They used 0.7 g of SA with EDC (SA: 
EDC; 1:10 ratio) conjugated with chitosan (MW 18 kDa). The reaction between SA 
and EDC was carried out for 30 min and the reaction between chitosan and SA: EDC 
solutions were kept for 6 hours.  
Du et al. (2010) prepared different molecular weight chitosan oligomer with 
different amounts of SA at 1:10 ratio between SA and EDC. The reaction between 
chitosan and SA: EDC solutions (200 mL) were continued for 24 h. The %DS 
(TNBS assay) of conjugated chitosan oligomer with SA were found to be 
approximately 14% when they synthesised 1 g of CSO (MW = 3 kDa) with 25% SA. 
Increasing the amount of SA from 25 to 80% increased the %DS from 14 to 63%. 
On the other study, Hu et al. (2009) prepared 0.825 g stearic acid with 5.5 g 
EDC (in 17 mL ethanol) and reacted with 0.5 g CSO (in 33 mL DI water). The 
reaction between SA and EDC was done at 80°C for 4 h, and the %DS was found to 
be approximately 6.5% using TNBS assay.         
 Yuan et al. (2010) synthesised chitosan with different amount of SA. 2 g of 
chitosan (5 kDa MW) was reacted with different amounts of SA (15%, 30% or 50% 
relating to the molar number of glucosamine unit in chitosan) with ratio between SA 
and EDC was 1:10 for 24 h. Increasing the amount of SA from 15 to 50% had 
increased the %DS from 4 to 40%.  
 
  
 
 
7
7
 
 
Table 2.3 Slope, percent of free amine groups and degree of substitution based on ninhydrin assay 
 Chitosan 
oligomer  
(CSO) 
Chitosan conjugated with stearic acid (CSO-SA) 
Sample  
SA: EDC.HCl/time of reaction (hours)/ amount of stearic acid (mg) 
 S1 S2 S3 S4 S5 S6 S7 S8 
  1:5/6/0.5 1:10/6/0.5 1:5/24/0.5 1:10/24/0.5 1:5/6/1 1:10/6/1 1:5/24/1 1:10/24/1 
Slope 0.0126 0.0093 0.0117 0.0129 0.0012 0.0092 0.0093 0.0097 0.0115 
Free amine 
(%) 
81.4 86.2 82.7 80.9 82.3 86.4 86.2 85.6 83.0 
%DS  6.0 1.64 -0.55 1.09 6.18 6.0 5.27 2.0 
%DS – degree of substitution calculated by assuming the D-glucosamine slope has 100% amine groups, and the CSO and CSO-SA were 
then identified by comparing each slope (slope of D-glucosamine = 0.0676)  
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As seen for the above mentioned studies, the %DS for all synthesised 
products had different values. Variation in the amount of chitosan used with different 
molecular weight and volume of chitosan solutions, time of reaction between 
chitosan and EDC, reaction time between chitosan and SA.EDC.HCl and also the 
amount of SA and EDC used affect %DS. In this study, all the conjugated products 
produced low %DS, even though the reaction between SA and EDC.HCl was done 
for 2 h and continue for another 6 or 24 h with ratios of SA:EDC.HCl at 1:5 or 1:10. 
In order to find the optimised CSO-SA synthesised product, factorial model 
was generated using ANOVA Design Expert 6.0.8 Software (State-Ease Inc, USA) 
(Table 2.4). This software indicated there was no significant difference (p>0.05) on 
the model term with the factors used. Due to the similar values of %DS for samples 
S1, S5, S6, and S7; S1 (0.5 g stearic acid and the ratio 1:5 of SA: EDC.HCl was 
reacted for 6 h) will be used for subsequent experiments in order to reduce the time 
and the materials used. 
 
Table 2.4 Analysis of variance (ANOVA) for a 2
3
 factorial design on degree of 
substitution (%DS) 
 Sum of 
squares 
df F-value p-value 
Model 38.67 3 4.28 0.0971 
A 4.76 1 1.58 0.2773 
B 18.03 1 5.98 0.0707 
C 15.88 1 5.27 0.0834 
A – Ratio of stearic acid with EDC. HCl, B –Time (hours), C – Amount of stearic acid (mg) 
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2.4.2 Conjugation between chitosan oligomer and lauric acid (CSO-LA) 
2.4.2.1 1HNMR and FTIR of CSO-LA 
In order to obtain a similar amount of conjugation of lauric acid with CSO, 
CSO-LA was synthesised based on the parameters used in the CSO-SA conjugation. 
Similar molar ratios between LA: EDC.HCl and SA: EDC.HCl was used in this 
section. The formation of CSO-LA was confirmed using FTIR and 
1
H NMR. Figure 
2.6 shows the IR spectra of all samples. Compared to lauric acid alone and chitosan 
oligomer, there were some changes to the IR spectrum of chitosan-lauric acid 
resulting from the binding between the lauric acid carboxylic group and the chitosan 
amine group.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 FTIR spectra of lauric acid (LA), chitosan oligomer (CSO) and chitosan 
oligomer-lauric acid (CSO-LA) based on a parameter of ratio 1:5; LA: EDC.HCl, 6 h 
reaction time and 0.5 g – lauric acid  
 
CSO <3 kDa 
CSO-LA 
LA 
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The IR spectra for CSO (without conjugation) showed absorption peaks 1620 
attributed to C=O stretching of the secondary amine (amide I band). The IR spectra 
of CSO-LA showed shifted two peaks at around 1635 and 1529 cm
-1
 corresponding 
to the N-lauroyl (amide I and II bands, respectively). The increase of the C-H 
absorption around 2977 and 2901 cm
-1
 indicated the presence of the lauroyl chain. 
The broad peak at around 3296 cm
-1
 represents the -OH group from the chitosan 
oligomer. The other peak indicating the presence of carboxyl groups (-COOH) from 
lauric acid is at ~1691 cm
-1
. After conjugation of lauric acid to chitosan oligomer, the 
peak around 1691 cm
-1
 was reduced which suggests that lauric acid has reacted with 
chitosan oligomer. Based on the 
1
H NMR spectra (Figure 2.7), there were chemical 
shifts that represented the methyl and methylene hydrogen of the laurate group.  
The chemical shifts shown at 0.85 ppm represent protons from CH3 of lauric 
acid whereas the peaks at 1.17 - 1.24 ppm correspond to the protons of the CH2 
group of acyl chain. The rest of the peaks were hydrogen peaks from the chitosan 
oligomer. These results confirmed that lauric acid was successfully conjugated to the 
chitosan oligomer. These results are in agreement with Zhao et al. (2014), who 
successfully conjugated LA with CSO for surface functionalization of titanium to 
enhance osteoblast functions and inhibit bacteria adhesion. 
 
 
 
 
 
 
 
 
 
Chapter 2  Conjugation of chitosan oligomer with different types of fatty acids 
81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 
1
H NMR spectra of lauric acid (A), chitosan oligomer (B) and CSO-
LA (C) based on ratio LA: EDC.HCl/time of reaction (hours)/amount of lauric 
acid (g), 1:5/6/0.5) 
.  
B 
C 
A 
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2.4.2.2 Ninhydrin assay of D-glucosamine, CSO and CSO-LA 
Based on the ninhydrin assay (Figure 2.8), the slopes for chitosan oligomer 
(CSO) was 0.0126, and 0.0165 for CSO-LA. By comparing the slopes from 
glucosamine, CSO and CSO-LA; the %DS of CSO-LA was found to be 6.2%. 
 
 
 
 
 
 
 
 
 
Figure 2.8 Graph of absorbance versus concentration from ninhydrin assay of 
D-glucosamine, CSO and CSO-LA (n=3, mean ± SD) 
 
The value for %DS of CSO-LA was close to that of CSO-SA (Section 
2.4.1.2). This shows that, by using the same molar ratio of fatty acid: EDC.HCl, 
consistent values are produced with using different types of fatty acids.   
Little research has been conducted on the preparation of CSO-LA. Zhao et al., 
(2014) synthesised LA with CSO, no information on the %DS was reported. 
However, based on 
1
HNMR and FTIR results, successfully grafting of lauric acid and 
CSO was claimed.  
Lauric acid previously showed good inhibition of androgenic activity and also 
has an inhibitory effect on lymph node carcinoma of the prostate cancer (LNCaP) 
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cells (Liu et al., 2009). Due to that, by conjugating lauric acid with chitosan oligomer 
and acts as a coating material for NLCs, it would help to deliver lauric acid in the 
nanocarrier system to be delivered to the skin. 
 
2.4.3 Size distribution, surface charge and morphology of CSO-SA and CSO-
LA micelles 
Table 2.5 shows the values for size distribution and surface charge of CSO-
SA (S1) and CSO-LA. No measurement on hydrodynamic diameter of CSO-SA 
using Zetasizer Nano ZS were conducted as the mean size was greater than 1000 nm 
and PDI was 1.0.  
 
Table 2.5 Size distribution and surface charge of CSO–SA and CSO-LA micelles 
(n=3, mean ± SD) 
Material Hydrodynamic 
diameter (nm) 
PDI Zeta potential 
(mV) 
CSO-SA (S1) - 1.0 +41.7 ± 0.5 
CSO-LA  220.3 ± 21.4 0.406 ± 0.013 +30.7 ± 3.2 
The size, PDI and zeta potential value of the micelles were determined in acetic acid solution 
 
In the DLS technique, the intensity is used to calculate the hydrodynamic 
diameter. However, if there are larger particles in the distribution (less than 1000 
nm), the larger particle normally will dominate scattering compared to the smaller 
sized particles, resulting in a large reported value for hydrodynamic diameter and 
broader PDI. In this case of CSO-SA micelles, if the size of particles was larger than 
1000 nm, particles would not undergo Brownian motion and data cannot accurately 
be translated to hydrodynamic diameter using Stoke-Einstein equation. Based on the 
cumulant fit analysis from DLS, this sample had predominantly larger particles.   
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However, for CSO-LA micelles in acetic acid solution (5 mg/mL), smaller 
size of micelles with 220.3 ± 21.4 nm and PDI less than 0.5 were found. A smaller 
particle size compared to CSO-SA micelles was found probably due to the shorter 
chain of lauric acid (C12) attached to chitosan oligomer back bone compared to 
stearic acid (C18).  
Both CSO conjugated micelles gave a positive zeta potential (Table 2.5). The 
surface charge of CSO-SA micelles was significantly higher than CSO-LA micelles 
at 5 mg/mL (p<0.05). Figure 2.9 shows the morphology of CSO-SA and CSO-LA 
micelles at 5 mg/mL in acetic acid solution. Both samples showed small size of 
particles, suggesting that CSO-SA and CSO-LA at this concentration appeared in 
micellar systems.  
There is a suggestion that larger sizes measured from DLS instrument is due 
to the possibility of poorly dispersed material that occurred while preparing the 
micelles. As both products would not dissolve in any solvents and water, no 
appropriate method of preparing and controlling the size of the micelles have been 
undertaken, resulting in larger mean particle size and higher PDI.    
 
 
 
 
 
 
 
 
  
 
8
5
 
  
           
Figure 2.9 Transmission electron micrographs of CSO-SA and CSO-LA micelles at 5 mg/mL in acetic acid solution 
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2.4.4 Critical micelles concentration (CMC) of selected CSO-SA and CSO-LA 
Due to the hydrophobic properties of fatty acid, stearic or lauric acid and 
hydrophilic properties of the backbone of chitosan in conjugated-chitosan oligomer, 
the synthesised CSO-SA and CSO-LA could self-aggregate and form micelles. 
Figure 2.11 shows the absorbance versus log concentration of CSO-SA and CSO-LA 
in 0.2% acetic acid solution.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Absorbance of pyrene versus logarithm of chitosan oligomer-stearic 
acid (CSO-SA) concentration (A) and chitosan oligomer-lauric acid (CSO-LA) 
concentration (B) (n=3, mean ± SD) 
 
A 
B 
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The starting concentration of CSO-SA or CSO-LA (5 mg/mL) of conjugated 
chitosan was prepared in 0.2% acetic acid solution and diluted with water to obtain 
serial dilution, to determine the CMC of CSO-SA and CSO-LA micelles.  This value 
was used to predict either at that concentration, CSO-SA or CSO-LA appeared in 
monomers or micelles when used in the coating process of DST-NLCs. The 
measured CMC was found to be 0.17 ± 0.01 mg/mL for both CSO-SA and CSO-LA, 
which indicated that CSO-SA and CSO-LA micelles had a self-assembling ability. 
The CMC for both samples was similar as indicated in previous sections that they 
produced similar values of %DS.  
Both measured CMC values from this study were in agreement with the 
previous study (Hu et al., 2009). Hu et al. (2009) synthesised CSO-SA and the CMC 
of the micelles was 0.140 mg/mL with degree substitution of 6.47%. Previous 
research (Hu et al., 2009; Yuan et al., 2010), suggest increasing the %DS of CSO-SA 
produced a decrease in CMC; i.e., modifying the amounts of hydrophobic chain that 
attach to chitosan oligomer affect CMC values.  
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2.5 Conclusions 
The aim of this chapter is to conjugate and characterise chitosan oligomer 
with stearic and lauric acid. It can be concluded that: 
1. All conjugations between chitosan oligomer and stearic acid or lauric acid were 
successful based on the 
1
HNMR and FTIR spectra.  For CSO-SA conjugation, 
due to the non-significant difference on the model on %DS from design of 
experiment, sample S1 was selected for further studies. S1 with 0.5 g stearic acid 
and the ratio of SA with 1:5 of SA: EDC.HCl was reacted for 6 h, in order to 
obtain the highest %DS value (6.0%) for this reaction. Product S1 was chosen as 
a coating material for the next chapter. 
2. CSO-LA based on the optimal CSO-SA molar ratio was synthesized and 
characterized. Based on the ninhydrin results for both CSO-SA and CSO-LA, the 
degree of substitution was very similar (~6.0%). This showed that the synthesis 
was reproducible. 
3. The CMC results for both optimised CSO-SA and CSO-LA were similar at 0.17 
mg/mL. 
4. The synthesised chitosan oligomer produced a positive charge which would be 
useful to be a coating material for nanoparticles for topical delivery as hair, skin 
and cell membrane are negatively-charged. 
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3.1 Preparation and characterisation of dutasteride-loaded nanostructured 
lipid carrier coated with chitosan oligomer-stearic acid  
3.1.1 Introduction 
This chapter describes the preparation and characterisation of dutasteride-
loaded nanostructured lipid carrier coated with chitosan oligomer-stearic acid. The 
formulation was optimised using a design of experiments approach, and DST-NLCs 
were produced by the melt dispersion-ultrasonication method. The size distribution 
of particles, entrapment efficiency, and drug loading were measured as dependent 
variables whereas the independent variables were the amount of stearic acid, Lutrol® 
micro 68 and Phosal® 53 MCT. The content of drug was scaled-up in later 
experiments. In order to obtain positively-charged nanoparticles, the optimised 
dutasteride-loaded nanostructured lipid carrier formulations were coated with 
chitosan oligomer-stearic acid (CSO-SA). Only the optimised CSO-SA (described in 
Chapter 2) was chosen at this stage. The highest degree of substitution (%DS), 
namely formulation S1 was chosen to be used in this study.  
3.1.2 Method development and validation using reverse-phase high-
performance liquid chromatography (RP-HPLC) assay for 
quantification of dutasteride 
3.1.2.1 Materials 
Dutasteride was purchased from Carbosynth Ltd (UK). HPLC grade 
trifluoroacetic acid, methanol and water were purchased from Sigma-Aldrich Ltd 
(UK).  
3.1.2.2 Instrumentation 
As described in the British Pharmacopeia 2017 (British Pharmacopeia 
Commission, 2017), dutasteride was assayed using liquid chromatography using 
40:60 v/v of water and acetonitrile as mobile phase and end-capped octadecylsilyl 
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silica gel column at 35°C (flow rate at 1 mL/min and the wavelength at 220 nm). The 
retention was 1.6 min.  
In order to avoid interference from other components present in the 
nanoparticles preparation, namely lipid and surfactant, an optimal separation should 
be undertaken using a suitable column as a stationary phase. Preliminary studies on 
the maximum wavelength (λmax) UV absorbance of dutasteride was undertaken. The 
prepared solutions of dutasteride in methanol were scanned for the λmax from 200 – 
600 nm using a UV-Vis Spectrophotometer (Agilent Cary 100, UK) and found to be 
at 241 nm.  
In this study, high-performance liquid chromatography (HPLC) with UV/Vis 
detector (Agilent 1100 Series, USA) at wavelength 241 nm was used to determine 
the content of dutasteride in the nanoparticle formulation. A Synergi™ 4 µm Polar-
RP 80 Å, 250 x 4.6 mm column (Phenomenex, Torrance, California) was selected as 
a stationary phase for the separation. This column has an ether-linked phenyl phase 
and is suitable for the separation of polar and aromatic compounds. As dutasteride 
has a phenyl group in its structure, this column can be useful for the separation of 
dutasteride from other components of the formulation. The quantitative 
determination of dutasteride was carried out using a mobile phase 70:30 (by volume) 
of acetonitrile and 0.1% v/v trifluoroacetic acid (TFA) in HPLC grade water. The 
injection volume was 30 µL (Table 3.1).   
3.1.2.3 Preparation of dutasteride standard solution 
10 mg dutasteride was weighed accurately and transferred to a 10 mL 
volumetric flask. 5 mL methanol was added and sonicated to dissolve the drug. 
Methanol was added to volume and the flask was shaken to mix the solution well. 
The stock solution concentration of dutasteride was 1000 µg/mL. Serial dilutions 
were prepared from the stock solution giving 1, 3, 5, 10, 25, 50, 70, 100 µg/mL 
dutasteride.  
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Table 3.1 HPLC chromatographic condition for determination of dutasteride 
Column: Synergi™ 4 µm Polar-RP 80 Å, 250 x 4.6 mm 
Mobile phase: Acetonitrile and 0.1% TFA in HPLC grade water (70:30) 
Wavelength: 241 nm 
Flow rate: 1 mL/min 
Injection volume: 30 µL 
Run time: 15 minutes 
3.1.2.4 Retention time 
In order to ensure there was no interference of the formulation components 
with dutasteride at the same wavelength, a preliminary analysis was undertaken by 
injecting a formulation with dutasteride and also blank formulation (formulation 
without dutasteride) into the HPLC system to determine the appropriate retention 
time.  
3.1.2.5 Method validation 
Linearity, accuracy, specificity, precision, limit of detection (LOD) and limit 
of quantification (LOQ) were determined according to ICH Q2 guidelines for 
validation of analytical procedures (International Conference on Harmonisation, 
1996).  
3.1.2.5.1 Linearity 
For linearity measurement, serial dilutions of dutasteride at 1, 3, 5, 10, 25, 50, 
70, 100 µg/mL of the stock solution were prepared. The solutions were sonicated and 
filtered through 0.22 µm PES membrane syringe filter (Millex®GP, Merck 
Millipore, UK) and transferred to the vials. 30 µL of each sample was injected onto 
the HPLC column. A calibration curve was prepared four times from fresh stock 
solutions. The standard curves were obtained by plotting peak area versus dutasteride 
concentration.  
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3.1.2.5.2 Accuracy 
The accuracy of the method was determined by the recovery method 
(Equation 3.1), which expresses the closeness between the determined value and the 
reference value (International Conference on Harmonisation, 1996). The recovery 
was checked at 3, 5, 10, 25, 50, 70 and 100 µg/mL.  
Accuracy = 100 − ⌊
(Reference value−measured value)
Reference value
 x 100 ⌋           Equation 3-1  
3.1.2.5.3 Precision 
The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions (International Conference on 
Harmonisation, 1996). In this study, precision (calculated using Equation 3.2) was 
determined using two methods. One is determined under the same operating 
conditions over a short interval of time (intra-day), and another is determined on a 
different day (inter-day). The intra-day and inter-day precisions were determined at 
three different concentrations (8, 40 and 90 µg/mL). The repeatability study was 
done by using the chosen 40 µg/mL concentration and injecting it for 9 times to get 
the RSD (relative standard deviation). 
 
Precision (%RSD) =  
Standard deviation
Mean value
 x 100                          Equation 3-2 
 
where; 
%RSD – percent relative standard deviation 
3.1.2.5.4 Limit of detection (LOD) and limit of quantification (LOQ) 
The detection limit (LOD) of an individual analytical procedure is the lowest 
amount of analyte in a sample which can be detected but not necessarily quantified as 
an accurate value; while the quantification limit (LOQ) of an individual analytical 
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procedure is the lowest amount of analyte in a sample which can be quantitatively 
determined with suitable precision and accuracy. The detection and quantification of 
limit can be determined using various methods. In this study, LOD and LOQ were 
determined using the equation (Equation 3-3 and Equation 3-4).  
LOD =
𝟑.𝟑 𝛔
𝐒
             Equation 3-3 
 
LOQ =  
𝟏𝟎𝛔
𝐒
                Equation 3-4 
 
where:  
σ = the standard deviation of the response 
S = the slope of the calibration curve estimated from calibration curve 
3.1.3 Preparation of dutasteride-loaded nanostructured lipid carriers (DST-
NLCs) 
3.1.3.1 Materials 
Stearic acid (n-octadecanoic acid) 98% and dutasteride (purity >98.0%) 
[(5a,17b)-N- [2,5-Bis(trifluoromethyl)phenyl] -3-oxo-4-azaandrost -1 -ene-17-
carboxamide] with molecular weight 528.53 were purchased from Tokyo Chemical 
Industry (TCI, UK). Chitosan oligomer (CSO) with molecular weight less than 3 kDa 
was obtained from Carbosynth Ltd (UK). Phosal® 53 MCT was a gift of Lipoid AG, 
Switzerland. Lutrol® micro 68 (Poloxamer 188) was obtained from BASF, 
(Germany). Ethanol (96% v/v analytical grade) was obtained from Sigma-Aldrich 
Company Ltd (UK). Deionised water (PURELAB Option, ELGA, UK) was obtained 
on site from a water system. Table 3.2 shows the description of main materials used 
in the nanoparticle preparation. 
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Table 3.2 Description of main materials used in the nanoparticle preparation 
Material Group Function Phase 
Dutasteride Drug 5α-reductase 
inhibitor 
Oil 
Stearic acid Fatty acid Solid lipid Oil 
Phosal® 53 MCT 
 
53% lecithin in 
caprylic/capric 
triglycerides, alcohol, 
glyceryl stearate, oleic 
acid and ascorbyl 
palmitate 
Emulsifier + 
liquid  lipid 
Oil 
Lutrol® micro 68 
(Poloxamer 188) 
Amphiphilic block 
copolymer with 1800 
g/mol molecular mass of 
polyoxypropylene and 
80% polyoxyethylene 
content 
Emulsifier Water 
3.1.3.2 Preparation of DST-NLCs 
DST-NLCs was prepared by the melt dispersion ultrasonication method (Patel 
et al., 2012; Uprit et al., 2013; Gomes et al., 2014). Dutasteride, stearic acid, and 
Phosal® 53 MCT were weighed into a glass vial (30 mL). Lutrol® micro 68 was 
added to another glass vial (30 mL) with water. Both glass vials were heated 
separately at 80-90° in a water bath. When the drug dissolved in the liquid lipid 
(using the micromagnetic bar to stir) and both vial contents reached the desired 
temperature, the aqueous solution was added to the oil phase solution. The mixture 
was homogenised using an IKA Ultra Turrax T25 (IKA-Werke GmbH & Co KG, 
Germany) at 19,000 rpm for 10 min. The hot solution was further processed using a 
probe-type sonicator (MSE Soniprep 150, MSE Ltd UK) at 18W, for 5 min. 
Procedures for DST-NLCs preparations and characterisation are summarised in 
Figure 3.1. 
. 
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Figure 3.1 Schematic diagram of preparation and characterisation of 
dutasteride-loaded nanostructured lipid carriers (DST-NLCs)  
 
2 mL of hot dispersion was syringed using a needle (25 gauges, 5/8th inch, 
BD Microlance™ 3, Becton Dickinson, Spain) into 10 mL of cold water (4-8°C) and 
stirred for 10 min. The final dispersion was stored at 4-8°C for 24 h before being 
characterised. The weight of dutasteride was maintained constant at 5 mg for all of 
the experiments, and 10 mL of water was used for all formulations. In order to 
proceed with this method, the formulation with the highest stearic acid, Lutrol ® F68, 
and Phosal® 53 MCT content was chosen. Statistical analysis using Student t-test, 
4-8°C 
2 mL hot DST-NLCs dispersed in 10 mL cold water (4-8°C) 
 
Dispersion 
 
Characterisation of DST-NLCs  
 (Size distribution, surface charge, entrapment efficiency and drug loading) 
 
Dutasteride, 
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68 and water 
(aqueous 
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with IBM SPSS 23 Statistic Data Editor Software (USA) was undertaken. A p-value 
of less than 0.05 was considered significant for all experiments. 
3.1.3.3 Experimental design of preparation of DST-NLCs using a 23 full 
factorial design 
The amount of solid lipid and surfactant used to prepare DST-NLCs was 
varied to obtain the smallest mean particle size, smallest polydispersity index, and 
highest entrapment efficiency and drug loading. Dutasteride content was maintained 
at 5 mg in all formulations. This was achieved with a 2
3 
full factorial design (Design 
Expert 6.0.8 Software; Stat-Ease, USA). The three factors evaluated were; the 
contents of stearic acid, Lutrol ® F68 and Phosal® 53 MCT, tabulated in Table 3.3 
with the value and coded number (-1 for the low level and +1 for the high level).  
 
Table 3.3 Value and coded units of a 2
3
 full factorial design for preparation of 
DST-NLCs 
Independent Variables Coded Level 
Low (-1) High (+1) 
Stearic acid (mg) A 50 100 
Lutrol® micro 68  (mg) B 25 50 
Phosal® 53 MCT (mg) C 25 50 
 
In this study, the design of experiments approach allows an understanding of 
the formulation parameters and permits the formulation to be optimised to achieve 
the smallest size (ideally ranging between 200-300 nm), smallest polydispersity 
index (<0.3) and the highest entrapment efficiency and drug loading. The 
experiments were conducted in triplicate in order to calculate the experimental error. 
The experimental design required in total 8 preparations (a total of 24 experiments 
were therefore conducted). Table 3.4 shows the actual and coded values for the lower 
and higher level. A factorial design was used in order to obtain maximum 
information such as the interaction between the factors without the need of a large 
Chapter 3  Preparation of dutasteride-loaded nanostructured lipid carriers coated with chitosan oligomer-fatty acid 
98 
 
number of experiments (Dillen et al., 2004). It is also can predict the cause-effect 
relationship of the experiment. The experiment results were analysed using ANOVA 
from Design Expert 6.0.8 (Stat-Ease Inc, USA). 
 
Table 3.4 Design of experiments for formulation of dutasteride-loaded 
nanostructured lipid carrier (DST-NLCs) using 2
3
 factorial design 
Formulation Stearic acid           
(mg) 
Lutrol® micro 
68 (mg) 
Phosal® 53 MCT 
(mg) 
S1 50 (-1) 25 (-1) 25 (-1) 
S2 100 (+1) 25 (-1) 25 (-1) 
S3 50 (-1) 50 (+1) 25 (-1) 
S4 100 (+1) 50 (+1) 25 (-1) 
S5 50 (-1) 25 (-1) 50 (+1) 
S6 100 (+1) 25 (-1) 50 (+1) 
S7 50 (-1) 50 (+1) 50 (+1) 
S8 100 (+1) 50 (+1) 50 (+1) 
Number in bracket represents the coded value 
3.1.3.4 Preparation of scaled-up DST-NLCs  
In this study, the optimised DST-NLCs preparation (Section 3.1.3.3) was 
chosen based on the statistical analysis. The formulation was scaled up from 100 mg 
to 300 mg of stearic acid to allow the use of the desired amount of dutasteride. 
Quantities of other materials (dutasteride, Phosal® 53 MCT and Lutrol® micro 68) 
were up-scaled employing the optimal ratio, with water kept constant at 10 mL Table 
3.5). In order to compare the effect of size distribution with or without dutasteride, a 
blank formulation (NLCs without dutasteride) was prepared. 
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Table 3.5 Before (x) and after scale-up (3x) contents of DST-NLCs 
Formulation Dutasteride 
(mg) 
Stearic 
acid  
(mg) 
Lutrol® 
micro 68 
(mg) 
Phosal® 
53 MCT 
(mg) 
x (with DST) 5 100 50 25 
3x (with DST) 15 300 150 75 
3x (without DST) 0 300 150 75 
3.1.3.5 Preparation of DST-NLCs coated with CSO-SA 
CSO-SA (2.5, 5 or 10% w/w of solid lipid content) and CSO (5% w/w of 
solid lipid content) were dissolved in acidified water (0.2% acetic acid in deionised 
water). 250 µL of the solution was added using a syringe, into 5 mL of DST-NLCs 
with constant stirring for 10 min. Chitosan oligomer-SA S1 (from Chapter 2) was 
selected based on the ninhydrin assay. Particle size and zeta potential of resultant 
coated NLCs were determined. Differences in charge between the negatively-charged 
DST-NLCs and the positive charge of CSO-SA should allow the coating material to 
deposit on the outer surface of DST-NLCs. Different amounts of CSO-SA solutions 
(in acidified water) added into the DST-NLCs would be expected to increase the 
hydrodynamic diameter of DST-NLCs.    
3.1.3.6 Characterisation of DST-NLCs 
3.1.3.6.1 Measurement of particle size distribution of DST-NLCs 
Dynamic light scattering (DLS) size analysis techniques measure 
hydrodynamic quantities, usually the translational and/or rotational diffusion 
coefficients, which are then related to sizes and shapes via theoretical relations 
(Pecora, 2000). DLS determines the mean size of particles (hydrodynamic diameter) 
undergoing Brownian motion and estimates the width of the distribution 
(polydispersity index). When a laser passes through the dispersion, the intensity of 
the scattered light fluctuates depending on the size of particles. The small particles 
diffuse faster which results in the intensity fluctuating more rapidly compared to the 
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larger sizes in the dispersion. Hydrodynamic diameter is calculated from the 
translational diffusion coefficient using the Stokes-Einstein equation with the 
assumption that all particles are spherical in shape, while polydispersity index (PDI) 
is the measurement of the heterogeneity of size distribution in a mixture. 
All formulations were analysed after 1 day using dynamic light scattering 
(DLS) equipment (Zetasizer Nano ZS, Malvern Instruments, UK) for determination 
of the particle size distribution. 1 mL of the sample was pipetted directly into the zeta 
potential DTS1070 folded capillary cell (Malvern, UK) without dilution at 25°C. The 
size distribution of nanoparticles was obtained as the hydrodynamic diameter (ZAve) 
and polydispersity index (PDI). The prepared formulation was analysed, and the 
measurement was performed in triplicate, and mean values were taken.  
3.1.3.6.2 Measurement of zeta potential of DST-NLCs 
In order to measure the surface charge of the particles, zeta potential (ZP) was 
measured using the Zetasizer Nano ZS (Malvern Instruments, UK). This equipment 
uses electrophoretic light scattering technology to measure zeta potential, calculated 
from electrophoretic mobility using the Helmholtz-Smoluchowski equation by the 
Malvern data analysis software.  
1 mL of the sample was pipetted directly into the zeta potential DTS1070 
folded capillary cell (Malvern, UK) without dilution. The measurements were 
recorded at 25ºC. The prepared formulation was analysed without further dilution, 
and the measurement was performed 3 times, and the average values were recorded.  
3.1.3.6.3 Determination of nanoparticle morphology by transmission electron 
microscope  
The morphology of the nanoparticles was determined using a transmission 
electron microscope (TEM; Philips/FEI CM120 Bio Twin, FEI Netherlands). 
Samples were placed on copper grid formvar/carbon support film 300 mesh (Agar 
Scientific, Stansted, Essex, UK), and excess droplets were blotted with filter paper. 
After a few seconds, a drop of 1% uranyl acetate was placed onto the copper grid for 
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negative staining. The grid was air-dried at room temperature and observed using 
TEM.  
3.1.3.6.4 Entrapment efficiency and drug loading measurement 
Entrapment efficiency and drug loading for each preparation were calculated 
as described previously (Gu et al., 2011).  Entrapment efficiency and drug loading 
were determined using Sephadex® gel G-50 (Sigma-Aldrich, UK) as a mini-column 
in a 5 mL syringe. Sephadex is a crosslinked dextran and used in the gel filtration 
(size-exclusion chromatography). This method was used in order to separate the 
unentrapped and entrapped DST in the NLCs system due to their different sizes. The 
larger size of DST-NLCs will pass through the gel, and the smaller size of DST (the 
unentrapped DST) will retain in the gel.  
5 mL of the gel was packed in the syringe which was placed in the centrifuge 
tube (size 50 mL). In order to remove excess water, the tube was centrifuged at 1000 
rpm for 10 s (angle rotor 19776-H, at 104 x g, brake no. 9) in a refrigerated 
centrifuge (Sigma Laborzentrifugen GmbH, Germany) at 20°C.  
After removing the excess water, 0.5 mL of the DST-NLCs solution was 
pipetted in the middle of the column and separated through column chromatography 
at 1000 rpm for 5 min. The column was washed with 0.5 mL distilled water at 1000 
rpm for another 5 min. The unentrapped dutasteride was retained in the Sephadex G-
50 gel. The collected sample which comprises dutasteride-entrapped in NLCs was 
diluted with ethanol in a 10 mL volumetric flask and sonicated for 10 minutes in 
order to dissolve the particles before being filtered using 0.22 µm PES membrane 
syringe filter (Millex®GP, Merck Millipore, UK). The solution was assayed using 
HPLC in order to determine the amount of entrapped dutasteride in the NLCs (as 
described in Section 3.1.2). The amount of entrapped dutasteride in the preparation 
(𝑛1) and total (𝑛2) were quantified by HPLC at 241 nm (Equation 3-5). Measurement 
was performed in replicate and the average values were recorded. Dutasteride 
loading was calculated using Equation 3-6. 
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Entrapment efficiency (%) = 
𝑛1
𝑛2
 × 100      Equation 3-5 
where; 
𝑛1 = concentration of entrapped dutasteride in DST-NLCs  
 𝑛2= total concentration of dutasteride in DST-NLCs 
Drug loading (%) = 
𝐶1
𝐶0
 × 100         Equation 3-6 
where; 
𝐶1 = total weight of entrapped dutasteride in DST-NLCs  
 𝐶0= total weight of solid lipid, surfactant and dutasteride in DST-NLCs 
3.1.3.6.5 Physical stability study 
The physical stability of DST-NLCs was investigated, exploring changes in 
the size distribution and surface charge with time. Each formulation was stored in a 
refrigerator 4-8°C and at 25°C (incubator). Particle size distribution and zeta 
potential were compared at day 1, 30, 60 and 180. Entrapment efficiency for DST-
NLCs was determined over 180 days. 
3.2 Preparation and characterisation of dutasteride-loaded nanostructured 
lipid carriers coated with chitosan oligomer-lauric acid 
This section describes the preparation and characterisation of a dutasteride-
loaded nanostructured lipid carrier coated with chitosan oligomer-lauric acid. 
Previous research (Liu et al., 2009) found that lauric acid has potent anti-androgenic 
activity compared to other free fatty acids. Chitosan oligomer was synthesised with 
lauric acid and used as a coating for DST-NLCs. DST-NLCs used in this section 
were prepared based on the optimised formulation from Section 3.1 and then coated 
with CSO-LA. The prepared formulations were then characterised for size 
distribution, zeta potential, morphology and stability as described in Sections 
3.1.3.6.1, 3.1.3.6.2, 3.1.3.6.3, 3.1.3.6.4 and 3.1.3.6.5, respectively. 
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3.3 Thermal behaviour and viscosity of DST-NLCs, uncoated and coated with 
5% CSO-SA and 5% CSO-LA 
3.3.1 Freeze drying of DST-NLCs, uncoated and coated with 5% CSO-SA and 
5% CSO-LA 
5 mL of DST-NLCs uncoated and coated with 5% CSO-SA or 5% CSO-LA 
samples was transferred into a 14 mL glass vial and closed with a Parafilm® (Merck 
Millipore, Ireland) and holes were applied using a syringe needle (25 gauges, 5/8th 
inch, BD Microlance™ 3, Becton Dickinson, Spain). Samples were kept frozen for 
an overnight at -20°C. Freeze drying process was conducted using a Savant 
MicroModulyo Freeze Dryer (Thermo Electron Corporation, UK) for 48 h without 
the addition of cryo-protectant. The freeze-dried formulations were stored in the 
desiccator prior to use. 
3.3.2 Determination of crystallinity using x-ray powder diffractometer 
(XRPD)  
In order to determine the crystallization behaviour between dutasteride and 
other materials used in the formulation, XRPD was employed. Freshly prepared 
nanoparticles, uncoated and coated with 5% CSO-SA and 5% CSO-LA were freeze 
dried. An X-ray diffractometer (Rigaku MiniFlex 600, Japan) equipped with a 600 W 
X-ray tube, a copper anode operating in reflectance mode at wavelength kα λ1.5418 
Å, with a voltage of 40kV and current 15 mA at room temperature, was used for 
diffraction studies. Samples of dutasteride alone, a physical mixture of dutasteride 
and formulation components (dutasteride, stearic acid, Phosal® 53 MCT, Lutrol® 
micro 68, CSO-SA/CSO-LA with similar ratio with DST-NLCs were mixed in the 
mortar using a pestle) and freeze-dried DST-NLCs/empty NLCs (uncoated and 
coated with 5% CSO-SA or 5% CSO-LA) were mounted to the horizontal axis to 
obtain a scanning range of 5 - 40°, a scanning rate of 5°(2θ)/min and scan step 
0.05°(2θ)/min.  
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3.3.3 Determination of the thermal behaviour of formulations using 
differential scanning calorimetry (DSC)  
DSC measures the heat of a sample relative to a reference (Kodre et al., 
2014). For instance, a solid sample melts to a liquid phase; more heat flows to the 
sample to produce the phase change, resulting in an absorption of heat by the 
samples, which is called endothermic. DSC analysis of dutasteride, stearic acid and 
physical mixture of all formulations was performed using a differential scanning 
calorimetry (Q2000 TA Instrument, USA). Calibrations for cell constant and 
enthalpy were performed with indium. Samples (~5 mg) were heated in aluminium 
pans under a dry nitrogen environment. TA aluminium pans and lids (Tzero, TA 
Instrument, USA) and heating rates of 10°C/min from 25 - 260°C were used in all 
experiments (Buanz et al., 2015). Data were analysed using the TA Instruments 
Universal Analysis 2000 software. Measurements were performed in triplicate, and 
the mean values were calculated. 
3.3.4 Measurement of dynamic viscosity using a micro viscometer 
In order to determine the effect of coating on the viscosity of the 
formulations, dynamic viscosity measurement for all coated and uncoated NLCs was 
performed. Viscosity for all nanoparticle formulations was measured using an AMVn 
Automated Micro Viscometer (Anton Paar GmH, Graz, Austria). AMVn is a falling 
ball viscometer that follows Hoppler’s falling ball principle. It is a closed system that 
does not allow the liquids to contact air and measures the time for a rolling ball to 
pass through opaque or transparent liquids. The instrument was equilibrated to 20 ± 
0.01 °C for 30 min prior to use. Using a syringe, formulation was loaded carefully, 
without allowing any bubbles to enter, into a 1.6 mm capillary containing a metal 
ball. The viscosity for all samples was measured at different angles (50, 60 and 70°). 
In order to determine the effect of different temperatures on the measured viscosity, 
different temperatures were investigated; ambient temperature (20°C), human skin 
surface temperature 32°C and internal body temperature (37°C). The measurement 
was performed in triplicate and mean values taken.  
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3.4 Statistical analysis 
All data were analysed either using t-test or one-way ANOVA and Tukey’s 
post-hoc test, using IBM SPSS 23 Statistic Data Editor Software (USA), except data 
from the experimental design for the model interaction among materials used which 
were analysed using Design Expert 6.0.8 Software (Stat-Ease, USA). A p-value of 
less than 0.05 was considered significant. 
3.5 Results and discussion 
3.5.1 Validation of RP-HPLC method for assay of dutasteride 
Based on preliminary studies, mobile phase comprising acetonitrile and 
0.1%v/v TFA in water, in the ratio of 70:30 (v/v) was selected. The retention time for 
dutasteride was 8.6 min. Figure 3.2 shows that there was no interference for the 
detection of dutasteride by other materials used in the formulation.  
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Peak area versus time for the dutasteride solution (A), NLCs without 
dutasteride (B), NLCs with dutasteride (C) 
 
B 
C 
mAU 
Time, min 
m
A
U
 
Time (min) 
Chapter 3  Preparation of dutasteride-loaded nanostructured lipid carriers coated with chitosan oligomer-fatty acid 
106 
 
y = 35.371x + 12.666 
R² = 1 
0
1000
2000
3000
4000
0 20 40 60 80 100 120
A
re
a
 (
m
A
U
) 
Concentration (µg/mL) 
For the linearity study, seven standard solutions of dutasteride were prepared; 
ranging from 3 to 100 µg/mL. The plot of concentration versus peak area was linear 
(Figure 3.3), with a correlation coefficient of 1.0.  
 
 
 
 
Figure 3.3 Calibration curve of dutasteride; peak area versus concentration 
(n=4, mean ± SD) 
 
As shown in Table 3.6, the linear regression data showed good linearity 
between 3 and 100 µg/mL. LOD and LOQ were found to be 0.38 and 3 µg/mL, 
respectively. The calculation of LOD and LOQ is shown in Appendix A1. 
 
Table 3.6 Regression characteristics and validation parameters of dutasteride 
using HPLC 
Parameters Value 
Linearity range (µg/mL) 3 - 100 
Number of sample per curve 7 
Correlation coefficient (R
2
) 1.0 
Slope (m) 35.371 
Intercept (c) 12.666 
a
LOD (µg/mL) 0.34 
b
LOQ (µg/mL) 3.0 
Accuracy (%) 97.3 – 104.4 
Repeatability, %RSD at 40 µg/mL (n=9) 1.27 
Precision, % (
c
RSD, n=3)  
Interday (n=3) 0.57 – 1.27  
Intraday (n=3) 0.27 – 2.08 
a
LOD is limit of detection, 
b
LOQ is limit of quantification and 
c
RSD is relative standard deviation at 
8, 40 and 90 µg/mL 
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The intra-day and inter-day precisions were determined at three different 
concentrations (8, 40 and 90 µg/mL). The RSD (%) for inter-day and intra-day 
precisions were 0.57 – 1.27% and 0.27 – 2.08%, respectively. The repeatability was 
calculated for nine injected samples (40 µg/mL), the RSD% of the measurement was 
found to be 1.27%. 
3.5.2 Preparation and characterisation of dutasteride-loaded nanostructured 
lipid carrier coated with chitosan oligomer-stearic acid  
3.5.2.1 Experimental design for preparation of DST-NLCs: hydrodynamic 
diameter and particle size distribution 
DST-NLCs were prepared based on the ratio of ingredients generated from 
the design of experiments (Design Expert 6.0.8, Stat-Ease Inc., USA). Each 
formulation was prepared three times. All of the formulations gave mean size of 
DST-NLCs with mean greater than 100 nm at day 1 and day 14 (Table 3.7). At day 1, 
all formulations had mean hydrodynamic diameter between 177 – 279 nm, in the 
desired range for skin delivery (Lademann et al., 2007; Mahe et al., 2009; Mittal et 
al., 2015). A large increase (2-fold) of size after 14 days storage at 4°C indicated the 
samples were unstable which is evident for formulation S3 and S7 where the size 
increased to more than 500 nm (p<0.05). Having the lowest amount of stearic acid 
(50 mg) and highest amount of Lutrol® micro 68 (50 mg), with 25 or 50 mg of 
Phosal® 53 MCT would not produce small particles (p>0.05). Usually, surfactant is 
used to emulsify and stabilise the formulation, however, having the highest amount 
of surfactant (50 mg Lutrol® micro 68) with stearic acid (50 mg) did not produce the 
small size of particles which can be seen for S7. This result shows that an optimum 
amount of surfactant should be used in the formulation.    
  
 
1
0
8 
Table 3.7 Particle size distribution of DST-NLCs at day 1 and 14 stored at 4°C (n=3, mean ± SD) 
Formulation Stearic 
acid 
(mg) 
Lutrol® 
micro 68 
(mg) 
Phosal® 
53 MCT 
(mg) 
Hydrodynamic 
diameter (nm) 
(day 1) 
PDI  
(day 1) 
Hydrodynamic 
diameter (nm) 
(day 14) 
PDI  
(day 14) 
S1 50 25 25 211.5 ± 32.5 0.193 ± 0.019 259.1 ± 36.3 0.176 ± 0.027 
S2 100 25 25 246.8 ± 40.5 0.176 ± 0.024 307.6 ± 6.1 0.193 ± 0.014 
S3 50 50 25 278.6 ± 44.1 0.243 ± 0.013 528.9 ± 25.6 0.269 ± 0.049 
S4 100 50 25 190.3 ± 12.5 0.101 ± 0.016 229.0 ± 16.3 0.124 ± 0.019 
S5 50 25 50 274.4 ± 28.8 0.267 ± 0.029 356.8 ± 13.4 0.298 ± 0.035 
S6 100 25 50 269.5 ± 22.9 0.225 ± 0.011 330.5 ± 17.2 0.243 ± 0.091 
S7 50 50 50 221.2 ± 27.7 0.340 ± 0.039 527.0 ± 55.2 0.376 ± 0.025 
S8 100 50 50 176.8 ± 27.2 0.150 ± 0.017 217.9 ± 23.6 0.180 ± 0.008 
All formulations contain 5 mg of dutasteride
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Formulation S4 and S8 produced the smallest mean sizes. There was no 
significant difference (p>0.05) between S4 and S8, showing that within this ratio 
(100 mg stearic acid and 50 mg Lutrol® micro 68), the amount of Phosal® 53 MCT 
did not affect the size. The same was found in PDI results where there was no 
significant difference between S4 and S8 (p>0.05). The experimental design was 
used in order to find the interaction among the materials used. The model of 
hydrodynamic diameter and polydispersity index was analysed using ANOVA from 
Design Expert 6.0.8 (Stat-Ease, USA) software. The main independent factors 
studied that might influence the model of hydrodynamic diameter and polydispersity 
index were the amounts of stearic acid (A), the amount of Lutrol ® F68 (B) and the 
amount of Phosal® 53 MCT (C). Based on the design, 8 batches of formulation were 
prepared. At day 1, there was no significant difference in model term for the 
hydrodynamic diameter results (p>0.05) which showed all particles had similar range 
and no interaction was found between the materials used. However, after 14 days 
(stored at 4-8°C), there was a significant difference in the model term for the 
hydrodynamic diameter (Table 3.8), and there was an interaction between the 
materials used.  
Based on the model, stearic acid (A), and interaction between stearic acid (A) 
and Lutrol® micro 68 (B) showed a significant difference (p<0.05) (Table 3.8). Even 
though Phosal® 53 MCT was used as a secondary emulsifier, different amount of 
Phosal® 53 MCT either 25 or 50 mg in NLCs preparation showed no significant 
difference on hydrodynamic diameter (p>0.05). Stearic acid which was a major 
component in the system influenced the size of particles. When the highest amount of 
stearic acid (100 mg) was used, it needed more emulsifier to stabilize the 
nanoparticles. 25 mg of Lutrol® micro 68 produced a larger mean size of particles, 
suggesting that 25 mg of Lutrol® micro 68 was not sufficient to maintain the size of  
particles. When 25 mg or 50 mg of Phosal® 53 MCT was used in this formulation, 
stable nanoparticles with respect to mean size were obtained. The mathematical 
modelling between the independent variables (the amount of materials used in the 
DST-NLCs preparation) and dependent variables (hydrodynamic diameter) was 
obtained by the following equation (coded value at day 14):  
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Hydrodynamic diameter (nm) = 344.60 – 73.35*A + 31.10*B – 78.90*A*B      
Equation 3-7 
where; 
A – Stearic acid  
B – Lutrol® micro 68  
 
Table 3.8 Analysis of variance (ANOVA) for a 2
3
 factorial design for 
hydrodynamic diameter at day 14 (storage at 4°C) 
 Sum of 
squares 
df F-value P value 
Model 99861.59 3 26.13 0.0043* 
A 42748.88 1 33.56 0.0044* 
B 7626.12 1 5.99 0.0707 
AB 49486.58 1 38.85 0.0034* 
A – stearic acid, B – Lutrol® micro 68, * Significance level p<0.05 
 
Figure 3.4 shows the plot of interaction between stearic acid (A) and Lutrol® 
micro 68 (B) for the hydrodynamic diameter. Based on the graph (model), it was 
predicted that 100 mg stearic acid, 50 mg Lutrol® micro 68 and 25 or 50 mg 
Phosal® 53 MCT, the smallest mean size of particles with a hydrodynamic diameter 
of 223.5 nm would be produced. This is due to sufficient amount of the main 
surfactant, having the capability to stabilise and coat the whole of nanoparticles, 
resulting in the smaller size of particles.  
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Figure 3.4 3D figure of interaction between stearic acid (A) and Lutrol® micro 
68 (B) for hydrodynamic diameter at day 14 
 
Hydrophilic-lipophilic Balance (HLB) of surface active agents is one of the 
main criteria to be considered in order to develop a stable emulsion. The higher HLB 
value, the more water-soluble is the surfactant. In this case, Lutrol ® F68 has high 
HLB value>24 and soy phosphatidylcholine (53% in Phosal® 53 MCT) has low 
HLB value (HLB 4). By using a mix of emulsifiers, the emulsion can be stabilised in 
terms of coalescence rate (Trotta et al., 2003). When all particles have adequate 
amount of stabiliser or emulsifier, smaller mean size was resulted. Figure 3.5A shows 
the normal percent probability versus studentized residuals on hydrodynamic 
diameter. All the error terms were normally distributed, as all of the points 
approximated to a straight line. Figure 3.5B shows the predicted versus actual value 
for hydrodynamic diameters. In order to accept the model term, the value of 
coefficient determination (R-squared) is considered. At day 14, hydrodynamic 
diameter ‘R-squared’ was 0.9515 while the Predicted R-squared was 0.8058. At the 
end of the model, this value was in reasonable agreement with the ‘Adjustment R-
squared’ which was 0.9150.  
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Figure 3.5 Normal percent probability versus studentized residuals (A) and 
predicted versus actual value for hydrodynamic diameter at day 14 (B) 
 
The model for PDI showed significant difference (p<0.05) at day 14, 
indicating that the particle size distribution significantly increased with time (Table 
3.9). Model A, C, AB, and AC were significantly different with respect to PDI. 
Compared to the hydrodynamic diameter result, Phosal® 53 MCT alone did not 
influence the measurement, however, for the PDI, it affected the measurement. When 
the same amount of stearic acid (50 or 100 mg) and Lutrol® micro 68 (25 or 50) 
were used, increasing the amount of Phosal® 53 MCT (25 or 50 mg) resulted in 
increased polydispersity index. This model also confirmed that the interaction 
between stearic acid and Lutrol® micro 68 and Phosal® 53 MCT affected the 
measured value. 
 
Table 3.9 Analysis of variance (ANOVA) for 2
3
 factorial design for 
polydispersity index at day 14 (storage at 4°C) 
 Sum of 
squares 
df F-value p-value 
Model 0.046 5 267.18 0.0037* 
A 0.018 1 527.01 0.0019* 
B 1.805 x 10
-4
 1 5.27 0.1486 
C 0.014 1 412.03 0.0024* 
AB 0.012 1 337.28 0.0030* 
AC 1.861 x 10
-3
 1 54.32 0.0179* 
A – stearic acid, B – Lutrol® micro 68, C – Phosal® 53 MCT, * Significance level p<0.05 
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Figure 3.6 shows a 3D plot of the interaction between stearic acid (A) and 
Lutrol® micro F68 (B). 100 mg stearic acid, 50 mg Lutrol® micro 68 and 25 mg 
Phosal® 53 MCT would produce a narrow particle size distribution (PDI=0.125). 
When the amount of surfactant was increased, the size of particles reduced and a 
narrower particle size distribution was produced. Previous research found that an 
optimal amount of surfactant used in nanoparticle preparation decreased the size of 
particle (Prozorov et al., 1999). At a very low concentration of surfactant, 
aggregation is accelerated where the proportion of the particle surface that is coated 
is small. At a higher surfactant concentration, all the particles were coated, 
agglomeration reduced, and the particle size was reduced (Prozorov et al., 1999). 
However, if the surfactant concentration (in this case Phosal® 53 MCT) was 
increased excessively, it might produce a population of agglomerated particles 
having a larger size (due to the presence of liquid lipid in this surfactant, and an 
insufficient amount of Lutrol® micro 68) resulting in a higher PDI. 
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Figure 3.6 3D plot of interaction between stearic acid (A) and Lutrol® micro 68 
(B) (above), and stearic acid (A) and Phosal® 53 MCT  (C) (bottom) for the 
polydispersity index at day 14. 
 
Figure 3.7A shows the normal percent probability versus studentized 
residuals for polydispersity index. All the error terms were normally distributed as all 
of the points approximated to a straight line. As shown in Figure 3.7B the ‘Predicted 
R-squared’ (0.9761) from the model was in reasonable agreement with the 
‘Adjustment R-squared’ (0.9948). Equation 3-8 shows the model of the amount of 
materials used in the DST-NLCs preparation  PDI at day 14 (in coded number).  
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PDI at day 14  = 0.23 – 0.048*A + 4.750 x 10-3*B + 0.042*C – 0.038*A*B – 
0.015*A*C              
Equation 3-8 
where; 
A – Stearic acid  
B – Lutrol® micro 68 
C – Phosal® 53 MCT 
 
 
 
 
 
 
Figure 3.7 Normal percent probability versus studentized residuals (A) and 
predicted versus actual value for polydispersity index at day 14 (B)  
3.5.2.1.1 Surface charge 
Based on ANOVA analysis (Design Expert 6.0.8, Stat-Ease Inc. USA) on 
zeta potential values at day 14, there was no significant difference (p>0.05) on the 
model (Table 3.10). All particles had a surface charge of approximately -20 mV. 
Honary and Zahir (2013) reported that for a low molecular weight of stabilizers, zeta 
potential value at +/- 30 mV or more can give good stabilisation.  
Saeb et al. (2014) prepared silver nanoparticles with strong and stable 
antimicrobial activity with highly negatively-charged particles. When the surface 
charge was low (zeta potential value near to 0), the particles aggregated and 
flocculated due to absence of repulsive forces which prevent agglomeration. This 
showed that surface charge values indicate the physical stability of nanoparticles, 
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where large negative or positive charge will tend to repel each other and no tendency 
to flocculate or aggregate (Saeb et al., 2014).   
 
Table 3.10 Analysis of variance (ANOVA) for a 2
3
 factorial design for zeta 
potential at day 14 
 Sum of 
squares 
df F-value p-value 
Model 10.28 6 3.80 0.3739 
A 1.84 1 4.07 0.2929 
B 0.031 1 0.069 0.8362 
C 2.17 1 4.81 0.2724 
AB 2.46 1 5.44 0.2578 
AC 1.25 x 10
-3
 1 2.77 x 10
-3
 0.9665 
BC 3.78 1 8.38 0.2118 
A – stearic acid, B – Lutrol ® F68, C – Phosal® 53 MCT 
 
However, comparison of the surface charge between day 1 and day 14 (Figure 
3.8) showed an insignificant reduction (p>0.05) on the zeta potential values in 
Formulation S4, suggesting better stability compared to other formulations. Change 
in the surface charge is probably due to instability, such as aggregation. As 
aggregated particles have a lower surface area and reduction of surface charge 
compared to a single particle which has a higher surface area resulting in an increase 
of surface charge.  This result showed that, the measurement of surface charge on 
different days could be a useful indicator to predict the physical stability of the 
nanoparticles.  
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Figure 3.8 Zeta potential measurement of DST-NLCs at day 1 and 14 stored at   
4-8°C (n=3, mean ± SD) 
3.5.2.1.2 Entrapment efficiency and drug loading 
The relationship model of DST-NLCs between materials used and the 
entrapment efficiency and drug loading was analysed using an ANOVA analysis. 
The independent factors investigated that may affect entrapment efficiency and drug 
loading of DST-NLCs in theses formulations were the amount of stearic acid (A), 
Lutrol® F68 (B) and Phosal® 53 MCT (C). The entrapment efficiency for the 
formulations investigated was between 63 and 98% (Table 3.11).  
 
 
 
 
 
Ratio - Stearic acid : Lutrol® F68 micro : Phosal® MCT 53 
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Table 3.11 Entrapment efficiency and drug loading of DST-NLCs at day 1 (n=3, 
mean ± SD) 
Formulation  Stearic 
acid 
(mg) 
Lutrol® 
micro 68 
(mg) 
Phosal® 53 
MCT    
(mg) 
EE         
(%) 
 
DL           
(%) 
 
S1 50 25 25 79.6 ± 10.3 4.40 ± 0.58 
S2 100 25 25 81.7 ± 20.3 3.31 ± 0.75 
S3 50 50 25 63.2 ± 21.8 2.98 ± 0.61 
S4 100 50 25 97.6 ± 2.4 3.27 ± 0.07 
S5 50 25 50 80.0 ± 0.6 2.49 ± 0.65 
S6 100 25 50 97.7 ± 1.2 3.09 ± 0.35 
S7 50 50 50 64.8 ± 7.7 2.09 ± 0.32 
S8 100 50 50 92.5 ± 5.6 2.66 ± 0.24 
EE – entrapment efficiency, DL – drug loading 
Table 3.12 shows ANOVA results for the entrapment efficiency at day 1. 
Based on the model, no interaction was found among the materials used for 
entrapment efficiency. Stearic acid (A) content was found to affect the entrapment 
efficiency. Figure 3.9 shows 100 mg stearic acid, 50 mg Lutrol® micro 68 and 25 or 
50 mg Phosal® 53 MCT produced the highest entrapment efficiency (predicted from 
the design of experiment model = 95.1%). The amount of stearic acid had a 
significant effect on the entrapment efficiency (p<0.05). By increasing the amount of 
stearic acid from 50 to 100 mg, it was predicted that the entrapment efficiency 
increased from 64 to 95.1%, suggesting a higher amount of stearic acid was needed 
in order to load dutasteride in nanoparticle preparation.   
At day 1, even though the mean size of particles were in a similar range 
(approximately 200 nm), some formulations produced lower entrapment efficiency. 
This may be due to insufficient amount of surfactant, resulting in lower entrapment 
of dutasteride. S4, S6, and S8 showed high entrapment, greater than 90% (Table 
3.11). However, the hydrodynamic diameter for S6 after day 14 was greater than 300 
nm, and therefore this formulation was not considered for the next set of 
experiments. Based on the results for entrapment efficiency and size, formulations S4 
and S8 were carried forward for the next experiment.  
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At this stage, entrapment efficiency was considered to be important, but 
secondary factor to particle size. The main factor to be considered was the size of the 
particles which should be stable and within a certain range (200 – 300 nm). 
Entrapment efficiency can be modified based on the amount of drug added into the 
carriers. Once the optimal formulation based on the hydrodynamic diameter and PDI 
was identified, optimisation based on entrapment efficiency was undertaken later. 
 
Table 3.12 Analysis of variance (ANOVA) for a 2
3
 factorial design for 
entrapment efficiency at day 1 
 Sum of 
squares 
df F-value p-value 
Model 1116.71 3 10.46 0.0230* 
A 838.45 1 23.56 0.0083* 
B 54.80 1 1.53 0.2832 
AB 223.66 1 6.28 0.0663 
A – stearic acid and B – Lutrol ® F68, * Significance level p<0.05 
 
The mathematical modelling of DST-NLCs between the materials used 
(independent variables) and entrapment efficiency (dependent variables) was 
described by the following equation (coded value): 
 
EE% = 82.14 + 10.24*A – 2.61*B + 5.29*A*B                            Equation 3-9 
 
where; 
A – stearic acid  
B – Lutrol® micro 68 
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Figure 3.9 3D plot of stearic acid (A) and Lutrol® micro 68 (B) for the 
entrapment efficiency (%) 
 
When drug loading was analysed using Design Expert ANOVA, there was no 
significant difference of the model between materials used and drug loading (p>0.05) 
(Table 3.13).  Changing the amount of materials used did not produce any linear 
model, suggesting that the large standard deviation values of total drug loading 
resulted in no significant model being generated. At this stage, drug loading can be 
neglected as a main criterion, whereas the size distribution would be considered.  
 
Table 3.13 Analysis of variance (ANOVA) for a 2
3
 factorial design on drug 
loading at day 1 
 Sum of 
squares 
df F-value p-value 
Model 3.03 5 4.07 0.2090 
A 0.017 1 0.11 0.7670 
B 0.66 1 4.40 0.1707 
C 1.65 1 11.05 0.0798 
AB 0.23 1 1.53 0.3419 
AC 0.49 1 3.25 0.2130 
A – stearic acid, B – Lutrol ® F68, C – Phosal® 53 MCT 
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3.5.2.1.3 Hydrodynamic diameter, particle size distribution and entrapment 
efficiency for DST-NLCs: effect of scaled-up formulation 
Based on the results of particle size distribution outlined in Section 3.5.2.1, 
only 1 formulation (Formulation S4) was chosen. Production quantities were scaled 
up 3 times (3x) with or without DST, using the same ratio of materials. Table 3.14 
shows the mean hydrodynamic diameter, PDI and entrapment efficiency which were 
not significantly altered by scaling up (p>0.05). The surface charge of scaled-up 
DST-NLCs and NLCs (without DST) was slightly lower (p<0.05) than non-scaled-up 
DST-NLCs. 
 
Table 3.14 Hydrodynamic diameter, PDI and zeta potential of DST-NLCs after 
scaled-up (day 1) (n=3, mean ± SD) 
Formulation Hydrodynamic 
diameter 
(nm) 
PDI Zeta 
Potential 
(mV) 
Entrapment 
efficiency  
(%) 
x (with DST) 190.3 ± 12.5 0.101 ± 0.016 -22.0 ± 1.2 97.6 ± 2.4 
3x (with DST) 178.6 ± 18.4 0.124 ± 0.025 -17.1 ± 0.9 96.6 ± 0.1 
3x (without DST) 176.5 ± 1.9 0.117 ± 0.010 -17.8 ± 2.8 - 
x - Refers to scale-up time, 15 mg dutasteride  
3.5.2.1.4 Entrapment efficiency and drug loading of DST-NLCs: Optimisation 
of dutasteride content in scaled-up NLCs 
The amount of dutasteride was optimised in order to determine the maximum 
dutasteride that could be loaded in the NLCs. 17.5 mg dutasteride (DST 17.5) was 
found to be the optimal content, giving highest entrapment efficiency (97.3 ± 1.2%) 
as shown in Figure 3.10. No significant difference in the entrapment efficiency 
between 15 mg and 17.5 mg of dutasteride was observed (p>0.05). When drug 
content was increased to 20 mg (DST 20), the entrapment efficiency decreased to 
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90.1 ± 1.1% (p<0.05), indicating the limitation of the amount of drug that can be 
loaded in this carrier system, as reported previously (Gaber et al., 2006). There was 
no significant difference (p>0.05) in drug loading (3.49 ± 0.10%) for 17.5 mg of 
dutasteride in the NLCs when the amount of drug was varied from 15 to 20 mg. 
 
 
Figure 3.10 Entrapment efficiency and drug loading of DST-NLCs with 
different amounts of dutasteride (15, 17.5 and 20 mg) (n=3, mean ±SD) 
3.5.2.2 Size distribution and zeta potential of DST-NLCs before and after 
coating with CSO-SA and CSO 
DST-NLCs were prepared and coated with different concentrations of CSO-
SA (2.5, 5 and 10%) and 5% CSO as shown in Table 3.15. Based on statistical 
analysis, there was no significant increase in mean particle size for DST-NLCs 
(p>0.05) when coated with 2.5% CSO-SA and 5% CSO. Coating of DST-NLCs with 
5 and 10% CSO-SA produced significant increases in mean size (p<0.05) compared 
to uncoated DST-NLCs. In term of the PDI, there was no significant difference 
(p>0.05) between uncoated DST-NLCs and those coated with different 
concentrations of CSO-SA preparations. All PDI measurements showed values less 
than 0.3 indicating the particles were in monodisperse nanoparticle populations 
(Tagalakis et al., 2015).   
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Table 3.15 Size distribution and surface charge for DST-NLCs before and after 
coating with different concentrations of CSO-SA and CSO (n=3, mean ± SD) 
Parameter DST-
NLCs 
DST-
NLCs 
2.5% 
CSO-SA 
DST-
NLCs 
5%  
CSO-SA 
DST-
NLCs 
10% 
CSO-SA 
DST-
NLCs 
5% 
CSO 
Hydrodynamic 
diameter (nm) 
187.6 ± 
7.0 
207.8 ± 
10.5 
220.1 ± 
11.9 
230.1 ± 
8.2 
208.4 ± 
1.6 
PDI 0.117 ± 
0.008 
0.124 ± 
0.009 
0.149 ± 
0.024 
0.147 ± 
0.026 
0.167 ± 
0.025 
Zeta potential 
(mV) 
-18.3 ± 
0.9 
+23.2 ± 
2.1 
+26.0 ± 
1.1 
+30.0 ± 
1.2 
+21.7 ± 
2.1 
   All preparations contain 17.5 mg dutasteride 
The zeta potential values of DST-NLCs changed from negative to positive 
following coating (p<0.05), with CSO-SA or CSO adsorbed to negative charged 
DST-NLCs, producing positively-charged nanoparticles (Table 3.15). Zeta potential 
increased from +26.0 to +30.0 mV when concentration of CSO-SA was increased 
from 5% to 10% (p<0.05). The charge was higher for DST-NLCs coated with 5% 
CSO-SA than with 5% CSO (p<0.05). These findings indicated a strong interaction 
between DST-NLCs and CSO-SA, potentially stabilising the nanoparticles. This may 
result in part, from CSO-SA having some amphiphilic properties, as reported by Hu 
et al., (2009) who produced stable doxorubicin-loaded polymeric micelles with 
surface charge of +32 to +44 mV using a chitosan oligomer-stearic acid conjugate. It 
is likely that the highly positively-charged CSO-SA was bound electrostatically to 
the negatively-charged surface of DST-NLCs.  
Previous studies (Fonte et al., 2011; Luo et al., 2011; Nair et al., 2012; Ridolfi 
et al., 2012; Kuo and Wang, 2013) have demonstrated the electrostatic interaction 
between positively-charged chitosan and negatively-charged nanoparticles. 
Generally, the colloidal system is stable if zeta potential value is higher than           
+/-30 mV (Xu et al., 2011).  
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3.5.2.2.1 Stability of DST-NLCs, uncoated and coated with CSO-SA and CSO 
3.5.2.2.1.1 Hydrodynamic diameter, PDI and surface charge 
Physical stability tests are important in order to evaluate the quality of 
formulation over a certain period. Determination of particle size changes allows for 
verification of the time-dependent stability of particles regarding the tendency for 
aggregation and sedimentation (Gomes et al., 2014). Uncoated DST-NLCs and those 
coated with 2.5, 5 and 10% CSO-SA were stable at 4-8°C over a period of 180 days, 
with all measured mean particle sizes in the range approximately 200 nm to 250 nm.  
DST-NLCs coated with 2.5, 5 and 10% CSO-SA had unchanged mean 
particle size and PDI (p>0.05) when compared between day 1 and day 60 (Table 
3.16). There was a significant difference in the mean particle size between day 1 and 
day 180 (p<0.05). Though, between samples at day 180, there was no significant 
difference (p>0.05). DST-NLCs coated with 5% CSO demonstrated physical 
instability, with aggregation even when stored at 4-8 and 25°C (day 30), possibly due 
to differences in the chemical structures of the CSO compared to CSO-SA, which has 
a  hydrophobic chain absent in unconjugated CSO. 
At day 30, DST-NLCs coated with 10% CSO-SA aggregated when stored at 
25°C. Increasing the concentration of CSO-SA to 10% produced aggregation, 
possibly resulting from excess CSO-SA in the formulation, not associated with the 
NLC coating. In addition, when uncoated DST-NLCs and those coated with 2.5 and 
5% CSO-SA were stored at 25°C, the mean particle size increased 2-fold at day 30 
compared to samples stored at 4-8°C.  
The data indicated NLCs coated with chitosan without conjugation were 
relatively unstable. Having the hydrophobic stearoyl chain which produces 
amphiphilic properties in the chitosan-conjugate may enhance the stability of the 
nanoparticles when the CSO-SA (at an appropriate concentration) is employed as a 
coating material. 
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Table 3.16 Size distribution and surface charge of DST-NLCs, uncoated and coated with CSO-SA or CSO (n=3, mean ± SD) 
Storage condition DST-NLCs DST-NLCs 
2.5% CSO-SA 
DST-NLCs 
5% CSO-SA 
DST-NLCs 
10% CSO-SA 
DST-NLCs  
5% CSO 
Day 1 (Initial)       
Hydrodynamic 
diameter (nm) 
187.6 ± 7.0 207.8 ± 10.5 220.1 ± 11.9 230.1 ± 8.2 208.4 ± 1.6 
PDI 0.117 ± 0.008 0.124 ± 0.009 0.149 ± 0.024 0.147 ± 0.026 0.167 ± 0.025 
Zeta potential (mV) -18.3 ± 0.9 +23.2 ± 2.1 +26.0 ± 1.1 +30.0 ± 1.2 +21.7 ± 2.1 
Day 30 at 4-8°C      
Hydrodynamic 
diameter (nm) 
216.8 ± 6.0 226.3 ± 19.8 239.0 ± 24.3 241.9 ± 7.5 Aggregation 
PDI 0.132 ± 0.017 0.162 ± 0.041 0.193 ± 0.064 0.213 ± 0.006 Aggregation 
Zeta potential (mV) -17.2 ± 2.6 +28.8 ± 3.6 +33.9 ± 1.8 +33.8 ± 1.8 Aggregation 
Day 30 at 25°C      
Hydrodynamic 
diameter (nm) 
435.3 ± 32.0 463.8 ± 34.5 443.6 ± 62.9 Aggregation Aggregation 
PDI 0.208 ± 0.036 0.280 ± 0.129 0.233 ± 0.032 Aggregation Aggregation 
Zeta potential (mV) -17.0 ± 0.7 +21.6 ± 6.6 +24.0 ± 1.0 Aggregation Aggregation 
 
 
 
 
 
  
 
1
2
6
 
      
      
Day 60 at 4-8°C      
Hydrodynamic 
diameter (nm) 
2 28.5 ± 6.8 234.5 ± 22.9 243.8.0 ± 18.8 259.8 ± 4.2 Aggregation 
PDI 0.128 ± 0.004 0.164 ± 0.048 0.155 ± 0.025 0.215 ± 0.020 Aggregation 
Zeta potential (mV) -17.2 ± 2.6 +31.4 ± 2.4 +32.2 ± 10.4 +29.4 ± 5.6 Aggregation 
Day 60 at 25°C      
Hydrodynamic 
diameter (nm) 
435.3 ± 32.0 631.8 ± 149.8 578.2 ± 27.0 Aggregation Aggregation 
PDI 0.208 ± 0.036 0.229 ± 0.016 0.274 ± 0.113 Aggregation Aggregation 
Zeta potential (mV) -18.9 ± 1.6 +20.0 ± 2.8 +20.0 ± 1.6 Aggregation Aggregation 
Day 180 at 4-8°C      
Hydrodynamic 
diameter (nm) 
242.4 ± 8.6 241.1 ± 8.4 246.5 ± 5.8 275.4 ± 10.0 Aggregation 
PDI 0.137 ± 0.026 0.147 ± 0.024 0.152 ± 0.008 0.248 ± 0.016 Aggregation 
Zeta potential (mV) -16.5 ± 0.9 +31.9 ± 1.9 +32.3 ± 2.0 +32.1 ± 1.1 Aggregation 
Day 180 at 25°C      
Hydrodynamic 
diameter (nm) 
Aggregation Aggregation Aggregation Aggregation Aggregation 
PDI Aggregation Aggregation Aggregation Aggregation Aggregation 
Zeta potential (mV) Aggregation Aggregation Aggregation Aggregation Aggregation 
      
 
(Table 3.16 continued) 
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Chitosan undergoes gradual chain degradation followed by the destruction of 
functional groups which results in loss of physicochemical properties (Szymańska 
and Winnicka, 2015). Szymańska and Winnicka, (2015) reported that many studies 
have been conducted in order to increase the stability of chitosan-based system such 
as adding stabilizer (mannitol, sorbitol, glycerol) during storage, or cryoprotectant 
(mannitol, sucrose, trehalose) during freeze-drying process, adding metal ion in 
chitosan/hyaluronate complexes, blending with other non-ionic polymers and also 
chemical or physical crosslinking with chitosan. Fernandes et al., (2013) found that 
chitosan crosslinked with genipin influenced the swelling ability, mucoadhesiveness, 
and acidic stability of the prepared microparticles. Chemical crosslinking has shown 
to give higher stability, where it reduces the gelation process. The conjugation 
between chitosan backbone and the hydrophobic chain has increased the chitosan 
stability. The data in Table 3.16 shows that having a hydrophobic chain (stearic acid) 
attached to the CSO has made the conjugated CSO-SA more stable compared to 
unconjugated chitosan. 
The size of particles (200 - 300 nm) showed an acceptable range for the 
topical delivery as in agreement with Mahe et al., (2009), where they found that 
particles of approximately 200 nm mean sizes applied to the skin were found around 
the hair follicles. Mittal et al., (2015) reported that particles with a size 
approximately 300 nm were found in the transfollicular region. These studies suggest 
to deliver the drug into the hair follicle regions, size of particles in the range of 200-
300 nm is appropriate. 
 
3.5.2.2.1.2 Entrapment efficiency 
Due to the gelling properties of chitosan, the DST-NLCs coated with CSO-
SA or CSO could not pass down the Sephadex gel, prohibiting measurement of the 
entrapment efficiency. Hence, entrapment efficiency was measured only for uncoated 
samples (DST-NLCs). Based on Figure 3.11, the entrapment efficiency was 
monitored for 6 months at 4-8°C. The results showed the entrapment efficiency was 
97.3 ± 1.2% on day 1 with no significant reduction (p>0.05) at day 180 (96.6 ± 
1.9%), indicating considerable stability.  
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Figure 3.11 Entrapment efficiency of DST-NLCs uncoated at day 1, 30, 60, 90 
and 180 stored at 4-8°C (n=3, mean ± SD) 
3.5.2.3 Morphology of uncoated and coated DST-NLCs 
Figure 3.12 shows TEM of uncoated DST-NLCs and those coated with 
CSO/CSO-SA nanoparticles. All samples showed monodispersed nanoparticles, 
spherical in shape, in the size range approximately 200 to 250 nm, consistent with the 
dynamic light scattering characterisation.  
Based on the figures, DST-NLCs coated with 5% CSO (Figure 3.12B) shows 
a denser layer of coating compared to DST-NLCs coated with 5% CSO-SA or 10% 
CSO-SA. Even though DST-NLCs coated with 5% CSO showed denser layer 
compared to those coated with 5% CSO-SA, however it did not help the stability of 
the samples after day 30 (Section 3.5.2.2.1). Smaller particles were present with the 
main larger DST-NLCs can be seen from Figure 3.12C and D, suggesting excess 
amounts of CSO-SA in the preparations. Absence of excess CSO can be seen for 
DST-NLCs coated with 5% CSO (Figure 3.12B), resulting all DST-NLCs particles 
have been fully coated with 5% CSO. 
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Figure 3.12 TEM images of DST-NLCs, uncoated (A), coated with; 5% CSO 
(B), 5% CSO-SA (C) and 10% CSO-SA (D) 
 
A similar trend can be seen from Figure 3.12A for uncoated DST-NLCs, 
suggesting all surfactants (Lutrol® micro 68 and Phosal® 53 MCT) have been fully 
emulsified and stabilised the formulation, with no evident excess of surfactants. 
These results were in agreement with the CMC results of CSO-SA (Section 2.4.4) 
where 2.5% CSO-SA (0.12 mg/mL of CSO-SA in DST-NLCs preparations) existed 
as a monomer, meanwhile concentrations greater than CMC values: 5% CSO-SA 
(0.24 mg/mL of CSO-SA in DST-NLCs preparations) and 10% CSO-SA (0.48 
A B 
C D 
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mg/mL of CSO-SA in DST-NLCs preparations), resulted in micelles in preparation 
of DST-NLCs.        
3.5.3 Preparation and characterisation of dutasteride-loaded nanostructured 
lipid carrier coated with chitosan oligomer-lauric acid  
3.5.3.1 Particle size distribution and zeta potential 
DST-NLCs were prepared and coated with different concentrations of CSO-
LA (2.5, 5 and 10% w/w of solid lipid) as shown in Table 3.17. Based on the 
statistical analysis, uncoated DST-NLCs produced a mean particle size of 184.2 ± 2.9 
nm, and no significant difference (p>0.05) was found with DST-NLCs coated with 
2.5 and 5% of CSO-LA. Coating DST-NLCs with 10% CSO-LA produced a 
significant increase (p<0.05) in mean size, suggesting a thicker layer of coating 
existed on DST-NLCs.  
 
Table 3.17 Size distribution and surface charge for DST-NLCs before and after 
coating with different concentrations of CSO-LA (n=3, mean ± SD) 
Storage 
condition 
DST-NLCs DST-NLCs 
2.5% CSO-LA 
DST-NLCs 
5% 
CSO-LA 
DST-NLCs 
10% 
CSO-LA 
Hydrodynamic 
diameter (nm) 
184.2 ± 2.9 183.8 ± 1.3 188.4 ± 2.2 199.5 ± 3.3 
PDI 0.118 ± 0.016 0.115 ± 0.015 0.124 ± 0.011 0.118 ± 0.009 
Zeta potential 
(mV) 
-18.0 ± 2.3 +19.9 ± 2.6 +24.8 ± 2.1 +29.2 ± 2.0 
All preparations contain 17.5 mg dutasteride 
In terms of PDI, there was no significant difference (p>0.05) between 
uncoated DST-NLCs and those coated with different concentrations of CSO-LA. All 
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PDI measurements were less than 0.3, indicating monodisperse nanoparticle 
populations (Tagalakis et al., 2015).   
For the surface charge, a similar trend was found as for coating with CSO-
SA, with DST-NLCs coated with different concentration of CSO-LA resulted in a 
significant change of zeta potential values from negative (-18.0 ± 2.3 mV) to more 
than +20 mV of charge (p<0.05). Significant increases (p<0.05) in surface charge 
were found when the amount of CSO-LA increased from 2.5 to 5.0 and 10%. Zhao et 
al. (2014) prepared chitosan conjugated with lauric acid, though no measurement of 
surface charge was reported. As chitosan normally is positively-charged, they found 
that surface modification of titanium substrate with chitosan-lauric acid was 
deposited onto an implant surface and improved the biological functions of 
osteoblasts, and at the same time reduced bacterial infection. In the in vitro tests, they 
have confirmed that the cell adhesion, cell viability, intracellular alkaline 
phosphatase activity and mineralization capacity of osteoblasts were significantly 
improved when cultured onto chitosan-lauric acid surface functionalized titanium 
substrates (Zhao et al., 2014), suggesting the positive charge of the chitosan 
improved the biocompatibility and addition of lauric acid improved antibacterial 
activity.  
3.5.3.2 Stability of DST-NLCs, uncoated and coated with CSO-LA 
3.5.3.2.1 Hydrodynamic diameter, PDI and surface charge 
Section 3.5.2.2.1.describes how the particles produced in this study were not 
stable when stored at room temperature, thus the stability of uncoated and DST-
NLCs coated with CSO-LA was determined at 4-8°C. DST-NLCs uncoated and 
coated with different concentrations of CSO-LA had significantly different mean 
particles size at day 1 and day 180 (p<0.05) (Table 3.18). DST-NLCs coated with 5% 
CSO-LA were stable with respect to mean size from day 30 to day 180 (p>0.05).  
  
 
1
3
2 
Table 3.18 Size distribution and surface charge of DST-NLCs, uncoated and coated with CSO-LA at day 1, 30, 60 
and 180 stored at 4-8°C (n=3, mean ± SD) 
Storage condition DST-NLCs DST-NLCs 
2.5% CSO-LA 
DST-NLCs       
5% CSO-LA 
DST-NLCs       
10% CSO-LA 
Day 1 (Initial)      
Hydrodynamic diameter 
(nm) 
184.2 ± 2.9 183.8 ± 1.3 188.4 ± 2.2 199.5 ± 3.3 
PDI 0.118 ± 0.016 0.115 ± 0.015 0.124 ± 0.011 0.118 ± 0.009 
Zeta potential (mV) -18.0 ± 2.3 +19.9 ± 2.6 +24.8 ± 2.1 +29.2 ± 2.0 
Day 30 at 4-8°C     
Hydrodynamic diameter 
(nm) 
221.7 ± 3.4 217.5 ± 7.8 228.7 ± 14.1 252.0 ± 4.4 
PDI 0.137 ± 0.017 0.131 ± 0.003 0.143 ± 0.054 0.196 ± 0.018 
Zeta potential (mV) -18.1 ± 1.9 +28.7 ± 3.4 +32.2 ± 1.6 +32.6 ± 1.6 
Day 60 at 4-8°C     
Hydrodynamic diameter 
(nm) 
235.1 ± 4.8 230.2 ± 9.5 237.0 ± 7.0 275.3 ± 18.9 
PDI 0.132 ± 0.015 0.131 ± 0.017 0.130 ± 0.009 0.198 ± 0.021 
Zeta potential (mV) -18.2 ± 0.5 +27.5 ± 3.1 +31.9 ± 5.0 +33.3 ± 2.7 
Day 180 at 4-8°C     
Hydrodynamic diameter 
(nm) 
265.3 ± 7.8 251.7 ± 10.0 249.4 ± 7.1 283.8 ± 12.0 
PDI 0.149 ± 0.015 0.130 ± 0.024 0.130 ± 0.024 0.197 ± 0.030 
Zeta potential (mV) -15.8 ± 1.0 +25.6 ± 6.2 +31.4 ± 6.0 +31.2 ± 3.0 
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DST-NLCs coated with 2.5 and 10% CSO-LA produced an insignificant 
difference (p>0.05) of mean size from day 30 to day 60 and significant increase 
(p<0.05) at day 180, suggesting the formulation of CSO-LA in the preparation 
resulted in gelation. Having the hydrophobic chain (lauroyl chain) in the chitosan-
conjugate could enhance the stability of the nanoparticles when the CSO-LA (at an 
appropriate concentration) was employed as a coating material. In this case, coating 
DST-NLCs with 5% CSO-SA showed the highest stability where there was no 
significant difference (p>0.05) in the hydrodynamic diameter when compared 
between day 30 to day 60 and day 180.  
In terms of PDI value, there was no significant difference (p>0.05) between 
day 1 to day 180 for all formulations except DST-NLCs coated with the highest 
concentration (10% CSO-LA) produced significant increase (p<0.05) from day 1 to 
day 30, 60 and 180. This result showed that there was a limitation of the amount of 
coating materials should be added in the nanoparticles formulation in order to control 
the PDI of the samples. Having the highest concentration of CSO-LA (10%) 
produced a larger size with a higher PDI value due to an excess amount of CSO-LA 
in the preparation. 
The zeta potential of uncoated DST-NLCs was changed from negative to 
positive charge (p<0.05), coated with CSO-LA (Table 3.18). Zeta potential values 
increased when the concentration of CSO-LA increased (p<0.05). These findings 
indicated a good interaction between DST-NLCs and CSO-LA. These results were 
similar to the previous section (3.5.2.2). Increasing concentration of CSO-LA added 
into DST-NLCs showed an increment of the surface charge; suggesting a presence of 
a thicker coating on DST-NLCs. 
3.5.3.3 Morphology of uncoated and coated DST-NLCs  
TEMs of the uncoated DST-NLCs and those coated with CSO-LA showed 
monodispersed spherical nanoparticles in the size range approximately 200 to 250 
nm, consistent with the dynamic light scattering results (Figure 3.13).     
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Figure 3.13 TEM images of DST-NLCs, uncoated (A), coated with; 2.5% CSO-
LA (B), 5% CSO-LA (C) and 10% CSO-LA (D) 
 
Coating with 5 and 10% CSO-LA showed a similar TEM image to the 
observation for DST-NLCs coated with CSO-SA (Section 3.5.2.3), where the smaller 
particles were present with the main larger particles (Figure 3.13C and D). At 5 and 
10% CSO-LA concentrations, CSO-LA was present in a micellar system; resulting 
due to concentration was higher than CMC value of CSO-LA (Section 2.4.4). There 
were no small particles present for coating with 2.5% CSO-LA, suggesting this 
concentration was lower than the CMC value, resulting CSO-LA present in a 
monomer (Figure 3.13B).   
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3.5.3.4 XRPD of DST-NLCs, uncoated and coated with 5% CSO-SA, 5% CSO-
LA and physical mixture of formulation components 
XRPD was performed to characterise the crystallinity of the formulations. 
The X-ray diffraction pattern of lyophilised DST-NLCs either uncoated or coated 
with CSO-SA or CSO-LA as well as the physical mixture of the ingredients used and 
also the pure stearic acid, Lutrol® micro 68 and combination of stearic acid and 
Phosal® 53 MCT are shown in Figure 3.14.  
The XRPD diffractogram of dutasteride shows a number of sharp diffraction 
peaks at 2θ of 15.6, 17.9, 19.7, 20.6, 21.6 and 22.9, indicating the crystalline nature 
of dutasteride (Figure 3.14). However, when dutasteride was formulated into NLCs 
either coated or uncoated with CSO-SA or CSO-LA, the crystallinity of the drug 
reduced with evidence of amorphous structure. There was only a broad diffraction 
peak at 2θ of 6.6 and 21.5 which came from the stearic acid as the main ingredient 
used in the formulation. By comparing pure stearic acid with DST in NLCs system, 
either coated or uncoated with CSO-SA or CSO-LA, the peak intensities were 
weaker, indicating the degree of crystallinity of stearic acid in the NLCs system was 
reduced. This result agrees with similar research where the degree of crystallinity of 
monocaprate was reduced when formulated in SLNs and NLCs (Lin et al., 2007). 
Coating DST-NLCs with 5% CSO-SA or 5% CSO-LA produced no difference in the 
XRPD diffractogram. 
The physical mixture (dutasteride, stearic acid, Phosal® 53 MCT, Lutrol® 
micro 68, either with or without 5% CSO-SA/5% CSO-LA was homogeneously 
mixed using pestle and mortar), gave sharp diffraction peaks at 2θ of 6.65, 21.5 and 
24.2 which came from the stearic acid. There were also broad peaks at 2θ of 23.2 
which came from Lutrol® micro 68. Hence, when dutasteride is loaded into NLCs, 
either coated or without coated, the degree of the crystallinity of dutasteride is 
reduced, and there is evidence of the amorphicity, and dutasteride appears 
homogeneously dispersed in the NLC system. 
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Figure 3.14 X-ray diffractograms of dutasteride, physical mixture and freeze-
dried formulations DST-NLCs uncoated and coated with CSO-SA and CSO 
(carriers: stearic acid, Phosal® 53 MCT, Lutrol® micro 68) 
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3.5.3.5 DSC of DST-NLCs, uncoated and coated with 5% CSO-SA, 5% CSO-
LA and physical mixture of formulations components 
Figure 3.15 shows DSC thermograms for dutasteride alone, stearic acid, 
Lutrol® micro 68, freeze-dried DST-NLCs, uncoated and coated with 5% CSO-SA 
or 5% CSO-LA, and physical mixtures of bulk materials with and without CSO-SA 
or CSO-LA. In this study, all samples show endothermic peaks. Dutasteride has a 
sharp endothermic peak at 249.97°C, corresponding to the melting point of 
dutasteride (GlaxoSmithKline Inc., 2013). This demonstrated the crystalline nature of 
the drug, in agreement with XRPD data (Section 3.5.3.4). Stearic acid, used as the 
main ingredient of NLCs also showed a sharp endothermic peak at 69.09°C which 
showed that it was in the crystalline state, in agreement with the literature (Inoue et 
al., 2004).  
The physical mixture of dutasteride, stearic acid, Phosal® 53 MCT and 
Lutrol® micro 68 (without coating) produced no endothermic peak for dutasteride. 
Medium chain triglyceride in the Phosal® 53 MCT as a liquid lipid acts as a solvent 
for dutasteride. The endothermic peaks for stearic acid melting in the physical 
mixture with or without 5% CSO-SA or 5% CSO-LA were 68.5, 67.9 and 68.6°C, 
respectively. 
A similar result was found for freeze-dried DST-NLCs uncoated and coated 
with 5% CSO-SA or 5% CSO-LA, where no endothermic peak of dutasteride was 
observed as it is likely that dutasteride dissolved in the lipid carriers. However, the 
endothermic peaks for stearic acid were shifted to 66.3, 66.1 and 66.0°C for the 
freeze-dried DST-NLCs uncoated and coated with 5% CSO-SA and 5% CSO-LA. 
Endothermic peaks for freeze-dried DST-NLCs uncoated were sharper compared to 
those coated with 5% CSO-SA or CSO-LA, which produced broader peaks. These 
results suggest that the presence of chitosan was in agreement with a previous study 
(El-Hefian et al., 2011). El-Hefian et al., (2011) reported that decreasing the ratio of 
chitosan/PVA produced broader peak and shifted the peak to a lower temperature. 
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Figure 3.15 DSC thermograms of dutasteride, physical mixture and freeze-dried 
formulations DST-NLCs uncoated and coated with CSO-SA and CSO (carriers: 
stearic acid, Phosal® 53 MCT, Lutrol® micro 68) 
 
The absence of an endothermic peak of drug melting in the nanoparticles 
formulation suggests that drug was in the amorphous state as in agreement with Lin 
et al. (2007). It can be concluded that dutasteride was in the amorphous phase and 
homogeneously dispersed in the NLCs, either coated or uncoated with 5% CSO-SA 
or 5% CSO-LA. These less crystallinity structure (due to the combination of solid 
lipid and liquid lipid in the NLCs system) suggests a sustained dutasteride release to 
the skin which is suitable for the topical application as described in the previous 
study (Pardeike et al., 2009). It is suggested that a sustained drug release is suitable 
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for drugs that are irritating at high concentrations or for drugs that need to be applied 
for long duration. 
3.5.3.6 Viscosity of DST-NLCs uncoated and coated with 5% CSO-SA and 5% 
CSO-LA 
As shown in Table 3.19, the dynamic viscosity of DST-NLCs uncoated with 
5% CSO-SA or % CSO-LA at an angle of 70° was 1.088 mPa.s at 20°C. There was 
no significant difference (p>0.05) when the angle of the capillary was decreased 
from 70° to 60° and 50°. However, when the temperature was increased from 20°C 
to 32°C and 37°C at a 70° angle, the viscosity of the sample significantly reduced 
(p<0.05).  
 
Table 3.19 Viscosity of DST-NLCs uncoated and coated with CSO-SA or CSO-
LA at different temperature and angles (n=3, mean ± SD) 
Temperature Dynamic viscosity at different angles, mPa.s  
70° 60° 50° 
DST NLCs    
20°C 1.088 ± 0.025  1.092 ± 0.030 1.095 ± 0.035 
32°C 0.856 ± 0.027 0.858 ± 0.029 0.860 ± 0.033 
37°C 0.785 ± 0.031 0.787 ± 0.034 0.792 ± 0.042 
    
DST NLCs           
5% CSO-SA 
   
20°C 1.160 ± 0.012 1.160 ± 0.011 1.161 ± 0.011 
32°C 0.881 ± 0.016 0.880 ± 0.015 0.879 ± 0.014 
37°C 0.787 ± 0.014 0.785 ± 0.013 0.783 ± 0.014 
    
DST NLCs           
5% CSO-LA 
   
20°C 1.156 ± 0.028 1.149 ± 0.018 1.145 ± 0.013 
32°C 0.878 ± 0.007 0.877 ± 0.006 0.878 ± 0.002 
37°C 0.797 ± 0.004 0.795 ± 0.003 0.794 ± 0.002 
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The dynamic viscosity for DST-NLCs coated with 5% CSO-SA at an angle 
70° (at 20°C) was significantly greater (p<0.05) than for the uncoated DST-NLCs. 
Similar results as with DST-NLCs were found, with no significant difference 
(p>0.05) when the angle was decreased to 60° and 50°. When the temperature was 
increased to 32°C and 37°C, the viscosity was found to reduce significantly (p<0.05). 
Similarly with DST-NLCs, coating with 5% CSO-LA, increased viscosity of 
the formulation to 1.156 mPa.s (70° angle at 20°C). No significant difference 
(p>0.05) was found when the angle was decreased to 60° and 50°. Similarly 
increasing the temperature to 32° and 37°, reduced viscosity (p<0.05). By increasing 
the temperature, the molecules move faster and reduced the viscosity (Al-Shammari 
et al., 2011). 
Usually, colloidal suspensions do not follow the Newtonian behaviour which 
has a linear relationship between shear stress and shear rate (Bergenholtz et al., 
2002). Based on these results, for coated and uncoated DST-NLCs, changing the 
angle of flow did not change the dynamic viscosity. These results indicate the 
formulations were acting as Newtonian fluids, suggesting the nanoparticles prepared 
were too dilute. As chitosan is used as a natural thickener for topical or oral 
applications, adding chitosan in the formulation increased the viscosity of the 
products, suggesting a better retention of drug on the skin and a reduction of drug in 
the receptor chamber, which could reduce the systemic side effects as reported from 
the previous study (Siqueira et al., 2011). The research was performed on the 
abdominal porcine skin using Franz diffusion cell and found benzophenone-3 loaded 
chitosan-coated polymeric nanoparticles has lower amount of drug was found in the 
receptor compartment compared to control formulation and uncoated nanoparticles. 
3.6 Conclusions 
The aim of this chapter is to prepare dutasteride-loaded nanostructured lipid 
carriers (DST-NLCs), coated with chitosan oligomer conjugated with stearic acid, 
and lauric acid. Based on the results, it can be concluded that: 
1. Formulation S4 (100 mg stearic acid, 50 mg Lutrol® micro 68, 25 mg Phosal® 
53 MCT and 5 mg dutasteride) was selected based on the ANOVA analysis from 
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the design of experiments for size distribution at day 14, which predicted the 
smallest hydrodynamic diameter 231 nm and narrow particle size distribution 
0.125 at day 14.  At this ratio, the entrapment efficiency was predicted to give 
95.1% at day 1.  
2. Using this ratio of components, production has been successfully scaled-up to 
300 mg of stearic acid content in order to increase the amount of dutasteride that 
can be incorporated from 0.083 mg/mL to 0.29 mg/mL. No significant difference 
(p>0.05) in the hydrodynamic diameter, PDI and entrapment efficiency was 
found on scale up. The hydrodynamic diameter, PDI, zeta potential entrapment 
efficiency and drug loading were 187.6 nm, 0.117, -18.3 mV, 97.3 % and 3.49%, 
respectively.    
3. The entrapment efficiency of DST-NLCs (17.5 mg DST) was 97.3 ± 1.2%, and 
these nanoparticles were stable for up to 180 days at 4-8°C.  
4. There was a significant increase (p<0.05) in the size of DST-NLCs coated with 5 
and 10% CSO-SA and 10% CSO-LA. The zeta potential values of DST-NLCs 
and those coated with CSO-SA and CSO-LA significantly increased (p<0.05) 
from negative to positive charge which strengthened the evidence of coating.  
5. Based on the physical stability study, DST-NLCs uncoated and coated with CSO-
SA or CSO-LA were only stable up to 6 months when stored at 4-8°C where all 
the mean particles sizes were in the range of 250 – 300 nm but not at 25°C (only 
for DST-NLCS coated with CSO-LA). DST-NLCs coated with CSO without 
conjugation showed aggregation even at day 30 when stored at both storage 
conditions.  
6. 5% CSO-SA or CSO-LA was chosen as the optimal coating concentration to 
stabilise the DST-NLCs, where at this concentration which was higher than CMC 
value, CSO-SA or CSO-LA exist in the micellar system, as in agreement from 
TEM images. 
7. Based on the XRPD and DSC diffractograms, the degree of the crystallinity of 
dutasteride in NLCs was reduced, and there was evidence of amorphicity of 
dutasteride and homogeneously dispersion in the NLCs. 
8. Values for the viscosity of DST-NLCs formulation either coated or uncoated with 
5% CSO-SA or 5% CSO-LA did not change with changes of angles of 
measurement.  These results suggest the formulations were acting as Newtonian 
fluids, as the sample was too dilute. Increasing the temperature from 20°C to 
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32°C and 37°C, significantly reduced the viscosity, whilst adding chitosan 
conjugated in the formulation increased the viscosity (p<0.05) of the products. 
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4.1 Introduction  
The first section of this chapter describes in vitro release and permeation 
studies of formulations described in Chapter 3 either uncoated or coated with CSO-
SA, CSO-LA or CSO. An in vitro release study was conducted in order to determine 
the rate of release of drugs from the nanoparticles systems. Additionally, in vitro 
permeation studies were conducted to quantify the amount of drug present in the skin 
and potential systemic exposure following application of the formulations. In order to 
mimic topical application of the formulation, both in vitro release and permeation 
studies were performed using a vertical Franz diffusion cell (PermeGear, USA). 
The second section of this chapter describes in vitro studies of cytotoxicity on 
hair follicle dermal papilla cells and skin irritation studies using 3D reconstructed 
human epidermis (3D RHE). In order to determine the maximum non-toxic 
concentration (EC90) of unencapsulated and encapsulated dutasteride-loaded NLCs, 
MTT assays on normal hair follicle dermal papilla cells were undertaken. Then, skin 
irritation study was further conducted in order to determine the irritant possibility of 
the formulation. Both experiments used cells and tissues from the normal human 
primary cell rather than immortalised cells.  
The third section of this chapter describes the preparation and characterisation 
of Cou-6-loaded nanostructured lipid carrier coated with chitosan oligomer-fatty 
acid. Cou-6 was chosen as a dye in this formulation, since the absence of fluorescing 
properties for dutasteride (λmax = 421 nm), meant the drug itself could not visualise 
by fluorescence microscopy. In order to determine the location of nanoparticles in the 
hair follicle dermal papilla cells (cell uptake study) or pig ear skin (permeation 
study), NLCs loaded with Cou-6 uncoated and coated with 5% CSO-SA and 5% 
CSO-LA were prepared. This dye is highly fluorescent and is hydrophobic (Log P = 
6.06), compared to dutasteride hydrophobicity (Log P = 5.09), and is a useful model. 
In order to standardise the exposure of the formulation on the cells and on the 
pigskin, the same amount of stearic acid, Phosal® 53 MCT, and Lutrol® micro 68 
were used. The amount of Cou-6 was optimised and coated with different types of 
coating materials (5% CSO-SA and 5% CSO-LA) and experiments repeated. 
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4.2 Materials and methods  
4.2.1 Materials 
Stearic acid (n-octadecanoic acid) 98% and minoxidil were purchased from 
Tokyo Chemical Industry (TCI, UK). Dutasteride (purity >98.0%) [(5a,17b)-N-[2,5-
bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-carboxamide] and chitosan 
oligomer (CSO) with molecular weight less than 3 kDa were obtained from 
Carbosynth Ltd (UK). Phosal® 53 MCT was a gift of Lipoid AG (Switzerland). 
Lutrol® micro 68 (Poloxamer 188) was obtained from BASF (Germany). Ethanol 
(96% v/v analytical grade), Cou-6, trifluoroacetic acid, Sephadex G-50 and 
amphotericin B were obtained from Sigma-Aldrich Company Ltd (UK). Hair follicle 
dermal papilla cells (passage 2 - cells were taken from a 78-year old man from the 
occipital area) and growth medium were obtained from Promo-Cell, Germany. 
Penicillin/streptomycin and PBS pH 7.4 were purchased from Gibco-BRL, USA. 
Deionised water (PURELAB Option, ELGA, UK) was obtained on site from a water 
system. 
 
4.2.2 In vitro release and permeation studies of DST from solution, DST-NLCs, 
uncoated and coated with CSO-SA, CSO-LA, and CSO 
4.2.2.1 Preliminary study of receptor media and types of membrane for release 
study 
Due to the limited solubility of dutasteride in PBS (pH 7.4), preliminary 
experiments to inform the selection of a suitable dissolution media were performed 
using 20% ethanol and 2% sodium dodecyl sulphate (SDS). A solubility study of 
dutasteride in DST-NLCs was undertaken by pipetting 200 µL of DST-NLCs (0.29 
mg/mL as theoretical solubility) into 10 mL of different types of media which was 
stirred at ambient temperature (~20°C) in a glass vial for 30 min. Next, the sample 
was diluted in ethanol and filtered using a 0.22 µm PES membrane syringe filter 
(Millex®GP, Merck Millipore, UK) before being injected into the HPLC system. 
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Selection of the membrane for the release study was conducted based on 
different types of membrane used in previous studies; using a dialysis membranes 
with molecular weight cut-off 1 kDa and 14 kDa (Spectrum Laboratories, USA) or 
0.45 µm nitrocellulose membrane (Merck Millipore, Ireland) (Madheswaran et al., 
2013; 2015). 
4.2.2.2 In vitro release of DST from solution, DST-NLCs, uncoated and coated 
with CSO-SA, CSO-LA and CSO 
In vitro release was studied using a Franz diffusion cell (PermeGear, USA). A 
0.45 µm nitrocellulose membrane (MF
TM
 Membrane Filters, Merck Millipore, 
Ireland) was mounted on the Franz diffusion cell (surface area = 0.64 cm
2
), 
maintained at 37 ± 1°C and stirred using a magnetic stirrer (600 rpm), with receptor 
chamber filled with 5 mL of PBS pH 7.4 with addition of ethanol or SDS. DST-
NLCs, with or without CSO conjugated or non-conjugated, and dutasteride in 70% 
ethanol as control (250 µL), were pipetted in the donor chamber and sampling (200 
µL) was performed at 0, 0.25, 0.5, 1, 2, 3, 6, 8, 12, 24, 30 and 36 h from the receptor 
chamber. Sample was replaced with 200 µL of temperature-equilibrated fresh buffer. 
Samples were injected into the HPLC to determine drug release using the assay 
described in Section 3.1.2. 
4.2.2.3 Preliminary study of types of membrane for permeation study 
Different types of membrane were studied for the permeation studies from 
synthetic and animal sources; a) synthetic membrane (Strat-M®, transdermal 
diffusion membrane from Millipore which comprised different layers of membrane 
mimicking the layers of the epidermis and dermis) and b) a full thickness pig ear 
skin. Strat-M® and pig ear skin were selected based on previous reports (Jacobi et 
al., 2007; Şenyiǧit et al., 2010; Raber et al., 2014; Uchida et al., 2015).  250 µL of 
DST-NLCs was pipetted in the donor chamber and sampling (200 µL) was 
performed at 0, 0.25, 0.5, 1, 2, 3, 6, 8, 12, 24, 30, 36 and 48 h, with 200 µL of 
temperature-equilibrated fresh buffer was added to the receptor chamber after 
sampling. 
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4.2.2.4 In vitro permeation of DST from solution, DST-NLCs, uncoated and 
coated with CSO-SA, CSO-LA and CSO 
An in vitro percutaneous absorption or permeation study of the developed 
formulations was conducted to quantify the amount of drug localised in the skin and 
potential systemic exposure as described by The Organisation for Economic Co-
operation and Development (OECD, 2004). In order to mimic topical application of 
the formulation, in vitro permeation was performed using a vertical Franz diffusion 
cell (PermeGear, USA). Pig ears were obtained from a local slaughterhouse 
(Farnborough, UK) from a freshly slaughtered pig (used for food consumption). The 
ears were washed with deionised water and hairs were trimmed carefully with 
scissors. The pig ear skin (Figure 4.1) was excised using a scalpel and forceps, and 
the subcutaneous tissue was removed. The average thickness of the skin was        
~0.5 mm. The skin was cut and frozen (-20°C) for future use. The diffusion surface 
area of the Franz cell was 0.64 cm
2
. The receptor chamber was filled with 5 mL of 
PBS (pH 7.4) with 2% SDS and 0.02% sodium azide and maintained at 37 ± 1°C 
whilst being stirred using a magnetic stirrer (600 rpm). This methodology assured 
that the skin surface facing the donor chamber was maintained at 32 ± 0.1°C during 
the entire experiment (Verkhovskiy et al., 2015).  
The skin was mounted between the donor and receptor chambers and allowed 
to equilibrate for 1 h. 250 µL of DST-NLCs formulation, with or without chitosan, 
was pipetted into the donor chamber. 200 µL samples were withdrawn at 0, 0.25, 0.5, 
1, 2, 3, 6, 8, 12, 24, 30, 36 and 48 h, and 200 µL of temperature equilibrated fresh 
buffer added to the receptor chamber. Nanoparticle formulations were compared to 
ethanolic solutions of dutasteride (0.29 mg/mL in 70%v/v ethanol).  
After 48 h, the left sample in the donor chamber was collected and dissolved 
in 2 mL ethanol. Then, the skin was removed from the Franz cell, and the stratum 
corneum was removed using a tape stripping method with slight modification (Tsai et 
al., 1991).  The skin patch was mounted on a board and a piece of adhesive tape 
(Scotch Magic Tape, 810,3M, USA), 1.5 cm wide and about 3 cm long, was used to 
strip the skin. The tape was of sufficient size to cover the full area of the skin which 
was in contact with the formulation.  
Chapter 4  In vitro characterisation of nanostructured lipid carrier formulations 
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Pig ear skin used for the permeation studies (A) and visualised using 
a light microscope after being cryotomed at 50 µm thickness (B) 
 
The stripping procedure was conducted 10 times, and the tapes were 
transferred into a small vial with the addition of 1 mL of ethanol and bath sonicated 
for 1 h. Meanwhile, the epidermis/dermis was chopped into small pieces using a 
Epidermis 
Dermis 
A 
B 
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scalpel and stirred for 24 h with 0.5 mL ethanol and further bath sonicated for 1 h. 
The solutions were filtered using a 0.22 µm PES membrane syringe filter 
(Millex®GP, Merck Millipore, Ireland) into an insert before injection into the HPLC 
for quantification of the drug which permeated in the skin. Figure 4.2 shows the in-
house set-up of Franz diffusion cells modified from Verkhovskiy et al. (2015). The 
large shallow water bath was filled with deionised water to the level of the 
circulation port of Franz cell.  
      
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 In-house set-up of Franz diffusion cells for permeation study 
(modified from Verkhovskiy et al., 2015) 
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The shallow water bath chamber was set-up on a multi-hot plate and stirrer, 
with a magnetic stirring bar and thermometer. The temperature was set at 37 ± 1°C. 
During the study, deionised water (pre-warmed at 37 ± 1°C) was added periodically 
to the water bath chamber to replace that lost by evaporation. The pig ear skin was 
mounted, and a cell clamp was used to hold both donor and receptor chambers in 
place. After pipetting the sample into the donor chamber, the open donor chamber 
and sampling port were covered with Parafilm® (Merck Millipore, Ireland) in order 
to prevent the evaporation. 
The total quantity of the drug (𝑄) that diffused to the receptor compartment in 
time period (𝑡) during the steady state and the flux at steady state, 𝐽𝑠𝑠 [µg/(cm
2
h)], 
were calculated by Fick’s first law using the linear portion of the correlation between 
the accumulated quantity of drug that diffused through the skin by unit area and time, 
and the permeation coefficient (𝐾𝑝) was obtained from the relation between the flux 
and the initial concentration of drug added to the donor compartment as shown in 
Equations 4-1 and 4-2 (Grams, 2005; Caon et al., 2014). All the experiments were 
performed 4 times and mean values calculated. 
                                  𝐽𝑠𝑠 =
1
𝐴
 𝑥 
𝑑𝑄
𝑑𝑡
            Equation 4-1 
 
                         𝐾𝑝 =  
𝐽𝑠𝑠
𝐶𝑑
            Equation 4-2 
where: 
𝐽𝑠𝑠 = flux at steady state, µg/cm
2
/h 
𝑄 = mass of drug diffused to the receptor compartment, µg 
𝐴 = surface area, cm2 
𝑡 = time, h 
𝐾𝑝 = permeation coefficient, cm/h 
𝐶𝑑 = initial concentration of drug added to the donor compartment, µg/cm
3
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4.2.3 In vitro proliferation and cytotoxicity of DST-NLCs/empty NLCs, 
uncoated and coated with 5%CSO-SA and 5% CSO-LA 
4.2.3.1 Proliferation and cytotoxicity study 
For the in vitro study of cytotoxicity, human hair follicle dermal papilla cells 
(HFDPCs) (Promo-Cell, Germany) were used (Figure 4.3A). The hair follicle dermal 
papilla cells were isolated from a Caucasian adult man aged 78-years old from an 
occipital area. The certificate of analysis of human follicle dermal papilla cells is 
shown in Appendix C. Figure 4.3B shows the cells at a higher magnification (cells 
with coumarin-6 dye). The cells were grown in HFDPCs growth medium (Promo-
Cell, Germany), with 100 IU/mL penicillin/streptomycin (Gibco-BRL, MD) and 2.5 
µg/mL amphotericin B (Sigma-Aldrich, UK) in a humidified 95% atmosphere with 5 
± 1% CO2 at 37 ± 1°C. Cultured HFDPCs from passage 4-6 were seeded (3.75 x 10
4
 
per mL) into 96-well plates (Nunc, Wiesbaden, Germany) and grown to a confluence 
of 60–70% for 24 h.  
The MTT assay is a colourimetric assay using the tetrazolium salt thiazolyl 
blue for detection of cell viability, cytotoxicity and proliferation (Mosmann, 1983). 
Many MTT studies have been improved in order to increase their accuracy  (Denizot 
and Lang, 1986; Gerlier and Thomasset, 1986; Hunt and Mchale, 2005).  This assay 
detects only living cells and the colour generated is dependent on the number of 
living cells present (Mosmann, 1983).  
In order to determine the proliferation and cytotoxicity of the cells, a 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) (MTT) assay was 
performed. For this study, optimisation of the methodology for cell 
proliferation/cytotoxicity was conducted whereby different cell densities (7.5 x 10
4
 
cell per mL and 3.75 x 10
4
 cell per mL) and duration of MTT assay (3 or 5 days) 
were investigated. Dutasteride in dimethyl sulfoxide (DMSO) was used in this study. 
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Figure 4.3 Hair follicle dermal papilla cells (A) and cells with coumarin-6 dye 
(B) 
 
Figure 4.4 shows the reaction underpinning the MTT assay. MTT solutions 
were added into the wells containing cells at a certain time point, and the living cells 
converted MTT (yellow) to MTT formazan producing a purple colour (absorbance at 
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570 nm). In this study, the MTT assay was performed for 4 hours after 5 days of the 
treatment time point.  
For the treatment, the cell was treated with dutasteride alone (1.6 - 100 µM), 
and with dutasteride incorporated into nanoparticles, either uncoated or coated with 
5% CSO-SA or 5% CSO-LA (3.125 - 100 µM). Empty NLCs uncoated and coated 
with 5% CSO-SA or 5% CSO-LA (at the same concentration as DST-NLCs uncoated 
and coated with 5% CSO-SA or 5% CSO-LA) were investigated in the same manner 
in order to study the cytotoxicity of the carrier without dutasteride. As a positive 
control, cells were treated with minoxidil (100 µM). After 5 days of treatment, the 
media were removed.  
Stearic acid and lauric acid alone in DMSO were also tested on the cells in 
order to study the proliferation effect. Different concentration of stearic acid and 
lauric acid in DMSO (200 – 6.25 µM) were tested on cells at a density at 3.75 x 104 
cell per mL and left for 5 days.   
On the day of the MTT assay, 5 mg/mL of MTT was dissolved in PBS pH 
7.4, vortexed and filtered using a 0.22 µm PES membrane syringe filter (Millex®GP, 
Merck Millipore, UK) and further diluted into fresh media to obtain a final 
concentration of MTT of 0.5 mg/mL. The MTT solutions were added into each well, 
and the plates were incubated for 4 h at 37 ± 1°C, 5 ± 1 % CO
2
. The supernatant was 
then removed, and 100 µL of DMSO was added to dissolve the MTT formazan 
products.  
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Figure 4.4 Chemical structure of MTT and MTT formazan (A) and absorption 
spectra of MTT in water and MTT formazan in sunflower oil (modified from 
Stockert et al., 2012) 
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Absorbance was measured spectrophotometrically at 570 nm using a 
microplate reader (SpectraMax®M2e, Molecular Devices, USA). The 50% inhibitory 
dose values (IC50) was defined as the concentration of formulation or drug inhibiting 
50% of the cells, and the maximum non-toxic concentration (MNTC), EC90 was 
defined as the concentration of formulation or drug inhibiting 10% of the cells. These 
were calculated by regression analysis of the dose-response curves generated using 
OriginPro 9.1 Software (USA). Results were calculated as percentages of untreated 
controls in four cultures, with values expressed as means ± SD. 
4.2.4 In vitro skin irritation study using EpiDerm™ SIT 3D reconstructed 
human epidermis (RHE) 
The skin irritation study was conducted in order to identify formulations that 
may be cutaneous irritants. Currently, there are two types of skin irritation studies, 
with the test compound either tested on animals (in vivo) or cells/tissue (in vitro). In 
vivo skin irritation studies are generally performed on rabbits (Draize rabbit test) as 
described in OECD TG 404 (OECD, 2002). The albino rabbits are exposed to test 
substances and left for 4 h. At the end of the exposure period, the test substances 
should be removed using water. All animals are then examined for signs of erythema 
and oedema, and the responses scored at 60 min, and then at 24, 48 and 72 hours 
after patch removal. 
In order to meet the 3R (Replacement, Reduction and Refinement) 
requirements regarding animal studies, several human-derived tissues have been 
produced and validated especially for cosmetic and pharmaceutical applications. In 
March 2009, the European Commission banned animal testing on any finished 
cosmetic product or ingredients, and in March 2013 they prohibited the marketing 
and sale of finished cosmetic products or ingredients tested on the animal (Fischer, 
2015). Hence, an in vitro skin irritation studies on human-derived tissue has been 
used widely and is considered the best alternative to in vivo studies for cosmetic and 
pharmaceutical products. Currently, all the validated protocols follow OECD 439 
Guidelines (OECD, 2015). Currently, there are number of tissues are commercially 
available such as EpiDerm™ SIT (MatTek, Slovak Republic), EpiSkin™ SM 
(SkinEthic, France), SkinEthic™ RHE (SkinEthic, France) and LabCyte EPI-
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MODEL 24 SIT (Japan Tissue Engineering Co, Japan) for in vitro skin irritation 
studies. 
In this study, EpiDerm™ SIT tissues were used (Figure 4.5), following the 
supplier’s protocol (MatTek In vitro Life Science Laboratories, Slovakia) (Figure 
4.6). EpiDerm™ SIT (3D Reconstructed Human Epidermal model) is a multi-layered 
highly differentiated tissue model consisting of normal, human-derived 
keratinocytes. The % cell viability was measured by comparing the negative control 
(Dulbecco’s phosphate-buffered saline, DPBS) with the test formulations. The tissues 
were transferred from agarose to assay medium on receipt, incubated (37 ± 1°C, 5 ± 
1 % CO2, 95 % RH) for 60 ± 5 min and transferred into fresh pre-warmed assay 
medium and incubated for another 18 ± 3 h (Kandárová et al., 2009). 
 
 
 
 
 
 
 
 
Figure 4.5 EpiDerm™ SIT (EPI-200) tissues in the medium for skin irritancy 
testing 
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Transfer tissues from agarose to assay medium 
 
Incubate (37 ± 1°C, 5 ± 1 % CO2) for 60 ± 5 min 
 
Transfer tissues to fresh assay medium 
 
Incubate (37 ± 1°C, 5 ± 1 % CO2) overnight (18 ± 3 h) 
 
Dose 3 tissues each with 30 μL TS, or PC, or NC 
 
 
 
Expose 60 min (37 ± 1°C, 5 ± 1 % CO2) 
 
Stop exposure after 60 min by rinsing with DPBS 
 
Transfer tissues to fresh assay medium 
 
Incubate (37 ± 1°C, 5 ± 1 % CO2) for 42  ± 2 hours 
 
Blot tissues and perform MTT assay 
 
Read optical density in a plate spectrophotometer at 570 nm 
Figure 4.6 Protocol of skin irritation studies using 3D reconstructed human 
epidermis skin 
 
(TS (Test substances): DST-NLCs, NLCs, DST-NLCs coated with 5% CSO-SA or 5% CSO-LA, NLCs 
coated with 5% CSO-SA or 5% CSO-LA, dutasteride in 70% ethanol and 70% ethanol), PC (Positive 
control): 5% sodium dodecyl sulphate and NC (Negative control): DPBS) 
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Tissues were dosed with 30 µL of test substances (TS: DST-NLCs, NLCs, 
DST-NLCs coated with 5% CSO-SA or 5% CSO-LA, NLCs coated with 5% CSO-
SA or 5% CSO-LA, dutasteride in 70% ethanol and 70% ethanol), positive control 
(PC: 5% sodium dodecyl sulphate, SDS) and NC: negative control (DPBS). Tissues 
were exposed to the formulations for 60 min, and then rinsed with DPBS 15 times 
and transferred into fresh assay medium and incubated for 42 ± 2 h. Tissues were 
blotted, and the MTT assay was performed. MTT kit containing MTT solutions and 
isopropanol were supplied by MatTek In vitro Life Science Laboratories (Slovak 
Republic). Formazan products from the cells were extracted using isopropanol for   
24 h and read at 570 nm using microplate reader (SpectraMax®M2e, Molecular 
Devices, USA). Based on the EU and GHS classification (R38/Category 2), an 
irritant is predicted if the mean relative tissue viability of three individual tissues 
exposed to the test substance is reduced below 50% of the mean viability of the 
negative controls (OECD, 2015) as shown in Table 4.1. 
 
Table 4.1 Interpretation of results of skin irritation study (OECD, 2015) 
In vitro result In vivo prediction 
Mean tissue viability ≤ 50% Irritant (I), (R38 or GHS Category 2) 
Mean tissue viability ≥ 50% Non-irritant (NI) 
         
4.2.5 Formulation of coumarin-6 loaded NLCs, uncoated and coated with 5% 
CSO-SA and 5% CSO-LA 
4.2.5.1 Method development and validation of coumarin-6 assay using reverse-
phase high-performance liquid chromatography (RP-HPLC) 
In this section, coumarin-6 (Cou-6), a fluorescence dye, was chosen as a 
model compound to be incorporated into the NLCs in order to observe cell and skin 
uptake, due to the absence of fluorescing properties of dutasteride. The quantitative 
and qualitative of the composition of others materials in the NLC formulations was 
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maintained constant. The entrapment efficiency and drug loading of this dye were 
optimised, requiring development of a reverse phase high-performance liquid 
chromatography (RP-HPLC) analytical method to determine the amount of Cou-6 in 
the formulations. In this chapter, a simple, accurate, linear and precise assay for 
determination of coumarin-6 in the formulation was developed, using reverse phase 
HPLC with a UV detector. 
4.2.5.1.1 Experimental 
4.2.5.1.2 Instrumentation and method validation 
High-performance liquid chromatography (HPLC) with UV/Vis detector 
(Agilent 1100 Series, USA) was used to determine the content of Cou-6 in the 
nanoparticle formulation. A similar mobile phase and stationary phase were used as 
for dutasteride, except the wavelength for detection of Cou-6 was 466 nm (Table 
4.2). Linearity, accuracy, specificity, precision and system suitability, limit of 
detection (LOD) and limit of quantification (LOQ) were determined according to 
ICH guidelines for validation of analytical procedures (International Conference on 
Harmonisation, 1996) as described in Section 3.1.2. 
 
Table 4.2 HPLC chromatographic condition for determination of Cou-6 
Column: Synergi™ 4 µm Polar-RP 80 Å, 250 x 4.6 mm 
Mobile phase: Acetonitrile and 0.1% TFA in HPLC grade water (70:30) 
Wavelength: 466 nm 
Flow rate: 1 mL/min 
Injection volume: 30 µL 
Run time: 15 min 
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4.2.5.1.3 Preparation of Cou-6 standard solution 
25 mg Cou-6 was weighed accurately and transferred to a 25 mL volumetric 
flask. Ethanol was added and sonicated to dissolve the dye. Ethanol was added to 
made up to volume, and the flask was shaken to mix the solution well. The stock 
solution concentration of Cou-6 was 1000 µg/mL. Serial dilutions were prepared 
from the stock solution giving 0.5, 1, 2.5, 5, 7.5, 10 and 12.5 µg/mL Cou-6 solutions. 
4.2.6 Preparation of Cou-6 loaded NLCs, uncoated and coated with 5% CSO-
SA and 5% CSO-LA 
Cou-6 loaded nanostructured lipid carriers (Cou-6-NLCs) were prepared 
based on the method described in Section 3.1.3.2. The weight of Cou-6 was varied 
from 0.2 to 1.0 mg. Cou-6, 300 mg of stearic acid, 75 mg of Phosal® 53 MCT, 150 
mg of Lutrol® micro 68 and 10 mL of water were used. Table 4.3 shows the 
formulation of the Cou-6-NLCs. Cou-6-NLCs coated with 5% CSO-SA or 5% CSO-
LA were prepared following the method described in Section 3.1.3.5. 250 µL of the 
solution (5 mg/mL of CSO-SA or CSO-LA in 0.2% acetic acid solution) was added, 
using a syringe, into 5 mL of Cou-6-NLCs with constant stirring for 10 min. 
 
Table 4.3 Formulation of Cou-6-loaded nanostructured lipid carrier (Cou-6-
NLCs) 
Materials Amount 
Stearic acid 300 mg 
Phosal® 53 MCT 75 mg 
Lutrol® micro 68  150 mg 
Cou-6 0.2 – 1.0 mg 
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4.2.6.1 Characterisation of Cou-6-NLCs, uncoated and coated with 5% CSO-
SA or 5% CSO-LA 
Characterisation of the nanoparticles for size distribution and surface charge 
using Zetasizer ZS were followed the previous method (3.1.3.6.1 and 3.1.3.6.2). 
Entrapment efficiency and drug loading were performed as described in the 
previous section (3.1.3.6.4) except the collected sample after centrifuge was diluted 
with ethanol in a 5 mL volumetric flask in order to achieve Cou-6 content above 
LOQ values.    
4.2.6.2 Skin and cell uptake studies of Cou-6 in NLCs, uncoated and coated 
with 5% CSO-SA or 5% CSO-LA and in ethanol 
4.2.6.2.1  Skin uptake study of Cou-6  
The optimised formulation of Cou-6 in NLCs was used in this experiment, 
and a comparable amount of free Cou-6 (3.3 µg/mL) was dissolved in 70% ethanol as 
a control. The set-up of the Franz diffusion cells was similar to that for the 
permeation study (Section 4.2.2.4). The pig ear skin was mounted in Franz diffusion 
cells and Cou-6-NLCs formulation uncoated and coated with 5% CSO-SA or 5% 
CSO-LA (250 µL) was pipetted to the donor chamber. At 6, 12 and 24 h, the pig ear 
skin was removed from the Franz cells and cut into smaller sizes. The skin was left 
frozen in the Leica CM1850 cryostat (Leica Microsystems, Wetzlar, Germany)         
(-30°C) before being mounted into the cryostat chuck using OCT (optimum cutting 
temperature) compound (VWR International, UK). The skin was cryotomed at a 
thickness of 50 µm using a Leica CM1850 cryostat at −30°C, and skin slices directly 
transferred to microscope adhesion slides and visualised using an inverted 
fluorescence microscope (EVOS® FL Imaging System, Life Technologies, USA) 
with a DAPI LED light cube without removing the stratum corneum.  
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4.2.6.2.2 Cell uptake studies of Cou-6 
For the cell uptake study, in order to ensure the concentration of Cou-6 
loaded NLCs would not kill the cells, 25 µM of NLCs (comparable with empty DST-
NLCs) as described in Section 4.2.3.2 were used on the hair follicle dermal papilla 
cells. 1 mL of cells at a density of 3.75 x 10
4
 cells/mL were transferred into each    
12-well plate (Nunc, Wiesbaden, Germany) and left for 24 h. On the treatment day, 
25 µM of uncoated NLCs containing Cou-6, COU-6-NLCs coated with 5% CSO-SA 
or 5% CSO-LA, and Cou-6 in ethanol were transferred into the 12-well plate. The 
final concentration of ethanol in the media was maintained at 0.1% in order to avoid 
cell death. At 1, 3, 6 and 12 h, the media was removed and washed with PBS (pH 
7.4) before being visualised using an inverted fluorescence microscope (EVOS® FL 
Imaging System, Life Technologies, USA) with a DAPI LED light cube at 10X 
magnification.  
4.3 Statistical analysis 
All data were analysed using either a t-test or one-way ANOVA and Tukey’s 
post-hoc test, using IBM SPSS 23 Statistic Data Editor Software (USA). A p-value of 
less than 0.05 was considered significant for all experiments. 
4.4 Results and discussion 
4.4.1 In vitro release of DST from solutions, NLCs, uncoated and coated with 
CSO-SA or CSO 
4.4.1.1 Preliminary study of receptor media and types of membrane 
Based on previous reports (Xie et al., 2014; Madheswaran et al., 2015), 
ethanol or sodium dodecyl sulphate was added into the media. In this study, 20% 
ethanol or 2% SDS were added to PBS (pH 7.4). With 20% ethanol in PBS pH 7.4, 
only 0.024 ± 0.024 mg/mL of dutasteride dissolved, a higher solubility of drug was 
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found with 2% SDS (0.252 ± 0.013 mg/mL). Based on these findings, 2% SDS in 
PBS pH 7.4 was selected as the receptor medium for future experiments. 
Different types of membrane were also screened in order to identify a suitable 
membrane for this study. Dialysis membranes (1 kDa and 14 kDa MW cut-off), and 
0.45 µm cellulose membrane were studied. Unfortunately, though the pore size of the 
dialysis membranes used was larger than the molecular weight of dutasteride (528 
g/mol), no drug was detected in the receptor medium using either sizes of dialysis 
membranes, suggesting an interaction may have occurred between dutasteride and 
the dialysis membranes. The 0.45 µm cellulose membrane permitted detection of 
dutasteride in the receptor chamber. Consequently, 0.45 µm cellulose membrane was 
used for the release study. 
4.4.1.2 In vitro release of DST from solution, DST-NLCs, uncoated and coated 
with CSO-SA, CSO-LA and CSO 
Figure 4.7 shows dutasteride release profile from DST-NLCs uncoated and 
coated with CSO-SA, CSO-LA and CSO, and release from a solution in 70% 
ethanol. All nanoparticles formulations produced a measurable release profile at 1, 2, 
3, 6 h. However, as the detected amounts were lower than LOQ for the HPLC assay, 
all values at these time points have not been plotted. All nanoparticle preparations 
showed rapid release over the first 12 h, with uncoated DST-NLCs exhibiting faster 
release (82.6 ± 6.0%) at 24 h  than all other formulations (p<0.05). DST-NLCs 
coated with 5% and 10% CSO-SA had slower drug release due to the presence of the 
polymer in the outer regions of the particles. The same trend was found for DST-
NLCs coated with 5 and 10% CSO-LA, which also had a slower release. Similar 
findings have been reported on chitosan coating delaying the release of dutasteride 
compared to uncoated liquid crystalline nanoparticles (Madheswaran et al., 2015). 
Though, the mean size of DST-NLCs coated with CSO-SA was significantly 
different (p<0.05) compared to CSO-LA, the release profile did not differ. 
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Figure 4.7 Dutasteride release from different DST-NLC formulations and 
control (dutasteride in ethanol) (n=3, mean ± SD) 
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There was no significant difference (p>0.05) between DST-NLCs coated 
with 5 and 10% of CSO-SA, and 5.0 and 10% CSO-LA, all formulations having 
approximately 26% and 66% drug release at 12 h and 36 h, respectively. Coating 
DST-NLCs with 5% CSO-SA or CSO-LA may represent the maximum coating of 
nanoparticles, additional CSO-SA or CSO-LA does not contribute to further 
retardation of drug release. This result showed that DST-NLCs were successfully 
coated with CSO-SA and CSO-LA, with a consequent reduction in release rate.  
Dutasteride in 70% ethanol (as a control) showed only 32.6 ± 10.7% release 
at 36 h into the receptor medium. This was due to the limited solubility of dutasteride 
in the receptor media. This result was similar to that described previously whereby 
dutasteride and finasteride (slightly soluble in water) were released more slowly from 
an ethanolic solution than from a nanocarrier formulation (Madheswaran et al., 
2015).  
There was no significant difference (p>0.05) in drug release at 36 h between 
DST-NLCs coated with 5% CSO (no conjugation) and control. DST-NLCs coated 
with 5% CSO (without conjugation) showed a significantly slower release (p<0.05) 
compared to DST-NLCs coated with CSO-SA and CSO-LA, with 40.7 ± 5.1% of 
drug release at 36 h, suggesting a possibility of unstable formulation and limited 
solubility of dutasteride in the receptor medium.  
Dutasteride in the nanoparticles coated with CSO-SA gave a sustained release 
of the drug into the receptor chamber, which may be useful for topical or 
transfollicular delivery. Moreover, when the nanoparticle formulations are applied to 
the balding scalp area and massaged for a certain time, particles may travel deeper in 
the transfollicular region from where they may release the drug slowly (Lademann et 
al., 2007). As a result, this would help to reduce the frequency of usage by the 
patient.  
4.4.2 In vitro permeation study of DST from solution, DST-NLCs, uncoated 
and coated with CSO-SA, CSO-LA and CSO 
In vitro permeation studies were performed in order to study the permeation 
profile of DST-NLCs coated with CSO-SA, CSO-LA and CSO. Different types of 
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membrane were studied in order to identify the suitable membrane for the permeation 
study.  
Tables 4.4 and 4.5 show permeation parameters of dutasteride from different 
formulations using Strat® membrane and pig ear skin, respectively. There was a 
significant difference (p<0.05) for the percent dutasteride permeated between both 
membranes used. Drug permeation of DST-NLCs was almost 5-fold higher in the 
Strat-M® membrane compared to pig ear skin over 48 h. At 36 h, some drug was 
detected in the receptor media from the Strat® membrane. The flux and permeation 
coefficient using Strat-M® membrane were found to be 0.646 µg/cm
2
/h and 0.065 
cm/h, respectively. No flux or permeation coefficient was calculated for the pig ear 
skin as no permeation of dutasteride was detected in the receptor chamber after 48 h.  
 
Table 4.4 Permeation parameters of DST from DST-NLCs using Strat-M® 
membrane after 48 h (n=4, mean ± SD)  
 Parameter Value 
DST in the membrane (µg) 26.81 ± 1.66 
Dutasteride permeated (%)  38.59 ± 1.81 
Flux, 𝐽𝑠𝑠 (µg/cm
2
/h) 0.646 ± 0.028 
Permeation coefficient, 𝐾𝑝, (cm/h) 0.065 ± 0.003 
Amount of dutasteride  in the membrane per area (µg/cm
2
) 41.66 ± 1.96 
Drug recovery (%) 81.0 ± 2.5 
 
 
  
 
1
6
7
 
Table 4.5 Permeation parameters of DST from solution, DST-NLCs, uncoated and coated with CSO-SA, CSO-LA and CSO 
using pig ear skin after 48 h (n=4, mean ± SD) 
  Parameter DST-NLCs  DST-NLCs 
5%     
CSO-SA 
DST-NLCs 
10%    
CSO-SA 
DST-NLCs 
5%       
CSO-LA 
DST-NLCs 
10%      
CSO-LA 
DST-NLCs    
5%       
CSO 
DST in 70% 
ETOH 
DST in the skin, 
µg 
4.96 ± 1.36 1.80 ± 0.26 1.71 ± 0.22 2.01 ± 0.22 1.84 ± 0.18 1.34 ± 0.41 8.03 ± 1.27 
% dutasteride 
permeated  
7.02 ± 1.93 2.91 ± 0.42 2.81 ± 0.37 3.45 ± 0.37 3.01 ± 0.31 2.16 ± 0.66 14.05 ± 2.05 
Flux (𝑱𝒔𝒔), 
µg/cm
2
/h 
N/D N/D N/D N/D N/D N/D N/D 
Permeation 
coefficient (𝑲𝒑), 
cm/h 
N/D N/D N/D N/D N/D N/D N/D 
Amount of 
dutasteride  in the 
skin per area, 
µg/cm
2
 
6.09 ± 1.09 2.82 ± 0.40 2.70 ± 0.35 3.16 ± 0.34 2.89 ± 0.28 2.11 ± 0.64 12.62 ± 1.72 
% recovery 93.2 ± 2.1 88.5 ± 11.4 85.1 ± 4.0 93.1 ± 1.10 116.1 ± 27.8 93.0 ± 2.9 71.2 ± 10.2 
N/D – non-detectable 
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The permeation parameters of nanoparticles for pig ear skin and synthetic membrane 
showed different results which likely due to their difference in structural properties. 
Uchida et al. (2015) found that the diffusion and partition parameters of certain drugs 
using Strat® membrane were similar to human and hairless rat skin. However, in 
their research, the Log P (Log partition octanol/water) was limited between -0.12 to 
3.5 at pH 7.4 and the molecular weight of the compound was in a range 152 to 289 
g/mol. In contrast with this study, the log P and the molecular weight of dutasteride 
were high. These characteristics may limit the permeation of drug to the skin and 
produce different results with pig ear skin. 
The follicular structure of pig ear skin is very similar to that of human skin, 
whereby the infundibula extend deep in the dermis, as in humans (Jacobi et al., 
2007). Permeation studies of DST-NLCs, uncoated and coated with CSO-SA, CSO-
LA and CSO were conducted using pig ear skin (Table 4.5). 
In this study, for all formulations using pig ear skin, no dutasteride was 
detectable by HPLC in the receptor chamber (LOQ = 3 µg/mL) after 48 h. Hence, 
considering the amount of dutasteride present in the skin, the highest permeation in 
the skin (12.62 ± 1.72 µg/cm
2
) was found from the control (ethanol solution). There 
was a significant difference (p<0.05) of dutasteride in the skin from ethanol and the 
nanoparticle formulations. This result was in agreement with the previous research, 
in that ethanol acts as a penetration enhancer in topical products (Williams and 
Barry, 2004). They found that, for an ethanol-water co-solvent vehicle, ethanol 
appears to be concentration dependent, where increasing the amount of ethanol 
produced dehydration of the biological membrane, thus reducing the permeation 
across the tissue. Additionally, permeation of ethanol into the stratum corneum can 
alter the solubility properties of the tissue, resulting in an improvement for drug 
partitioning into the membrane (Megrab et al., 1995). In this study, 70% ethanol was 
used and showed higher permeation compared to nanoparticle formulations.  
There was a significantly higher (p<0.05) amount of dutasteride in the skin 
per area for DST-NLCs (6.09 µg/cm
2
) compared to DST-NLCs coated with 5% 
CSO-SA (2.82 µg/cm
2
), 10% CSO-SA (2.70 µg/cm
2
), 5% CSO-LA (3.16 µg/cm
2
) 
and 10% CSO-LA (2.89 µg/cm
2
) and 5% CSO (2.11 µg/cm
2
). There was no 
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significant difference (p>0.05) of amount of dutasteride in the skin per area between 
5% and 10% of CSO-SA/CSO-LA. 
This result was in agreement with previous research (Siqueira et al., 2011). 
They found that benzophenone-3 was found less in the dermis and epidermis from 
chitosan coated polymeric nanocapsules of benzophenone-3 compared to those 
uncoated with chitosan. Firstly, the results can be explained due to different surface 
charge between chitosan and the skin. As described from the previous research where 
nanocapsules coated with chitosan increased the retention in the superficial layers of 
the epithelium (Campos et al., 2003). Secondly, it is due to bioadhesive 
characteristics of chitosan (Rinaudo, 2006) which limit the penetration of drug to the 
skin. Thirdly, different viscosities of DST-NLCs, uncoated and coated with CSO-SA 
or CSO (Section 3.5.3.6) may prevent the nanoparticles penetrating deeper into the 
skin. 
Further experiments, such as in vivo studies, are required to confirm and 
further explore these observed formulation effects on skin permeation. During 
clinical use, dutasteride will be applied on the scalp, where the surface area will be 
much larger than the membrane used in this in vitro study. Moreover, massaging the 
scalp will increase the total amount of the drug in the skin; previous research has 
shown that massage resulted in deeper penetration of nanoparticles in the follicular 
hair region (Lademann et al., 2007). The small size of these DST-NLCs uncoated and 
coated with CSO-SA or CSO-LA (200 - 250 nm) will ensure deep penetration into 
the hair follicle duct (Lademann et al., 2007), whilst the different sizes of 
nanoparticles may affect the penetration depth (Patzelt et al., 2011). Particles in the 
size range used in this study would be predicted to penetrate the upper part of the 
follicle of terminal hair, and would likely penetrate deeper in the vellus hair follicles, 
especially on the balding site, where the hair is short, thin and fine. Application of 
ethanol-based formulations produces adverse reactions such as scalp dryness, 
irritation, burning and contact dermatitis (Lachenmeier, 2008), which can be 
overcome through nanoparticle formulations. 
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4.4.3 Optimisation of methodology for cytotoxicity studies 
4.4.3.1 Effect of different cell density on MTT assays 
The cell proliferation study using MTT assay was optimised in terms cell 
density. Dutasteride alone in DMSO was used for this initial experiment. Based on a 
previous study (Han et al., 2004), 7.5 x 10
4
 cells per mL was initially selected. Then, 
the cell density was reduced by half, 3.75 x 10
4
 cells per mL and the results were 
compared. Cells at different densities were treated with dutasteride in DMSO and left 
for 5 days.  
After 5 days of treatment, there was no significant difference (p>0.05) in cell 
viability at the highest concentration (100 µM) between both cell densities due to the 
effect of cell death (Figure 4.8). 
 
 
 
 
 
 
 
 
Figure 4.8 Percentage cell viability for different cell densities of dutasteride in 
DMSO after 5 days (n=4, mean ± SD) 
 
The highest proliferation observed was only 90 ± 7.9% at 1.56 µM for the  
7.5 x 10
4
 cells per ml. At 3.75 x 10
4
 cells per mL, cell proliferation increased to 
approximately 110 ± 12.4% at the same concentration. However, there was a 
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significant difference (p<0.05) in cell viabilities between both cell densities at lower 
concentrations (1.56 – 50 µM), suggesting that after 5 days of treatment, when the 
higher cell density was used, insufficient nutrients for the cells and accumulation of 
metabolic by-products, resulted in cell death, as previously reported (Butler, 2005). 
Based on these data, the cell density of 3.75 x 10
4
 cells per mL (7.5 x 10
3
 cells per 
well) was selected for subsequent studies. 
4.4.3.2 Effect of different experimental durations on the MTT assay 
To establish the optimum duration of the experiment, different durations of 
treatment were studied. In previous research, most MTT assays for hair growth 
compounds were conducted for 2 to 5 days of treatment (Han et al., 2004; Jo et al., 
2013; Choi et al., 2015; Park et al., 2016). As this experiment was undertaken to 
study cell proliferation after treatment, a longer duration would be appropriate. In 
this study, the cells were treated with different concentrations of dutasteride in 
DMSO for 3 or 5 days. The results showed there was no significant difference 
(p>0.05) in cell viability between day 3 and 5 (Figure 4.9). The longer duration of 
the MTT assay (5 days) was chosen for all studies.  
 
 
 
 
 
 
 
Figure 4.9 Cell viability study of dutasteride alone in DMSO at different days 
(n=4, mean ± SD) 
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4.4.4 In vitro cytotoxicity study of DST-NLCs, uncoated and coated with 5% 
CSO-SA and 5% CSO-LA 
Figure 4-10 shows cytotoxicity profiles of dutasteride (in DMSO), empty 
nanoparticles, uncoated and coated with 5% CSO-SA or 5% CSO-LA and also DST-
NLCs, uncoated and coated with 5% CSO-SA and 5% CSO-LA. After 5 days of 
treatment with various concentrations of dutasteride (alone) and nanoparticles, there 
was a significant difference (p<0.05) in the cytotoxicity values (IC50) between 
dutasteride in DMSO and nanoparticles.  
Dutasteride alone showed cytotoxicity at a very low concentration (IC50 = 
10.4 ± 1.82 µM). Values of IC50 for DST-NLCs, uncoated and coated with 5% CSO-
SA or 5% CSO-LA  (Figure 4-11B) were much higher, being 58.1 ± 13.0 µM, 59.3 ± 
13.1 µM and 58.9 ± 14.8 µM,  respectively. However, NLCs alone (without 
dutasteride) uncoated and coated with 5% CSO-SA or 5% CSO-LA also showed 
cytotoxicity (IC50), 58.1 ± 13.0 µM, 59.0 ± 14.6 µM and 56.2 ± 12.6 µM, 
respectively in a dose-dependent manner. No significant difference in IC50 was found 
between DST-NLCs and NLCs (p>0.05).  
The maximum non-toxic concentration (MNTC, EC90) is defined as the 
concentration of a formulation or drug inhibiting 10% of the cells. EC90 for 
dutasteride in DMSO (2.1 ± 0.2 µM) was significantly lower (p<0.05) than 
dutasteride in nanoparticles and empty nanoparticles. There was no significant 
difference (p>0.05) in EC90 between uncoated DST-NLCs and those coated with 5% 
CSO-SA or 5% CSO-LA. The EC90 for DST-NLCs uncoated and coated with 5% 
CSO-SA or 5% CSO-LA was 38.1 ± 13.1 µM, 53.6 ± 8.3 µM and 39.3 ± 11.5 µM, 
respectively. The EC90 for NLCs uncoated and coated with 5% CSO-SA or 5% CSO-
LA was 42.3 ± 12.4 µM, 49.4 ± 6.0 µM and 39.3 ± 11.5 µM, respectively. Similar 
results were found, with no significant difference (p>0.05) in EC90 between NLCs 
uncoated and coated with 5% CSO-SA or 5% CSO-LA. 
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Figure 4.10 Cytotoxicity of dutasteride alone (A), empty NLCs uncoated and 
coated with 5% CSO-SA and 5% CSO-LA and DST-NLCs uncoated and coated 
with 5%CSO-SA and 5%CSO-LA (B) on hair follicle dermal papilla cells (n=4, 
mean ± SD) 
 
Based on these findings, dutasteride in the nanoparticles, either coated with 
5% CSO-SA or 5% CSO-LA could be applied at a higher concentration compared to 
the dutasteride without nanoparticles. This shows that when dutasteride was 
delivered in the nanoparticles, it increased the EC90 more than 20-fold. This finding 
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is supported by the release study (Section 4.2.2) showing a slow release of the drug 
from the nanocarrier system, which would potentially reduce the toxicity on the cells. 
When dutasteride was formulated in a nanoparticle formulation, the drug was 
released slowly allowing a longer period for the drug to interact with the cells and 
exert its activity, and at the same time preventing the cells being killed immediately. 
At 25 µM dutasteride, some of the nanoparticles formulations showed cell 
proliferation, especially the DST-NLCs and NLCs (empty) coated with 5% CSO-LA 
which exhibited the highest proliferation of 120.2 ± 9.5% and 136.6 ± 18.3%, 
respectively. DST-NLCs and NLCs coated with 5% CSO-SA showed least cell 
proliferation, 86.8 ± 20.6% and 96.7 ± 22.3%, respectively. 
It should be noted that NLCs (empty nanoparticles) coated with 5% CSO-LA 
proliferated the hair follicle dermal papilla cells at 25 µM (comparable with the 
formulation containing dutasteride). As stearic acid is a main ingredient in the 
nanoparticle preparation, a combination of nanoparticles with 5% CSO-LA may 
enhance the proliferation of the cell. These findings are in agreement with previous 
research (Liang and Liao, 1992; Liu et al., 2009), showing that lauric acid had potent 
5α-reductase inhibition activity and inhibited proliferation of lymph-node carcinoma 
cells. 
These findings suggest that combination of dutasteride with the carrier and 
coated with 5% CSO-LA at 25 µM can promote the proliferation of human follicles 
dermal papilla cells. 
4.4.4.1 Effect of stearic acid and lauric acid on cell proliferation 
In order to study whether the observed proliferation of the cells in Section 
4.4.4 was due to the presence of stearic and lauric acids, both were dissolved 
separately in DMSO (200 – 6.25 µM in a final concentration in media). Stearic acid 
(carbon chain, C18) was selected in this study as it was a major component used in the 
preparation of NLCs. Lauric acid (carbon chain C12) was used in the conjugation of 
chitosan oligomer which then used for coating. Due to the limited solubility of stearic 
acid in DMSO, the highest concentration of fatty acids studied was 200 µM (in final 
concentration).  
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Figure 4.11 shows the results of the proliferation study using stearic and 
lauric acid. Stearic and lauric acid show no cytotoxicity on human follicle dermal 
papilla cells even at the highest concentration (200 µM). There was no significant 
difference (p>0.05) between these two fatty acids on cell proliferation at all 
concentrations tested. Both fatty acids at the highest concentration (200 µM) showed 
the highest proliferation; 122.7 ± 13% for lauric acid and 115.6 ± 6.6% for stearic 
acid.  
 
 
 
 
 
 
 
 
Figure 4.11 Cell proliferation study of lauric and stearic acids on hair follicle 
dermal papilla cells (n=4, mean ± SD) 
 
This result showed that lauric acid promoted cell proliferation, probably by 
inhibiting the 5α-reductase enzyme. This result is in agreement with Liu et al. (2009), 
who found that the unsaturated fatty acid, oleic acid and the saturated fatty acid, 
lauric acid had a potent effect on the inhibition of the 5α-reductase enzyme. Raynaud 
et al. (2002) have also reported that free fatty acids (oleic and lauric), the main 
compounds in a lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) inhibit 
type I and II 5α-reductase activity. 
It has been reported previously that stearic acid has very low 5α-reductase 
activity (Liu et al., 2009), so the result of cell proliferation observed may be due to 
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the higher concentration has been used in this study. By combining stearic acid and 
dutasteride in the NLCs system, followed by coating with CSO-SA or CSO-LA, 
suggesting to enhance the growth of the hair follicle dermal papilla cells. These 
results showed that NLCs are a promising carrier for delivery of dutasteride to the 
transfollicular area.   
4.4.5 Evaluation of in vitro skin irritation using 3D Reconstructed Human 
Epidermis (RHE) 
In order to explore the potential irritancy of the drug and the NLCs 
formulations, skin irritation on the 3D reconstructed human epidermis (EpiDerm™ 
RHE) was investigated using the manufacturer’s validated protocol. Using this 
model, cell viability less than 50% indicates the potential irritancy of ingredients, 
classified as a GHS Category 2. Figure 4.12A shows the colour of MTT formazan 
from cells treated with different formulations after MTT assay, as strong purple 
indicates higher cell viability. All formulations showed no irritancy with the mean 
cell viability greater than 50% (Figure 4.12B). There was a significant difference 
(p<0.05) between the positive control (with 5% sodium dodecyl sulphate, produced 
7% cell viability) which showed irritancy compared to the negative control (DPBS) 
and all the formulations. There was no significant difference (p>0.05) in the percent 
cell viability between the nanoparticles uncoated and coated (with 5% CSO-SA and 
5% CSO-LA) formulations and with the negative control (DPBS).  
The percent cell viability for 70% ETOH and 0.29% dutasteride in 70% 
ETOH was significantly decreased (p<0.05) compared to the negative control 
(DPBS), being 78.7 ± 7.3% and 87.6 ± 4.7%, respectively. There was no significant 
difference (p>0.05) in cell viability between 70% ETOH and 0.29% dutasteride in 
70% ETOH. Previous research has found that ethanol at a concentration greater than 
60% produced irritancy on the EpiDerm™ Skin Model (Genno et al., 1998). Golla et 
al. (2009) developed a skin irritation quantitative structure-property relationship 
model using rabbit Draize test data and found that ethanol was an irritant. Typical 
adverse effects of dryness, erythema and desquamation were found when ethanol, 
propylene glycol, water-based solutions of minoxidil were repeatedly applied to the 
skin (Padois et al., 2011). Minoxidil-loaded SLNs produced no irritancy/corrosive 
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while the commercial products (5% minoxidil in ethanol-propylene glycol and water 
based) exhibited corrosive potential (Padois et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Skin irritation results for different formulations on 3D 
reconstructed human epidermis (RHE) (n=3, mean  ±  SD) 
 
By comparing the cell viability results of DST-NLCs and DST in 70% 
ethanol (at the same concentration of dutasteride), there was a significant difference 
(p<0.05). DST-NLCs, uncoated or coated and those without DST showed no 
irritation (greater than 96% cell viability), indicating no irritancy effect on the skin. 
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Dutasteride is categorised as R38, Skin irritation 2 (Fluorochem, 2012), suggesting 
that delivering dutasteride in the nanoparticles (water being the continuous phase in 
nanoparticle preparations) to the skin promoted higher cell viability, and lower 
toxicity compared to ethanol.  
Previous studies found that delivering drugs in nanoparticles decreased and/or 
eliminated skin irritation (Shah et al., 2007; Mandawgade and Patravale, 2008). Shah 
et al. (2007) prepared tretinoin in SLNs and found that such a formulation was 
significantly less irritating (p<0.05) to the rabbit skin than a marketed tretinoin 
cream. Castro et al. (2009) prepared retinoic acid-loaded SLNs and found reduced 
skin irritation compared to a retinoic acid-based cream, using a female rhino mouse 
model. These findings showed that drug-loaded nanoparticles protect the skin from 
direct contact with the drug, allowing the drug to gradually present to the skin and 
reducing skin irritation.    
4.4.6 Method development and validation of a coumarin-6 assay using RP-
HPLC 
A similar mobile phase and HPLC set-up developed for dutasteride (Section 
3.1.2) were used for the assay of Cou-6, except the wavelength of detection was    
466 nm. The retention time for Cou-6 was 9.2 minutes. Due to the comparable 
hydrophobicity characteristics of the two compounds (Log P dutasteride = 5.09 and 
Log P Cou-6 = 6.06), their retention times were close. Figure 4.13 shows there was 
no interference in the detection between Cou-6 and the other materials used in the 
formulation. 
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Figure 4.13 Peak area versus time for the NLCs with Cou-6 (A) and Cou-6 in 
ethanol, 10 µg/mL (B) 
 
The graph of concentration versus peak area was plotted and (Figure 4.14); 
the regression data showed a linear relationship between 0.25 and 12.5 µg/mL. Table 
4.6 shows the regression characteristics and validation parameters of Cou-6. LOD 
and LOQ were 0.06 and 0.25 µg/mL, respectively. The calculation of LOD and LOQ 
is shown in Appendix A2. The intraday and interday precisions were determined at 
three different concentrations (1.5, 6.0 and 11.0 µg/mL). The RSD (%) for interday 
and intraday was 0.24 – 3.20% and 1.79 – 4.20% respectively. The repeatability was 
calculated by injecting nine samples (6.0 µg/mL) and determining the RSD%; this 
was 1.78%. 
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Figure 4.14 Calibration curve of Cou-6, peak area versus concentration (n=4, 
mean ± SD) 
 
Table 4.6 Regression characteristics and validation parameters of Cou-6 
Parameters Values 
Linearity range (µg/mL) 0.25 – 12.5 
Number of samples per curve 8 
Correlation coefficient (r
2
) 0.9999 
Regression equation (y = mx + c)  
Slope (m) 279.83 
Intercept (c) -10.763 
a
LOD (µg/mL) 0.06 
b
LOQ (µg/mL) 0.25 
Accuracy (%) 97.3 – 113.2 
Repeatability, %RSD at 6 µg/mL (n=9) 1.78 
Precision, % (
c
RSD, n=3)  
Interday (n=3) 0.24 – 3.20  
Intraday (n=3) 1.79 – 4.20 
a
LOD is limit of detection, 
b
LOQ is limit of quantification and 
c
RSD is relative standard deviation at 
1.5, 6.0 and 11.0 µg/mL 
 
y = 279.83x - 10.763 
R² = 0.9999 
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The data for validation of the Cou-6 assay met the acceptance criteria from 
the ICH Q2 Guideline. The method developed for assay of Cou-6 was found to be 
sensitive, precise, accurate and simple. Hence, this RP-HPLC method could be used 
for routine analysis, and for determining entrapment efficiency and drug loading for 
the formulation containing Cou-6.  
4.4.7 Characterisation of Cou-6-loaded NLCs, uncoated and coated with 5% 
CSO-SA or 5% CSO-LA  
4.4.7.1 Effect of Cou-6 content on size distribution, entrapment efficiency and 
drug loading 
Increasing the amount of the Cou-6 dye from 0.2 (3.33 µg/mL) to 1 mg 
(16.67 µg/mL) in a total of 300 mg stearic acid, 150 mg Lutrol® micro 68 and 75 mg 
Phosal® 53 MCT in NLCs produced no significant change (p>0.05) in the 
hydrodynamic diameter and polydispersity index compared to DST-NLCs as 
described in Section 3.5.2.1.3 (Figure 4.15). Mean size ranged from 193 to 201 nm 
and PDI from 0.119 to 0.143.  
 
 
 
 
 
 
 
Figure 4.15 Hydrodynamic diameter and polydispersity index for Cou-6-NLCs 
for different contents of Cou-6 (n=3, mean ± SD) 
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In terms of the entrapment efficiency, 0.2 mg Cou-6 was incorporated in the 
NLCs rather than 0.1 mg (1.67 µg/mL), as the lower amount could be quantified 
accurately (lower than LOQ) by HPLC. The entrapment efficiency of Cou-6-loaded 
NLCs significantly decreased (p<0.05) from 0.2 mg to 1 mg (Figure 4.16). The 
loading efficiency was low (0.05 ± 0.01%) compared to dutasteride (3.49 ± 0.10%) 
as described in Section 3.5.2.1.4, showing that the carrier formulations had a limited 
loading of Cou-6 compared to dutasteride. These findings may be due to the limited 
solubility of Cou-6 in the oil-based carrier (stearic acid), which limits the amount of 
dye encapsulated in the NLCs. Sobhani et al., (2015) reported that solubility of the 
drug in oil for the preparation of nanoemulsion was very important in order to 
maintain the drug solubilisation in nanoemulsion.  
The encapsulation efficiency of Cou-6 in NLCs can be increased by 
increasing the amount of carrier. The current formulation comprised of 300 mg of 
stearic acid, 150 mg of Lutrol® micro 68 and 75 mg of Phosal® MCT 53. However, 
in this study, a similar amount of carriers were employed as for dutasteride in order 
to minimise the cytotoxicity effect on hair follicle dermal papilla cells. 
 
 
 
 
 
 
 
Figure 4.16 Entrapment efficiency for Cou-6 loaded NLCs (n=3, mean ± SD) 
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4.4.7.2 Effect of coating of Cou-6-NLCs with 5% CSO-SA or 5% CSO-LA on 
mean particle size and zeta potential 
Figure 4.17 shows the effect of coating Cou-6-NLCs, with 5% CSO-SA and 
5% CSO-LA on hydrodynamic diameter and surface charge. The mean size of Cou-
6-NLCs (192.4 ± 14.4 nm) did not significantly increase (p>0.05) when coated with 
either chitosan conjugates. Particle surface charge increased (p<0.05), changing from 
negative to positive on coating from -16.8 ± 0.7 mV uncoated to +24.4 ± 1.2 and 27.7 
± 0.6 mV when coated with 5% CSO-SA and 5% CSO-LA, respectively. 
Hydrodynamic diameter and zeta potential results in Cou-6-NLCs uncoated or coated 
with 5% CSO-SA or 5% CSO-LA were not significantly difference (p>0.05) with 
those uncoated DST-NLCs or coated with 5% CSO-SA or 5% CSO-LA as described 
in Sections 3.5.2.2 and 3.5.3.1. These findings indicate Cou-6 was appropriate as a 
model for dutasteride for uptake studies of NLCs formulations. 
      
 
 
 
 
 
 
Figure 4.17 Hydrodynamic diameter and polydispersity index for Cou-6-NLCs, 
uncoated and coated with 5% CSO-SA and 5% CSO-LA (n=3, mean ± SD) 
4.4.8 Skin uptake of Cou-6 in solution and Cou-6-loaded NLCs, uncoated and 
coated with 5% CSO-SA and 5% CSO-LA  
Figure 4.18 shows the skin uptake of Cou-6 from NLCs and in ethanol at 
different times.  
  
 
 
 
 
 
 
 
 
 
 
 
                    
 
Figure 4.18 Skin uptake of Cou-6 in full thickness pig ear skin (cryostat was set at 50 µM thickness) from Cou-6-loaded 
NLCs, uncoated and coated with 5% CSO-SA and 5% CSO-LA and Cou-6 in solution  
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No quantification of the dye could be obtained from the skin due to the 
limited amount of Cou-6 which could be included in the formulations, resulting in 
concentrations lower than the LOQ of the assay.  
All formulations showed skin uptake in a time-dependent manner in the upper 
layer of the skin, with greater uptake at 12 and 24 h than at 6 h especially in the 
upper region of the skin. The dye was also observed in the deeper layer of the skin. 
At 6 h, less intensity of fluorescent dye could be seen in the skin from Cou-6-NLCs 
uncoated and coated with 5% CSO-SA or 5% CSO-LA, suggesting the slow release 
of the dye from the NLCs at the beginning of the experiment, and the intensity of the 
colour increased as a longer time of dye exposed to the skin.  
Cou-6 in ethanolic solution showed the highest intensity compared to the 
nanoparticle formulations, due to direct contact of the dye with the skin even at 6 h. 
This finding agrees with the previous permeation study, in which dutasteride in 
ethanol showed the highest permeation (Section 4.4.2).  
In this study, the mean particle size of the NLCs was approximately 200 – 
250 nm (Section 4.4.7.2) which is in agreement with Lin et al. (2013). They prepared 
diphencyprone-loaded NLCs, having a hydrodynamic diameter approximately 208 to 
265 nm. This size range produced localization of NLCs in follicles and intercellular 
lipids of stratum corneum, following in vivo percutaneous absorption after 6 h. 
Another study investigated nanoparticle deposition in mammalian skin and 
found nanoparticles in mean size of 20 – 200 nm could not penetrate beyond the 
superficial layers of the barrier (Campbell et al., 2012). This result proved that 
nanoparticles could not penetrate the skin barrier, but it is useful as skin surface 
reservoirs in order to control the drug release over time (Campbell et al., 2012). 
Patlolla et al., (2010)also reported that nanoparticles do not cross the skin but 
possibly permeate into stratum corneum and release the drug in a controlled manner 
into the upper epidermis. 
However, nanoparticles have a tendency to diffuse and accumulate in the hair 
follicles (Fang et al., 2014). An earlier study demonstrated that nanoparticles with 
size 320 nm showed high drug accumulation in the transfollicular region after the 
massage, and were retained for up to 10 days in the hair follicle (Lademann et al., 
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2007). In this study, massaging was not applied, and the intensity of Cou-6 can only 
be seen mostly in the upper layer of the skin. If massaging was applied, the 
nanoparticles may go to the transfollicular region and stay longer in the hair follicles. 
However, no transfollicular region could be seen in these skin samples. 
4.4.9 Cell uptake of Cou-6 in solution and Cou-6-loaded NLCs, uncoated and 
coated with 5% CSO-SA and 5% CSO-LA 
Figure 4.19 shows the uptake of Cou-6 in ethanolic solutions and NLCs 
uncoated and coated with 5% CSO-SA and 5% CSO-LA in the hair follicle dermal 
papilla cells at different times. Due to the limited amount of Cou-6 taken up by the 
cells; no quantification of the dye would be conducted using HPLC or UV 
spectrophotometer (lower than LOQ). There was a similar trend for cell uptake and 
the skin uptake (Section 4.4.8), with Cou-6 in all formulations being taken up in a 
time-dependent manner. There was no apparent difference in the intensity of the 
fluorescence dye within cells either in solution or nanoparticle formulations. The 
intensity for all formulations was highest at the longest time point. This result shows 
Cou-6 was successfully taken by the cells. As the Log P of Cou-6 and dutasteride 
were close, Cou-6 can be considered a good model for studying cell uptake of these 
NLCs systems.  
This is supported by Rivolta et al. (2011) who prepared Cou-6 loaded SLNs 
and demonstrated alveolar epithelial cells took up the Cou-6 loaded SLNs. No 
specific co-localization in the cells was found with the dye. Similar finding was 
reported for Cou-6 loaded SLNs treated for A549 lung cancer cells (Zhang et al., 
2013), with increasing amounts of Cou-6 were taken up by cells with increased 
concentration and time. From these findings, Cou-6 loaded NLCs either uncoated or 
coated can be used as a model dye that represents dutasteride-loaded NLCs for 
uptake study as both have close similar characteristic of the nanoparticles (size 
distribution and surface charge) were not significantly different. 
  
 
 
 
 
 
 
 
 
      
 
Figure 4.19 Cell uptake study of Cou-6 in hair follicle dermal papilla cells from Cou-6-loaded NLCs, uncoated and coated 
with 5% CSO-SA and 5% CSO-LA and Cou-6 in solution 
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4.5 Conclusions  
This chapter aims to characterise the release and permeation, cytotoxicity and 
irritation, skin and uptake using Cou-6 as a model dye, of DST-NLCs, uncoated and 
coated with 5% CSO-SA and 5% CSO-LA. Based on the results, it can be concluded 
that: 
1. DST-NLCs without coating showed a higher release over 24 h. DST-NLCs 
coated with CSO-SA and CSO-LA had a lower drug release at 12, 24 and    
30 h. Increasing the concentration of CSO-SA or CSO-LA had no significant 
impact on the release parameters. 5% CSO-SA and 5% CSO-LA were found 
to be the optimal coating concentration for the DST-NLCs.  
2. For all formulations, no dutasteride was detectable by HPLC in the receptor 
chamber after 48 h of the permeation studies, suggesting no systemic 
exposure from these formulations in clinical studies. The highest permeation 
in the skin was found from ethanol-based solutions, then from DST-NLCs 
uncoated and coated with CSO-SA or CSO-LA.  
3. Dutasteride alone showed an IC50 of 10.4 µM for cytotoxicity. Values for 
DST-NLCs, uncoated and coated with 5% CSO-SA or 5% CSO-LA were 
higher approximately by 5-fold. Empty NLCs for both uncoated and coated 
with 5% CSO-SA or 5% CSO-LA showed cytotoxicity in a dose-dependent 
manner. The maximum non-toxic concentration (EC90) for dutasteride in the 
nanoparticles increased by more than 20-fold compared to dutasteride in 
DMSO. 
4. For in vitro skin irritation study on the 3D Reconstructed Human Epidermis 
(RHE), all formulations with or without dutasteride either coated or uncoated 
with 5% CSO-SA or 5% CSO-LA showed no irritancy with a mean cell 
viability greater than 50%. The positive control (5% sodium dodecyl 
sulphate) gave the lowest cell viability.  
5. Cou-6 was chosen as a model compound with properties similar to dutasteride 
and loaded with NLCs for the uptake study. In terms of mean hydrodynamic 
diameter, polydispersity index and surface charge, no significant differences 
were found between the formulations (0.2 mg Cou-6 in 300 mg stearic acid, 
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150 mg Lutrol® micro 68 and Phosal® 53 MCT) either coated or uncoated 
with 5% CSO-SA or 5% CSO-LA when compared to DST-NLCs, coated or 
uncoated with 5% CSO-SA or 5% CSO-LA. The entrapment efficiency and 
drug loading of Cou-6-NLCs were 88.0% and 0.05%, respectively. 
6. All formulations showed skin uptake in a time-dependent manner where at    
6 h, less dye was taken up compared to 12 and 24 h especially in the upper 
region of the skin. The dye could also be seen in the deeper layer of the skin. 
Cou-6 in ethanol showed the highest intensity compared to the nanoparticle 
formulations, due to direct contact of the dye on the skin surface, whereas 
nanoparticles either coated or uncoated with 5% CSO-SA or 5% CSO-LA 
showed less intensity.  
7. A similar trend between the cell and skin uptake was found, where Cou-6 in 
all formulations was taken up in a time-dependent manner. No specific co-
localization in the cells was found from the dye. The intensity for all 
formulations was highest at the longest time point. No difference regarding 
the intensity of the fluorescent dye either in solutions or nanoparticles 
formulations was found. This result showed Cou-6 was successfully taken up 
by the cells. 
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5.1 Summary 
The skin is the largest organ in humans with a surface area of 1.8 - 2.0 m
2 
(Uchechi et al., 2014). The skin has advantages for topical/transdermal delivery of 
drug to the targeted area by local delivery. It is suggested that by delivering drug 
topically directly on the scalp area, smaller amounts of drugs may be required to 
produce a therapeutic effect at the specific targeted site (Zhang et al., 2013) 
compared to oral delivery. However, drug permeation through the skin is usually 
limited by the stratum corneum (Uchechi et al., 2014). For effective delivery of drug 
to the skin, drug must partition from the formulation into the stratum corneum, and 
then diffuse within the stratum corneum, and partition to local tissues including 
epidermis, dermis, subcutis and appendages for topical delivery, and/or into 
epidermis, dermis and bloodstream for effective transdermal delivery (Kandavilli et 
al., 2010). 
Both topical and transdermal delivery provides convenient, and pain-free self-
administration for patients, thus makes this delivery route particularly popular. In the 
case of hair loss treatment, which requires a long duration of treatment, this is also 
likely to enhance patient adherence. For some drugs that produce systemic adverse 
effects, limiting the penetration of drug to the systemic area, achieved by engineering 
an appropriate carrier for the drug, such as nanoparticle (including nanospheres, solid 
lipid nanoparticles, micelles and micellar-like nanoparticles, liposomes and 
nanoemulsions), is an appropriate strategy for topical delivery (Zhang et al., 2013).  
In this project, a topical/dermal or transfollicular delivery system for 
dutasteride was designed and characterised. The general aim of this project was to 
prepare and characterise dutasteride-loaded nanostructured lipid carrier (DST-NLCs) 
coated with chitosan oligomer conjugated with stearic acid, or lauric acid for dermal 
delivery in order to increase the stability of nanoparticles, enhance local drug 
delivery, sustained drug release and reduce cytotoxicity. Dutasteride, which has both 
Type I and Type II 5α-reductase inhibitory activity was chosen as an anti-androgenic 
drug. Stearic acid, which is one of the main ingredients in the DST-NLCs preparation 
used in this project, also acts as a less potent 5α-reductase inhibitor.  
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The hypothesis of this project was, that modifying the surface of DST-NLCs 
with chitosan conjugated with different types of fatty acids will enhance the stability 
of nanoparticle, delivery and safety of dutasteride therapy. Encapsulating dutasteride 
in the lipid nanoparticle system for dermal application and incorporation of fatty acid 
as a carrier may provide a synergistic effect between drug and the carrier with respect 
to the anti-androgenic activity, due to the presence of the fatty acid, promoting cell 
growth, especially with lauric acid which has higher 5α-reductase inhibitory activity 
than stearic acid (Liu et al., 2009). At the same time, having positively-charged 
nanoparticles for topical delivery, due to coating with chitosan oligomer-stearic or 
lauric acid, should produce slower drug release and retention at the targeted area, 
especially the hair follicles, reducing systemic effects and cytotoxicity on the hair 
follicle dermal papilla cells. 
In Chapter 2, the conjugation between chitosan oligomer and different types 
of fatty acids and characterisation of the conjugates was described. The synthesised 
product was used as a coating material for the next experimental chapter. Chitosan 
oligomer was conjugated with stearic acid (SA) or lauric acid (LA) in order to 
produce amphiphilic chitosan, with stearic or lauric acid (attached to chitosan 
oligomer backbone) being the hydrophobic region, and the chitosan oligomer 
backbone being the hydrophilic region. The synthesised products used as coating 
materials were suggested as likely to increase the physical stability of nanoparticle 
formulations. All conjugations between chitosan oligomer and stearic acid or lauric 
acid were successful, based on 
1
HNMR, FTIR and ninhydrin assays.  In the 
optimisation of CSO-SA synthesis, sample S1 (0.5 g stearic acid; SA: EDC.HCl 1:5 
reacted for 6 h) was selected. CSO-LA was also produced using the previously 
optimised CSO-SA reaction parameters.  The degree of substitution of CSO-SA and 
CSO-LA was very similar (~6%). The critical micelle concentration values for both 
CSO-SA and CSO-LA were 0.17 mg/mL.   
Chapter 3, describes the main body of experimental work in this thesis, 
specifically describes the preparation and characterisation of DST-NLCs coated with 
CSO-SA or CSO-LA. The formulations were produced by the melt dispersion-
ultrasonication method. The optimisation of DST-NLCs was achieved using a design 
of experiments approach, whereby the size distribution of particles, entrapment 
efficiency and drug loading were measured as dependent variables whereas the 
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independent variables were the amount of stearic acid, Lutrol® micro 68 and 
Phosal® 53 MCT. To obtain positively-charged nanoparticles, the optimised 
negatively-charged DST-NLCs were coated with positively-charged CSO-SA or 
CSO-LA using a physical adsorption method.  
The ratio of contents with 100 mg stearic acid, 50 mg Lutrol® micro 68, 25 
mg Phosal® 53 MCT and 5 mg dutasteride gave the optimal physical properties; the 
smallest hydrodynamic diameter and narrowest particle size distribution. The 
formulation was scaled-up 3 times in order to increase the amount of dutasteride 
incorporated from 0.083 mg/mL to 0.29 mg/mL. The hydrodynamic diameter of 
DST-NLCs was increased with 5% CSO-SA, but not significantly increased when 
coated with 5% CSO-LA. Based on TEM micrographs, the uncoated DST-NLCs and 
those coated with CSO-SA or CSO-LA were spherical and in the size range, 
approximately 200 to 250 nm, comparable to the size measured by DLS.  
The surface charge changed from negative to positive charge for DST-NLCs 
when coated with CSO-SA and CSO-LA, showing that the particles were 
successfully coated. Increasing the amount of CSO-SA or CSO-LA in the DST-
NLCs formulation, further increased the positive charge. 
The DST-NLCs were very stable at 4-8°C, with no significant difference 
(p>0.05) in entrapment efficiency from day 1 to day 180 (~97%). The mean 
hydrodynamic diameter was in the range 200 to 250 nm when stored at 4-8°C for 
DST-NLCs, either uncoated or coated with CSO-SA or CSO-LA up to 6 months. 
These are acceptable particle size for the topical delivery; Mahe et al., (2009) found 
the particles of approximately 200 nm mean size applied to the skin were found 
around the hair follicles. Mittal et al., 2015 also reported that particles with a size of 
approximately 300 nm were found in the transfollicular region following topical 
application. 
When DST-NLCs were coated with 5% CSO (no conjugation), the NLCs 
were not stable and aggregated by day 30 at 4 – 8°C. All DST-NLCs formulations 
either uncoated or coated with CSO-SA or CSO were not stable when stored at 25°C; 
the mean size and PDI increased by 2-fold, with some formulation showing 
aggregation.  
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Dutasteride showed crystalline peaks in XRPD spectra and a sharp peak with 
DSC at 249.2°C corresponding to the drug melting temperature. The degree of 
crystallinity of dutasteride in the NLC systems was reduced, suggesting that 
dutasteride was present in an amorphous structure and homogeneously dispersed in 
the NLCs, whether the NLCs were uncoated or coated with 5% CSO-SA or 5% CSO-
LA. These less crystallinity structure due to the combination of solid lipid and liquid 
lipid in the NLCs system, suggesting to produce a sustained dutasteride release to the 
skin which is suitable for the topical application as described in the previous study 
(Pardeike et al., 2009). Pardeike et al., (2009) reported that sustained drug release is 
important for drugs that are irritating at high concentrations or delivering drug for a 
long duration. 
In Chapter 4, the in vitro characterisation of the optimised formulation of 
DST nanoparticles is described. In vitro release study was performed in order to 
compare the release of dutasteride from DST-NLCs, uncoated or coated with 
different percentages of CSO-SA and CSO-LA in PBS pH 7.4 solutions (with 2% 
SDS) to that of the control (DST in 70% ethanol), and also to confirm the presence of 
coating materials around the nanoparticles. DST-NLCs without coating showed the 
highest release of ~82% after 24 h. DST-NLCs coated with CSO-SA and CSO-LA 
showed slower drug release at 24 h (approximately 60 - 66%). By increasing the 
concentration of CSO-SA or CSO-LA from 5% to 10%, there was no significant 
difference in the release rate. These results indicate the successful presentation of 
coating materials on the surface of DST-NLCs.  
An in vitro permeation study using full thickness pig ear skin was conducted 
in order to quantify the potential systemic exposure. After 48 h, no dutasteride was 
detectable by HPLC in the receptor chamber of Franz diffusion cells for all 
formulations, suggesting no systemic exposure of dutasteride from these 
formulations. The amount of dutasteride present in the skin from uncoated DST-
NLCs was 2-fold higher than from those coated with 5% CSO-SA or 5% CSO-LA. 
The highest permeation in the skin was found from dutasteride in 70% ethanol which 
was in agreement with the previous research, in that ethanol acts as a penetration 
enhancer in topical products (Williams and Barry, 2004). Megrab et al. (1995) found 
for ethanol: water co-solvent vehicle, the effect of ethanol appears to be 
concentration-dependent, where increasing the amount of ethanol produced 
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dehydration of the biological membrane, thus reduce the permeation across the 
tissue. Additionally, permeation of ethanol into the stratum corneum can alter the 
solubility properties of the tissue, resulting in an improvement for drug partitioning 
into the membrane.  
In vitro cytotoxicity was studied in order to determine the cytotoxic and 
proliferation effects of various concentrations of dutasteride alone and dutasteride in 
the nanoparticles either uncoated or coated with 5% CSO-SA or 5% CSO-LA. The 
same nanoparticles formulation (empty NLCs) was also tested in order to investigate 
whether the carrier itself potentially promoted cell proliferation. Dutasteride alone 
showed cytotoxicity (IC50) at very low concentration (~10.4 µM). Values of IC50 for 
DST-NLCs, uncoated and coated with 5% CSO-SA or 5% CSO-LA were up to 5-
fold higher. NLCs alone (empty NLCs) uncoated and coated with 5% CSO-SA or 5% 
CSO-LA showed cytotoxicity in a dose-dependent manner. The maximum non-toxic 
concentration (EC90) for DST-NLCs either uncoated or coated with 5% CSO-SA or 
5% CSO-LA was increased up to 20-fold compared to dutasteride alone. This was 
due to the slow release of drug from nanoparticle formulations, whereby the drug 
was released slowly allowing a longer period for the drug to interact with the cells 
and exert its activity, preventing the cells being killed immediately. 
The irritation caused by the developed formulations was studied using 3D 
Reconstructed Human Epidermis. All formulations (DST-NLCs and empty NLCs) 
either uncoated or coated with 5% CSO-SA or 5% CSO-LA and dutasteride in 70% 
ethanol showed no irritancy (the mean cell viabilities were greater than 50%), with 
less cell viability for dutasteride in 70% ethanol. These results were due to water 
being the continuous phase in nanoparticle preparations, and slow dutasteride release 
from nanoparticle formulation, preventing the skin being irritated.   
For skin and cell uptake studies, Cou-6 was used as a model fluorescent dye 
with similar properties to dutasteride. Cou-6-NLCs were prepared and optimised. In 
term of the hydrodynamic diameter and polydispersity index, no significant 
differences (p>0.05) were found for all formulations either coated or uncoated with 
5% CSO-SA or 5% CSO-LA when compared to DST-NLCs. The maximum 
entrapment efficiency was found to be ~88%. 
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Based on the skin uptake studies of Cou-6 in ethanol, or Cou-6-NLCs, 
uncoated and coated with 5% CSO-SA or 5% CSO-LA, all formulations showed 
fluorescent intensity within the skin in a time-dependent manner. The intensity for all 
formulations was highest in the upper skin layer at the longest time point. For cell 
uptake of Cou-6 in ethanol or Cou-6-NLCs, uncoated and coated with 5% CSO-SA 
or 5% CSO-LA, no specific localisation of dye was found with the cells. This result 
suggests that Cou-6 was successfully prepared and used as a model dye in the NLCs 
for both uptake studies, though it is not possible to state that the NLCs were located 
preferentially in the hair follicles. 
5.2 General conclusions 
The main aim of this study has been achieved. DST-NLCs coated with CSO-
SA or CSO-LA were successfully formulated and characterised; NLCs were stable 
and showed enhanced local drug delivery, reduced systemic exposure, slower drug 
release and reduced cytotoxicity.  
The optimisation of the formulation vitally important in order to develop 
good, safe, effective and stable dosage forms. These can be undertaken by designing 
and optimise the formulation using different types of carrier, different methods of 
preparation and also varying the amount of excipients to be used in the preparation. 
In this study, optimisation was achieved using quality by design (QbD) principles, 
using a Design of Experiments software.  This software could predict the cause-and-
effect in the optimisation of the formulation. As described in Chapter 3, DoE was 
applied to optimise the carrier formulation, using a full-factorial design approach in 
order to optimise critical quality attributes; small mean particles size, narrow PDI and 
a stable formulation. DoE reduced the number of experiments or formulations 
prepared in order to achieve the target, by varying the different independent variables 
(factors) at the same time, as compared to traditional approaches where one-factor-at-
a time experiment are employed. This approach produced a mathematical model of 
the response (dependent variables) from the factors used and predicted some 
interaction between the factors used.  
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The lipid nanoparticles coated with CSO-SA or CSO-LA engineered in this 
research could be used to deliver other hair growth therapeutic molecules for topical 
application. Having positively-charged nanoparticles from conjugated-CSO, 
produced higher stability of nanoparticles compared to non-conjugated CSO. 
Nanoparticles prepared in water as the continuous phase, showed higher cell viability 
on the 3D reconstructed human epidermis, suggesting these NLCs were a better 
carrier to be used compared to ethanol. Moreover, delivering 5α-reductase inhibitor 
molecules in the nanocarriers reduced the cytotoxicity on the hair follicle dermal 
papilla cells. Lipid nanoparticles coated with chitosan could reduce the systemic 
exposure by limiting drug permeation as described in the permeation result, where 
DST-NLCs coated with CSO, CSO-SA or CSO-LA produced half of drug 
permeation compared to DST-NLCs.  
The selection of a potent 5α-reductase inhibitor compound to be conjugated 
with chitosan oligomer used as a coating material could enhance the hair follicle 
dermal papilla cell proliferation, suggesting it could enhance the synergistic activity 
with dutasteride. As revealed in the proliferation study of DST-NLCs coated with 
CSO-LA, these carriers gave better cell proliferation compared to DST-NLCs coated 
with CSO-SA.  
In this study, empty NLCs coated with CSO-LA also showed an interesting 
result, producing cell proliferation with no irritancy on the 3D reconstructed human 
epidermis, suggesting that this formulation could be used for women, for whom 
dutasteride is not indicated. Stearic acid is the main ingredient in the nanoparticle 
preparation, and lauric acid (CSO conjugated with CSO-LA) could promote cell 
proliferation as described in the previous literature (Liu et al., 2009), lauric acid is 
more potent reductase inhibitor. Stearic and lauric acid can be found abundantly in 
the palm and coconut oils, and thus these oils are widely used as traditional remedies 
for hair loss treatment in tropical countries (Rele and Mohile, 1999; Gopala Krishna 
et al., 2010; DebMandal and Mandal, 2011; Kumar et al., 2012). This result showed 
that this empty nanoparticle formulation, when combined with CSO-LA, gave 
promising results as a therapy for hair growth. 
Delivering dutasteride with the other therapeutic agents could also enhance 
the hair growth.  Kandavilli et al., (2010) have filed a patent of topical compositions 
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comprising a combination of different types of 5-alpha reductase inhibitors, which 
one is dutasteride. Rafi and Katz, (2011) conducted an efficacy study on 15 male 
patients of a new formulation (topically applied of NuH® Hair containing 
dutasteride, finasteride and minoxidil; formulation and method of production 
undisclosed) applied daily in combination with administration of oral finasteride. 
Topical 5% minoxidil foam, and/or topical ketoconazole applied to the scalp, 
produced the most significant improvement in hair counts and overall appearance 
compared to the NuH® Hair product combined with two or fewer other interventions 
to treat androgenic alopecia. Thus, these combinations showed promising results. 
However, additional safety studies should be conducted. Based on this literature, co-
delivering dutasteride with other hair growth promoter compounds in the 
nanoparticles described in this thesis could produce enhanced results, giving slow 
drug release, reduced cytotoxicity and potentially synergistic hair proliferation 
effects.  
Clinical studies have shown that dutasteride is useful for treating androgenic 
alopecia when taken orally or applied topically. However, currently no dutasteride-
based topical products have been approved in US or EU for the hair loss treatment. 
From a patient perspective, such a product would be beneficial to regrow the hair to 
be applied to the scalp at a reduced frequency. Hopefully, in a relevance short time, it 
is anticipated that a dutasteride-based topical product could be marketed and 
commercialised, and be one of several treatment options for the androgenic alopecia 
patients.  
The findings of this study thus support the hypothesis that, by modifying the 
surface of NLCs with CSO-SA or CSO-LA, the stability of nanoparticles is 
enhanced, drug retention in the skin due to positively-charged nanoparticles is 
achieved with slow drug release, reducing toxicity and irritation. Figure 5.1 shows 
the overall schematic diagram of preparation of lipid nanoparticles for topical 
delivery of hair growth therapeutic molecules, based on the work presented in this 
thesis and the potential for future formulation development. 
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Hair growth therapeutic molecules 
Lipid nanoparticles 
Selection of carrier and 
surfactant that can 
promote hair growth 
Selection of coating material - 
chitosan oligomer conjugate 
with compound that can 
promote hair growth  
 
In vitro release – sustained drug release 
In vitro skin permeation – no systemic exposure 
In vitro cell cytotoxicity and proliferation – less cytotoxicity and 
promote hair follicle dermal papilla cell proliferation 
In vitro skin irritation study – no irritation 
 
Optimisation on the 
mean size, PDI, 
entrapment efficiency 
and stability 
Future work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Schematic diagram of preparation of lipid nanoparticles for topical 
delivery of hair growth therapeutic molecules and potential future work 
 
5α-reductase inhibition study   
Hair growth promoting activity on animal 
Formulation of commercially-acceptable product 
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5.3 Future work  
There are three main experimental studies to be considered for the future: 
a. Study of the reductase inhibition activity of DST-NLCs, uncoated and coated 
with CSO-SA or CSO-LA, using rat microsomal suspension 
b. Study of the hair growth promoting activity using an animal model (in vivo) 
of DST-NLCs, uncoated and coated with CSO-SA or CSO-LA 
c. Formulation development for a commercially-acceptable product 
 
The cytotoxicity study described in this thesis has demonstrated that 
delivering dutasteride in the NLC system reduced cell cytotoxicity. As dutasteride is 
claimed to block the intracellular conversion of testosterone to DHT by 5α-reductase 
particularly for men, incorporating dutasteride in the nanoparticles (with a carrier 
itself also potentially inhibits 5α-reductase), enhance the inhibition of reductase 
enzyme activity. Study of the reductase inhibition activity of dutasteride with 
nanocarriers should therefore be undertaken, and this will give an idea of how the 
cell proliferation activity of the nanoparticles formulations has been achieved. This 
work should be undertaken using rat microsomal suspension from the liver as 
described previously (Kumar et al., 2011). DST-NLCs or empty NLCs, uncoated and 
coated with CSO-SA or CSO-LA will be reacted with the supernatants from the 
homogenated-liver with the addition of testosterone. 5α-reductase inhibition activity 
can be calculated, with finasteride used as a standard enzyme inhibitor (Kumar et al., 
2011). The results will be expressed as finasteride equivalent 5α-reductase inhibitory 
activity value (units of mg finasteride equivalent per 1 g sample).     
The second aspect of future work will be a study of hair growth promoting 
activity using an animal model. Based on the current characterisation and efficacy 
results, nanoparticle formulations showed good properties in term of drug sustained 
release, no systemic exposure, lower cytotoxicity, good stability, no skin irritation 
and promising results for skin and cell uptake and potential commercialisation. 
Therefore, the efficacy study on the mice of hair growth promoting activity should be 
performed using DST-NLCs and also the empty NLCs coated CSO-SA or CSO-LA. 
The study could be conducted as described in the previous literature (Park et al., 
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2016). Different groups of male C57BL/6 mice will be used. The hair on the dorsal 
skin will be removed and randomly divided into different groups and treated with 
different types of formulation once a day for 3 weeks (2% minoxidil for positive 
control, negative control (DI water), DST-NLCs, empty NLCs, DST-NLCs coated 
with CSO-LA, and empty NLCs coated with CSO-LA). The lengths of 30 randomly 
plucked hairs will be measured at 19 day after topical application for each group, and 
histological study on the skin will be conducted in order to visualise the appearance 
of hair follicles. 
The final aspect that needs consideration is the development of the 
formulation to yield a more patient-acceptable formulation and ultimately a 
commercially-acceptable product. Currently, DST-NLCs, uncoated and coated with 
CSO-SA or CSO-LA formulations are dispersed in water, which yields a low 
viscosity product. To enhance the formulation and aid dose delivery, it is proposed to 
deliver this nanoparticle dispersion either deliver as a liquid, in unmodified form 
(using a dropper) or it can be formulated into a semi-solid dosage form, such as 
foam, an emulsion (i.e. lotion) or hydrogel. The current formulation has low 
viscosity, and the formulation could run over the scalp, though such lotions are an 
established dosage form for application to the scalp. A preservative would be 
required to prevent microbial growth. Secondly, these nanoparticles dispersion could 
be delivered in a foam type. The latest foaming technology uses compressed air or 
nitrogen in polyethylene terephthalate (PET) packaging, this is potentially easier to 
use and at the same time more environmentally friendly,  avoiding harmful emissions 
(typically propane or butane) from aerosol-based foam. Alternatively, a finished 
product based on these NLCs could be prepared by mixing this nanoparticle 
dispersion with an emulsion, formulating in an emulsion or adding a thickener such 
as Carbopol® polymer to form a hydrogel. Optimisation on the type of carrier should 
be performed as NLCs having chitosan (CSO-SA or CSO-LA) may affect the 
properties of the gel, the product formulating these NLCs into an emulsion or 
hydrogel carrier, the product would potentially easier to use by patient, having non-
greasy properties, retarding flow of the formulations, and permitting easy distribution 
of small amounts of formulations evenly on the scalp. However, the physical stability 
of the NLCs, drug release and permeation profiles may be changed, and additional 
characterisation of nanoparticles and the complete formulation would be required.     
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Appendix A 
1. Calculation of the LOD and LOQ from the regression analysis using 
Microsoft Excel software for dutasteride 
Nominal 
conc. (x) 
AUC 
Ave (y) 
Cal. abs 
(Yi) 1 2 3 4 
1 55.8 36.5 58.9 59.9 52.8 48.0 
3 131.5 101.2 134.4 126.5 123.4 118.8 
5 194.7 179.3 205.0 184.5 190.9 189.5 
10 379.4 351.2 327.7 369.4 356.9 366.4 
25 906.5 898.1 876.9 897.7 894.8 896.9 
50 1817.5 1795 1762.5 1762.3 1784.3 1781.2 
70 2561.5 2452.1 2473.1 2505.1 2498.0 2488.6 
100 3595.0 3498.6 3500.1 3578.2 3543.0 3549.8 
              Cal – calculation from the equation 
Result for regression analysis (from 3 – 100 µg/mL) 
  Coeffcients 
Std 
Error t Stat 
P-
value 
Lower 
95% 
Upper 
95% 
Lower 
95.0% 
Upper 
95.0% 
Intercept 12.67 4.034 3.140 0.026 2.297 23.036 2.297 23.036 
Variable 1 35.37 0.079 446.595 0.000 35.167 35.575 35.167 35.575 
Equation from the regression analysis 
LOD = 3.3σ/slope = (3.3 x 4.034)/35.37 = 0.38 µg/mL 
LOQ = 10σ/slope = (10 x 4.034)/35.37 = 1.14 ~> 3 µg/mL 
Therefore the LOD and LOQ were 0.38 and 3 µg/mL, respectively. 
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2. Calculation of the LOD and LOQ from the regression analysis using 
Microsoft Excel software for coumarin-6 
Nominal 
conc. (x) 
AUC 
Ave (y) 
Cal. abs 
(Yi) 1 2 3 4 
0.25 19.8 77 66.4 69.9 64.7 59.2 
0.5 39.6 137.8 129.4 139.5 133.1 129.2 
1.0 82.0 294.9 266.1 277.6 280.6 269.1 
2.5 194.5 707.7 672.6 677.4 653.5 688.8 
5.0 390.4 1454.4 1350.4 1364.1 1443.1 1388.4 
7.5 600.8 2209.3 2044 2052.1 2180.6 2088.0 
10.0 897.1 2951.2 2716.7 2769.5 2862.8 2787.5 
12.5 1088.2 3761.1 3368 3486 3624.1 3487.1 
              Cal – calculation from the equation 
Result for regression analysis (from 0.25 – 12.5 µg/mL) 
  Coeffcients 
Std 
Error t Stat P-value 
Lower 
95% 
Upper 
95% 
Lower 
95.0% 
Upper 
95.0% 
Intercept -10.76 5.464 -1.969 0.096 -24.13 2.608 -24.133 2.608 
Variable 1 279.83 0.832 336.32 
4.66 x 
10
-14
 
277.798 281.870 277.798 281.870 
 
Equation from the regression analysis 
LOD = 3.3σ/slope = (3.3 x 5.464)/279.83 = 0.064 µg/mL 
LOQ = 10σ/slope = (10 x 5.464)/279.83 = 0.2 ~> 0.25 µg/mL 
Therefore the LOD and LOQ were 0.06 and 0.25 µg/mL, respectively.
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Appendix B 
Graph of intensity and volume versus size (nm) for scaled-up DST-NLCs 
measured by dynamic light scattering 
 
 
1. DST-NLCs (uncoated) 
 
  
2. DST-NLCs coated with 5% CSO-SA 
 
 
3. DST-NLCs coated with 5% CSO-LA 
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